WO2017105990A1 - Ph-responsive mucoadhesive polymeric encapsulated microorganisms - Google Patents
Ph-responsive mucoadhesive polymeric encapsulated microorganisms Download PDFInfo
- Publication number
- WO2017105990A1 WO2017105990A1 PCT/US2016/065535 US2016065535W WO2017105990A1 WO 2017105990 A1 WO2017105990 A1 WO 2017105990A1 US 2016065535 W US2016065535 W US 2016065535W WO 2017105990 A1 WO2017105990 A1 WO 2017105990A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- polymers
- microorganism
- lactobacillus
- microorganisms
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 111
- 230000003232 mucoadhesive effect Effects 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 73
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 61
- 201000010099 disease Diseases 0.000 claims abstract description 49
- 238000009472 formulation Methods 0.000 claims abstract description 39
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 17
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 10
- 230000000890 antigenic effect Effects 0.000 claims abstract description 9
- 239000006041 probiotic Substances 0.000 claims description 129
- 235000018291 probiotics Nutrition 0.000 claims description 104
- 229920000642 polymer Polymers 0.000 claims description 86
- 235000010443 alginic acid Nutrition 0.000 claims description 79
- 229920000615 alginic acid Polymers 0.000 claims description 79
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 78
- 229940072056 alginate Drugs 0.000 claims description 78
- 229920001661 Chitosan Polymers 0.000 claims description 75
- 241000193749 Bacillus coagulans Species 0.000 claims description 67
- 229940054340 bacillus coagulans Drugs 0.000 claims description 66
- -1 poly(methacrylic acids) Polymers 0.000 claims description 66
- 230000000529 probiotic effect Effects 0.000 claims description 66
- 241000894006 Bacteria Species 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 235000018102 proteins Nutrition 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 230000002496 gastric effect Effects 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 229920002678 cellulose Polymers 0.000 claims description 25
- 235000010980 cellulose Nutrition 0.000 claims description 23
- 239000001913 cellulose Substances 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 20
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 20
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 20
- 239000001814 pectin Substances 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 229920001277 pectin Polymers 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 235000010987 pectin Nutrition 0.000 claims description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 11
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 10
- 229920002807 Thiomer Polymers 0.000 claims description 10
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 10
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 229940014259 gelatin Drugs 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 244000005709 gut microbiome Species 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 229920003119 EUDRAGIT E PO Polymers 0.000 claims description 5
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 241000186012 Bifidobacterium breve Species 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 4
- 108010068370 Glutens Proteins 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 201000010538 Lactose Intolerance Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 235000021312 gluten Nutrition 0.000 claims description 3
- 229940124590 live attenuated vaccine Drugs 0.000 claims description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 claims description 3
- 230000001123 neurodevelopmental effect Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001241 acetals Chemical class 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229920001567 vinyl ester resin Polymers 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 125000002092 orthoester group Chemical group 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract description 39
- 230000004083 survival effect Effects 0.000 abstract description 26
- 241001465754 Metazoa Species 0.000 abstract description 18
- 230000000813 microbial effect Effects 0.000 abstract description 12
- 230000002035 prolonged effect Effects 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 58
- 239000010410 layer Substances 0.000 description 56
- 239000003795 chemical substances by application Substances 0.000 description 44
- 238000000576 coating method Methods 0.000 description 42
- 230000012010 growth Effects 0.000 description 38
- 239000011248 coating agent Substances 0.000 description 34
- 239000000463 material Substances 0.000 description 33
- 239000003814 drug Substances 0.000 description 28
- 210000000936 intestine Anatomy 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 241000186660 Lactobacillus Species 0.000 description 24
- 239000011324 bead Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 230000002378 acidificating effect Effects 0.000 description 22
- 230000008685 targeting Effects 0.000 description 20
- 210000002784 stomach Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000499 gel Substances 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 16
- 229940039696 lactobacillus Drugs 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 229920001282 polysaccharide Polymers 0.000 description 15
- 150000004804 polysaccharides Chemical class 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 210000001072 colon Anatomy 0.000 description 14
- 230000007935 neutral effect Effects 0.000 description 14
- 239000005017 polysaccharide Substances 0.000 description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 13
- 239000003833 bile salt Substances 0.000 description 13
- 238000001035 drying Methods 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 13
- 229920003134 Eudragit® polymer Polymers 0.000 description 12
- 108090000288 Glycoproteins Proteins 0.000 description 12
- 102000003886 Glycoproteins Human genes 0.000 description 12
- 241000736262 Microbiota Species 0.000 description 12
- 239000000227 bioadhesive Substances 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 230000035899 viability Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 239000000017 hydrogel Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000003097 mucus Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 239000012620 biological material Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 244000000021 enteric pathogen Species 0.000 description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 8
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 8
- 240000006024 Lactobacillus plantarum Species 0.000 description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 229940009289 bifidobacterium lactis Drugs 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- 239000000679 carrageenan Substances 0.000 description 8
- 229940113118 carrageenan Drugs 0.000 description 8
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 235000013365 dairy product Nutrition 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001879 gelation Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001468157 Lactobacillus johnsonii Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000991587 Enterovirus C Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 description 5
- 241000186605 Lactobacillus paracasei Species 0.000 description 5
- 229920002732 Polyanhydride Polymers 0.000 description 5
- 241000282849 Ruminantia Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 229940093761 bile salts Drugs 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000008199 coating composition Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000011162 core material Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000010432 diamond Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 229940017800 lactobacillus casei Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229920005615 natural polymer Polymers 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229940083542 sodium Drugs 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 241000194031 Enterococcus faecium Species 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229920006317 cationic polymer Polymers 0.000 description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000007140 dysbiosis Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000028774 intestinal disease Diseases 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000004215 spore Anatomy 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 239000000216 gellan gum Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108010052500 Calgranulin A Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000207202 Gardnerella Species 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108010061711 Gliadin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 2
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000203736 Mobiluncus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical class O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000019824 amidated pectin Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000000398 anti-amebic effect Effects 0.000 description 2
- 230000001136 anti-cestodal effect Effects 0.000 description 2
- 230000000842 anti-protozoal effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- 229940036589 antiprotozoals Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004666 bacterial spore Anatomy 0.000 description 2
- 230000035587 bioadhesion Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001057 ionotropic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000018612 quorum sensing Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940108461 rennet Drugs 0.000 description 2
- 108010058314 rennet Proteins 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- WQQPDTLGLVLNOH-UHFFFAOYSA-M sodium;4-hydroxy-4-oxo-3-sulfobutanoate Chemical class [Na+].OC(=O)CC(C([O-])=O)S(O)(=O)=O WQQPDTLGLVLNOH-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- CTXGTHVAWRBISV-UHFFFAOYSA-N 2-hydroxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCO CTXGTHVAWRBISV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- VCNPGCHIKPSUSP-UHFFFAOYSA-N 2-hydroxypropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(C)O VCNPGCHIKPSUSP-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- 238000013335 3D tissue model Methods 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- CPIVYSAVIPTCCX-UHFFFAOYSA-N 4-methylpentan-2-yl acetate Chemical compound CC(C)CC(C)OC(C)=O CPIVYSAVIPTCCX-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000235858 Acetobacter xylinum Species 0.000 description 1
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 108010052495 Calgranulin B Proteins 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000589986 Campylobacter lari Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241001135528 Campylobacter upsaliensis Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000227342 Candidatus Arthromitus sp. SFB-mouse Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- 244000239659 Eucalyptus pulverulenta Species 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003150 Eudragit® E 12,5 Polymers 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920003142 Eudragit® S 12,5 Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590010 Helicobacter fennelliae Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 108091005686 NOD-like receptors Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000790234 Sphingomonas elodea Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 241000287436 Turdus merula Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 208000019789 abdominal cramp Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical group OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229920003147 ammonioalkyl methacrylate copolymer Polymers 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001679 anti-nematodal effect Effects 0.000 description 1
- 230000000538 anti-polioviral effect Effects 0.000 description 1
- 230000002953 anti-rotaviral effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000011037 discontinuous sequential dilution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 229940104788 entyvio Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000004783 epithelial tight junction Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 108010054561 gastric mucus glycoproteins Proteins 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940062737 gengraf Drugs 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000006171 gluten free diet Nutrition 0.000 description 1
- 235000020884 gluten-free diet Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940083461 halotestin Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000012690 ionic polymerization Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940066544 lactobacillus sporogenes Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940094506 lauryl betaine Drugs 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920003146 methacrylic ester copolymer Polymers 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000016768 molybdenum Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- QCTVGFNUKWXQNN-UHFFFAOYSA-N n-(2-hydroxypropyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCC(C)O QCTVGFNUKWXQNN-UHFFFAOYSA-N 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
- 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229940056099 polyglyceryl-4 oleate Drugs 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000129 polyhexylmethacrylate Polymers 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001444 polymaleic acid Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000182 polyphenyl methacrylate Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940063222 provera Drugs 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 229940069591 purixan Drugs 0.000 description 1
- 229960000996 pyrantel pamoate Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000009754 rhamnogalacturonan I Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- IDXHDUOOTUFFOX-UHFFFAOYSA-M sodium;2-[2-hydroxyethyl-[2-(tetradecanoylamino)ethyl]amino]acetate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)NCCN(CCO)CC([O-])=O IDXHDUOOTUFFOX-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
Definitions
- the invention relates generally to microencapsulation delivery systems and in particular to the enhancement of site-specific delivery of microorganisms within the gastrointestinal tract to treat or prevent diseases and/or conditions.
- GI gastrointestinal
- the gastrointestinal (GI) microbiome has been widely investigated for its role in many diseases, ranging from diabetes to depression to cancer.
- the roles of specific GI microorganisms in regulation and progression of these diseases have recently been defined and described, and as such, efforts to modulate the microbiome (e.g., decreasing disease-causing bacterial populations and increasing probiotic populations) are of particular interest.
- technologies facilitating the controlled and direct modulation of the GI microbiome are lacking, mostly due to the challenges arising from the delivery of microbes through the stomach (e.g., low pH and high bile salt concentration) to target areas in the GI tract (e.g., intestines and colon).
- WO2009070012 discloses protein-based probiotic encapsulates to enhance the survival of the probiotics.
- Cook, et al. used a model probiotic, Bifidobacterium breve, encapsulated into an alginate matrix before coating in multilayers of alternating alginate and chitosan (Cook MT et al, J. Mater. Chem. B, 2013,1, 52-60).
- a significantly improved viability of the probiotics targeted to the intestine was observed when encapsulated.
- Cook et al developed the probiotic delivery system mainly to overcome the challenges of survival through the gastric insults of low pH and enzymatic activity.
- these systems have been relatively crude at ensuring delivery to the desired anatomical region.
- compositions to maintain viability of microorganisms following ingestion as well as the abilities to adhere to the target tissue(s) so that its contents will be delivered to targeted tissues as a function of proximity and duration of the contact.
- compositions for targeting encapsulated microorganism to a specific site within the GI tract are provided.
- compositions of encapsulated microorganism with an improved survival and retention.
- compositions and methods of use for preferentially targeting therapeutic, prophylactic or diagnostic microorganisms, or antigenic components thereof, with prolonged survival to select sites within the gastrointestinal tract have been developed.
- the compositions may also include therapeutic, prophylactic and/or diagnostic agents.
- compositions for selectively targeting microorganisms with prolonged survival include encapsulated single-cell microorganisms, encapsulated in one or more layers of mucoadhesive polymers, coated with an outer layer of pH-responsive polymers.
- the pH-responsive polymers dissolve at a specific pH or range of pHs.
- the pH or range of pH can correspond with the local pH of a specific target site which allows the release of the encapsulated microorganism at the site.
- the layer- by-layer mucoadhesive polymeric coating prolongs viability and enhances the retention of the encapsulated microorganism so that it will not be eliminated before it has had a chance to exert an effect.
- the layer-by-layer encapsulating polymers include one or two bilayers of chitosan and/or alginate, and a pH-responsive polymer outer layer.
- Exemplary pH-responsive polymers include EUDRAGIT® E PO and EUDRAGIT®L 100.
- the methods include administering single-cell microorganisms encapsulated in one or more layers of mucoadhesive polymers, and further coated with an outer layer of pH- responsive polymers to a subject.
- the subject is suffering from a condition associated with alteration in the gut microbiota.
- Such conditions include Crohn's disease, ulcerative colitis, diverticulitis, irritable bowel syndrome, gluten insensitivity, lactose intolerance, obesity, asthma, allergies, metabolic syndrome, diabetes, psoriasis, eczema, rosacea, atopic dermatitis, gastrointestinal reflux disease, cancers of the
- an effective dosage is administered in one or more doses, over a time period of once a day, once every other day, once a week, biweekly, etc. until one or more symptoms of the condition or disease status is improved.
- Figure 1 is a schematic showing layer-by-layer templating of polymeric materials onto a bacterial cell.
- Figures 2A-2B are line diagrams showing layer characterization for chitosan (CHI) and alginate (ALG) coatings on model probiotic organism Bacillus coagulans (BC).
- Figure 2A shows zeta potential for each sequential layer of chitosan and alginate, and for two chitosan and alginate bilayers, (CHI/ALG)2, at pH 1 and 7.
- Figure 2B shows relative fluorescence of Bacillus coagulans coated with 2, 4 or 6 layers of fluorescent chitosan or alginate.
- Figures 3A-3B are graphs showing fold enhancement of polymer release from 2-bilayer templating on Bacillus coagulans over time (hours) in either simulated intestinal fluid (SIF/PBS) or simulated gastric fluid (SGF/PBS) relative to their release in PBS.
- Figure 3A shows the polymer release kinetics of chitosan from (CHI/ALG)2 coated Bacillus coagulans
- Figure 3B shows the polymer release kinetics of alginate from
- Figures 4A-4C are bar graphs showing the survival rate of non- formulated Bacillus coagulans (plain) and Layer-by-Layer (LbL) coated
- FIG. 4A shows the survival rate of plain Bacillus coagulans under SGF insult for 30min, lhr and 2hr.
- Figure 4B shows the survival rate of unmodified Bacillus coagulans under 4% bile insult for each of 30min, lhr and 2hr, respectively.
- Figure 4C shows the survival rate of plain or LbL-formulated (CHI/ALG)2 Bacillus coagulans in PBS, SGF and 4% bile after 2 hours incubation.
- CHI/ALG plain or LbL-formulated
- Figure 5 is a bar graph showing mucoadhesive capabilities (measured in total radiant efficiency) of non-formulated Bacillus coagulans (plain), chitosan coated Bacillus coagulans (Chitosan) and 2-bilayers of chitosan and alginate coated Bacillus coagulans (Chitosan/Alginate) 2 .
- Figures 6A-6B are line graphs showing layer characterization for enteric pH-responsive polymers EUDRAGIT® EPO (EPO) and
- FIG. 6A Zeta potential for non-formulated Bacillus coagulans (BC), BC with sequential layer(s) of EPO and ALG including BC(EPO), BC(EPO/ALG)j and BC(EPO/ALG)i.5 in simulated intestinal fluid (SIF).
- zeta potential is also shown for BC(EPO/ALG)i.5 after exposure to simulated gastric fluid (SGF, black circle) or remaining in SIF (open squares and black diamond).
- Figure 6B Zeta potential for non-formulated Bacillus coagulans (BC), BC with sequential layer(s) of LI 00 and chitosan (CHI) including BC(CHI), BC(CHI/L100)i.
- zeta potential is also shown for after exposure to SGF (black diamond) or SIF (open square and black circle).
- Figure 7 is a line graph showing growth of bacteria with 0, 1, 2, or 3 bilayers of coating over time (hours) estimated by the absorbance at 600 run (OD 600).
- (CHI/ALG), (CHI/ALG) 2 , and (CHI/ALG) 3 on Bacillus coagulans was used as the layer formulation for 1, 2 and 3 bilayers, respectively. Plain was used to describe 0-bilayer Bacillus coagulans.
- Figure 8 is a bar graph showing viability of model probiotics Bacillus coagulans (BC) at different probiotic to EUDRAGIT® LI 00 emulsion ratio. Hatched bars show EUDRAGIT® L 100 microencapsulated BC exposed directly to simulated intestinal fluid (SIF) and then plate counted. Black bars show the same mass of particles first exposed to acidic simulated gastric fluid (SGF) and then to neutral SIF. White bars show the same mass of particles first exposed to neutral SIF, followed by exposure to acidic SGF.
- BC Bacillus coagulans
- Figures 9A and 9B are line graphs showing the growth (measured in
- Figure 1 OA is a line graph showing the growth rate (measured in Radiance (p/sec/cm 2 /sr)xl0 5 ) of plain, uncoated, bacteria (closed circles) and (CHI/ALG)2-coated LbL-probiotics over time (hours) in Epilntestinal® 3D tissue model at 37°C (* p ⁇ 0.05).
- Figure 10B is a line graph showing the fold-enhancement of LbL-probiotics' growth over that of plain, uncoated, probiotics at each time point.
- Figure 12 is a bar graph showing the recovery of Type II oral polio virus (OPV) after 4 days at 37°C when encapsulated in a single layer of EPO, a single layer of Glycol Chitosan, or a single layer of 50:50 mixture of EPO and glycol chitosan compared to a standard salt buffer of ⁇ 3 ⁇ 4 ⁇ 2.63 ⁇ 40.
- OSV Type II oral polio virus
- An optimal controlled release system designed to administer beneficial microorganisms in specific areas of the gastrointestinal tract requires three critical areas of consideration: (1) protecting the beneficial microorganisms from harsh conditions such as stomach acid or bile salt to enhance their survival; (2) facilitating mucoadhesion to the lining of the appropriate viscus so that the probiotic microorganisms will not be entrained beyond the desired site of action and eliminated before it has had a chance to exert a topical effect; and (3) controlling release, for example via pH sensitive polymers so as to facilitate growth in pH-regulated areas of the GI tract.
- Cell encapsulation technology has the potential to protect microorganisms and to deliver them into the gut.
- challenges to overcome with respect to the microencapsulation process and the conditions prevailing in the gut.
- Single cell encapsulation offers advantages such as increasing surface area for attachment at target sites as well as avoiding quorum sensing which could have negative effects on the encapsulated cells.
- mucoadhesive is a property of a material (e.g. a polymer or a protein) that has the ability to adhere to mucosal membranes in the aqueous environment of the gastrointestinal tract.
- enteric refers to a polymer/protein coating on bacteria that facilitates safe transit (e.g. avoiding acidic or bile salt mediated death) tlirough stomach for delivery to the small intestine and/or the colon.
- safe transit e.g. avoiding acidic or bile salt mediated death
- tlirough stomach for delivery to the small intestine and/or the colon.
- This can be tested by subjecting different coating formulations against specific biological insults. For example, incubating coated bacteria in acidic or bile- salt solutions at 37°C and compaiing their survival to non-coated bacteria, either by direct counting or colorimetric methods. The result will capture the enteric potential of the coating formulation.
- pH responsive generally refers to a polymer/protein coating that degrades or dissolves in response to changes in the pH of its immediate surrounding.
- coatings that are stable in acidic conditions (pH ⁇ 5), but degrade in neutral conditions (pH > 7) since these coatings will facilitate stability in the stomach and dissolve in the small intestines and/or colon. This can be tested by subjecting different coating formulations to solutions of vaiying pHs. Confirmation of layer removal can be performed by testing for surface charges (if the coated polymers are of opposite or distinct charge) or by testing the solution for labeled (e.g.
- microbiome or “microbiota” are used interchangeably, and refer to collectively, to the entirety of microbes found in association with a higher organism, such as a human.
- Organisms belonging to a human's microbiota may generally be categorized as bacteria, archaea, yeasts, and single-celled eukaryotes, as wells as various viruses and parasites such as Helminths.
- probiotic utilizes the World Health Organization's 2001 definition of "live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host". Probiotics must be alive when administered, have viability and reproducibility based on in vivo results, and during use and storage.
- biocompatible and “biologically compatible” generally refer to materials that are, along with any metabolites or degradation products thereof, generally non-toxic to the recipient, and do not cause any significant adverse effects to the recipient.
- biocompatible materials are materials which do not elicit a significant inflammatory or immune response when administered to a patient.
- biodegradable generally refers to a polymer that will degrade or erode by enzymatic action and/or hydrolysis under physiologic conditions to smaller units or chemical species that are capable of being metabolized, eliminated, or excreted by the subject.
- the degradation time is a function of polymer composition, morphology, such as porosity, particle dimensions, and environment.
- an effective amount or "therapeutically effective amount” means a dosage sufficient to alleviate one or more symptom of the disease or disorder state being treated or to otherwise provide a desired pharmacologic and/or physiologic effect.
- the precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected.
- treat refers to the reduction or amelioration of the progression, severity and/or duration of a disease or disorder, delay of the onset of a disease or disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of a disease or disorder, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents).
- therapies e.g., one or more therapeutic agents.
- treatment and “treating” also encompass the reduction of the risk of developing a disease or disorder, and the delay or inhibition of the recurrence of a disease or disorder.
- enteral administration means administration via absorption through the gastrointestinal tract. Enteral administration can include oral and sublingual administration, gastric administration, or rectal administration.
- controls are known in the art. For example, an increase response in a subject or cell treated with a compound is compared to a response in subject or cell that is not treated with the compound.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” means one or more carrier ingredients approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, mammals, and more particularly in humans. .
- in combination refers to the use of more than one therapeutic agent.
- the use of the term “in combination” does not restrict the order in which said therapeutic agents are administered to a subject.
- compositions for preferentially targeting microorganisms with prolonged survival to select sites along the gastrointestinal tract generally include a beneficial microorganism associated encapsulated in one or multilayers of polymer(s).
- the compositions are targeted to the small intestine of a subject. In other embodiments, the compositions are targeted to the colon of a subject.
- the composition includes encapsulating polymers that resist the physiological conditions present within the mammalian digestive tract, such as gastric acids and bile salts, to enhance the survival of the encapsulated microorganisms.
- a preferred agent is an organism that is non- pathogenic in humans, such as probiotic bacteria.
- the compositions include pH-responsive polymers that adhere and dissolve at targeted site within the GI tract to allow the attachment and proliferation (growth) of the encapsulated organism at the site.
- the compositions contain encapsulating polymers that regulate the growth of the probiotic agent at the target site.
- multiple microorganisms are encapsulated within the same polymeric particle.
- the encapsulated agents are live attenuated vaccines such as Type II oral poliovirus.
- Agents to be encapsulated include probiotic microorganisms, such as bacteria and yeast, genetically transformed prokaryotic or eukaryotic cells, as well as viruses.
- Probiotic is a term that means “for life” and defined as “live microorganisms that beneficially affect the host's health by improving its microbial balance”.
- Lactobacillus and Bifidobacteria are the two most common types of microorganisms which are extensively used as probiotics in humans. Probiotics are different based on the species. For examples, in dogs and cats the most common probiotic organism is Enterococcus faecium. In ruminants, Lactobacillus pentosus WE7 is useful for the prevention and treatment of enteric disease in horses.
- the use of probiotic bacterial culture stimulates the growth of preferred microorganisms, crowds out potentially harmful bacteria, and reinforces the body's natural defense mechanisms.
- a non-limiting list of exemplary probiotic microorganisms includes Lactic acid bacteria (LAB), such as Lactobacillus spp., Leuconostoc spp., Pediococcus spp., Lactococcus spp., Bifidobacterium spp. and Streptococcus spp., as well as certain yeasts and bacilli.
- LAB Lactic acid bacteria
- probiotics such as LAB or Bacillus species generally target the lower intestine and represent an interesting means to stabilize the gut microbiota and decrease the risk of pathogen colonization.
- Probiotics for adult ruminants have mainly been selected to improve fiber digestion by rumen microorganisms.
- probiotics have positive effects on various digestive processes, especially cellulolysis and the synthesis of microbial proteins.
- the main form of probiotic commonly used in dairy cows is various strains of yeast (mostly Saccharomyces cerevisiae).
- lactate-producing bacteria ⁇ Enterococcus, Lactobacillus
- Streptococcus bovis may represent a possible means of limiting acidosis in high-concentrate-fed animals, especially feedlot cattle.
- Propionibacterium species which utilize lactate, have also been administered as direct fed microbials to avoid the accumulation of ruminal lactate.
- Some bacterial strains have been widely discussed in the literature and clinical studies have demonstrated their therapeutic effect in a human subject (Solanki HK, et ah, BiomedRes Int. 2013:620719 (2013)).
- Examples of probiotic strains and their intended therapeutic applications include Lactobacillus plantarum 299v, Bacillus coagulans ATCC no.
- Lactobacillus acidophilus LI for hypercholesterolemia and cardiovascular disease
- Lactobacillus rhamnosus GG for prevention of atopy
- Lactobacillus rhamnosus GG Bifidobacterium lactis
- Lactobacillus paracaseifor eczema Lactobacillus rhamnosus GG, Bifidobacterium lactis
- Lactobacillus paracasei for food allergies
- Lactobacillus rhamnosus Bifidobacterium lactis, Lactobacillus johnsonii, Lactobacillus rhamnosus, and Lactobacillus acidophilus for lowered immunity
- Lactobacillus rhamnosus GG Saccharomyces cerevisiae, Lactobacillus acidophilus, and Lactobacillus plantarum 299v for antibiotic use (during and after);
- Lactobacillus rhamnosus GG for nonsteroidal anti-inflammatory drug; Lactobacillus rhamnosus GG, Saccharomyces cerevisiae for intestinal hyperpermeability; Lactobacillus rhamnosus GG, Lactobacillus reuteri MM53, Lactobacillus paracasei CRL431, Lactobacillus acidophilus CRL730, Lactobacillus johnsonii Lai, Bifidobacterium lactis Bbl2, Lactobacillus plantarum 299v, and Lactobacillus paracasei for
- Lactobacillus johnsonii Lai a Lactobacillus plantarum 299v, and Lactobacillus rhamnosus GG for giardia infection
- Lactobacillus rhamnosus GG Lactobacillus johnsonii Lai
- Lactobacillus plantarum 299v Lactobacillus paracasei
- propionibacterium freudenreichii HA-101 and HA- 102 for intestinal dysbiosis
- Lactobacillus acidophilus Lactobacillus johnsonii Lai for lactose intolerance
- Lactobacillus johnsonii Lai
- Lactobacillus acidophilus, and Lactobacillus rhamnosus for GG for peptic ulcer disease & nonerosive gastritis
- Lactobacillus plantarum 299v, VSL no. 3 ⁇ for irritable bowel syndrome
- Lactobacillus acidophilus NCFB 1748, VSL no. 3a for radiation- induced diarrhea
- Lactobacillus rhamnosus GG Bifidobacterium lactis Bbl2, Lactobacillus acidophilus, Saccharomyces • cerevisiae, and Lactobacillus plantarum 299v for traveller's diarrhea
- Lactobacillus rhamnosus GG Saccharomyces cerevisiae for Crohn's disease; Escherichia coli Nissle 1917, VSL no. 3 ⁇ , Lactobacillus plantarum 299 for ulcerative colitis; Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus acidophilus, and Lactobacillus delbrueckii ssp.
- Lactobacillus rhamnosus GR-1 Lactobacillus fermentumB-54, Lactobacillus fermentum RC-14, and Lactobacillus acidophilus for urinary tract infection
- Lactobacillus acidophilus Lactobacillus rhamnosus GG, Lactobacillus rhamnosus GR-1, and Lactobacillus fermentum RC-14 for vaginal candidiasis (thrush).
- the microorganisms to be delivered in a subject for general health or for helping recovery after a course of antibiotics or chemotherapy include Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum, Lactobacillus fermentum, and
- Table 1 Microbial populations in the digestive tract of normal humans.
- the microorganisms to be delivered in a subject for diarrhea treatment are Lactobacillus rhamnosus, Lactobacillus reiiteri, and Saccharomyces boulardii.
- the microorganism to be delivered in a subject for stomach ulcer is Bifidobacterium bifidum.
- the microorganisms to be delivered in a subject for gluten insensitivity include Lactobacillus casei, Lactobacillus fermentum, Lactobacillus parcasei, Lactobacillus bifidus, and
- the microorganisms to be delivered to preterm babies include Bifidobacterium breve, Saecharaomyces boulardii,
- Bifidobacteria infantis Streptococcus thermophiles, Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus sporogenes, Lactobacillus planatarum, Lactobacillus rhamnosus, and Bifidobacterium lactis.
- the compositions contain probiotics for dogs.
- Some exemplary microorganisms include Inter ococcus faecium, and Bacillus coagulans for general health; Lactobacillus acidophilus, and Lactobacillus rhamnosus for treating diarrhea. Further non-limiting examples include Bifidobacterium animalis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus fermentum, and
- Lactobacillus reuteri Lactobacillus reuteri.
- the disclose composition contain probiotics for horses.
- Some exemplary microorganisms include Lactobacillus plantaruin, Enterococcus faecium, Lactobacillus casei, and Lactobacillus acidophilus as well as Saccharomyces boulardii, and Lactobacillus reuteri.
- the disclose composition contain probiotics for cattle.
- Some exemplary microorganisms include Lactobacillus fermentum, Enterococcus faecium, Lactobacillus acidophilus, and
- the disclosed composition contain probiotics for cats.
- Some exemplary microorganisms include Enterococcus faecium and Lactobacillus acidophilus.
- probiotic formulations contain a mixture of one or more types of organisms.
- the bacteria may be in diy or lyophilized form, or sporulated.
- the encapsulated microorganisms are live prokaryotic or eukaryotic cells.
- the cells are a transformed or modified form of a naturally occurring strain. Methods for transforming cells are known in the art.
- the microorganisms are bacterial spores or other senescent forms of the bacteria. When bacterial spores are used, the spores can be dormant spores. In one embodiment the spores are spores of Bacillus subtilis. In other embodiments, the bacteria are attenuated or otherwise non- viable bacteria, such as killed bacteria. In some embodiments the bacteria are selected for a property associated with the genotype or phenotype of the specific genus, strain or sub-strain. Exemplaiy characteristics include antibiotic resistance.
- these probiotic microorganisms are genetically engineered to be resistant to common antibiotics such as penicillins, cephaolsporins, tetracyclines, aminoglycosides, and macrolides. These can be used to complement antibiotic treatment to restore healthy microbiota.
- common antibiotics such as penicillins, cephaolsporins, tetracyclines, aminoglycosides, and macrolides. These can be used to complement antibiotic treatment to restore healthy microbiota.
- microorganisms are genetically engineered to include a reporter system.
- reporter systems include bioluminescent and fluorescent proteins such as green fluorescent proteins from jellyfish. These bacteria can be used as a diagnostic tool to detect pathological conditions within the GI tract including inflammation and ulcer.
- microorganisms are genetically engineered to secrete therapeutic, prophylactic or diagnostic products.
- microorganisms are engineered to secret insulin for treating diabetes to act as living "drug factories"; or bacteria are engineered to secret fluorescent proteins for detection of defined conditions within the GI tract.
- a vaccine is a biological preparation that provides active acquired immunity to a particular disease.
- a vaccine typically contains the same antigens (or parts of antigents) from a microorganism that causes disease.
- measles vaccine contains measles virus.
- the antigens in vaccines are either killed, or weakened to the point that the do not cause disease but they are strong enough to stimulate the body's immune system so that the immune system can readily recognize and kill any of
- An antigen can include any protein or peptide that is foreign to the subject organism.
- Preferred antigens can be presented at the surface of antigen presenting cells (APC) of a subject for surveillance by immune effector cells, such as leucocytes expressing the CD4 receptor (CD4 T cells) and Natural Killer (NK) cells.
- APC antigen presenting cells
- CD4 T cells CD4 T cells
- NK Natural Killer
- the antigen is of viral, bacterial, protozoan, fungal, or animal origin.
- the antigen is a cancer antigen.
- Cancer antigens can be antigens expressed only on tumor cells and/or required for tumor cell survival.
- antigenic protein refers to the ability of the molecule to elicit a B or T cell mediated response, which may be humoral (resulting in antibody) or cell mediated (resulting in activation of dendritic cells, macrophages, T cells or the pathway resulting in activation thereof).
- Antigens are recognized by those skilled in the art as immuno- stimulatory (i.e., stimulate effective immune recognition) and provide effective immunity to the organism or molecule from which they derive.
- Antigens can be peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof.
- the antigen can be derived from a virus, bacterium, parasite, plant, protozoan, fungus, tissue or transformed cell such as a cancer or leukemic cell and can be a whole cell or immunogenic component thereof, e.g., cell wall components or molecular components thereof.
- Suitable antigens are known in the art and are available from commercial government and scientific sources.
- the antigens may be purified or partially purified polypeptides derived from tumors or viral or bacterial sources.
- the antigens can be recombinant polypeptides produced by expressing DNA encoding the polypeptide antigen in a heterologous expression system.
- the antigens can be DNA encoding all or part of an antigenic protein.
- Antigens may be provided as single antigens or may be provided in combination. Antigens may also be provided as complex mixtures of polypeptides or nucleic acids.
- live attenuated or inactivated vaccines are incorporated within the pH-responsive mucoadhesive polymeric encapsulation.
- exemplary vaccines include live, attenuated viral vaccines, such as the cold-adapted, recombinant nasal influenza and oral rotavirus vaccines, and adenovirus-based vaccine as well as the poliovirus and Salmonella typhi vaccines.
- the vaccine can include live, attenuated or inactivated microorganisms or a protein, DNA or lipid component thereof.
- Suitable vaccines for encapsulation include, but are not limited to, vaccines against anthrax, chickenpox, diphtheria, hepatitis A, hepatitis B, HIB, HPV, influenza, Japanese encephalitis, measles, viral meningitis, mumps, whooping cough, pneumonia, polio, rabies, ritavirus, rubella, shingles, smallpox, tetanus, tuberculosis, typhoid, and yellow fever. These are typically in the form of attenuated organisms, although isolated proteins can also be incorporated.
- Antigenic molecules can be encapsulated alone, or in combination with microorganisms, which may be present in an amount effective as an adjuvant to enhance the immune response, or to broaden the response.
- agents may also be incorporated with the microorganisms and/or components thereof.
- Representative agents may be proteins, lipids, sugars, nucleic acid molecules, or combinations thereof, small molecule drugs (typically less than 1000 Da although some may be higher), or radiopaque, radionuclide, or magnetic imaging agents.
- anti-parasitic agents are incorporated into the particles.
- Anti-parasitic agents such as anti-protozoa agents, antihelminthics, and combinations thereof, include, but are not limited to, antinematodes, anticestodes, antitrematodes, antiamoebics, antiprotozoals, and combinations thereof.
- Suitable antinematodal drugs include, but are not limited to, benzimiadazoles (e.g., mebendazole, thiabendazole), avermectins (e.g., ivermectin), pyrantel pamoate, diethylcarbamazine, and combinations thereof.
- benzimiadazoles e.g., mebendazole, thiabendazole
- avermectins e.g., ivermectin
- pyrantel pamoate diethylcarbamazine, and combinations thereof.
- Suitable anticestodes include, but are not limited to, niclosamine, praziquantel, albendazole, and combinations thereof.
- Suitable antitrematodes include, but are not limited to, praziquantel.
- Suitable antiamoebics include, but are not limited to, rifampin, amphotericin B, and combinations thereof.
- Suitable antiprotozoals include, but are not limited to, melarsoprol, eflornithine, metronidazole, tinidazole, miltefosine, and combinations thereof.
- the particles can contain one or more antiviral and/or antimicrobial agents.
- Suitable agents include anti-influenza agents, anti-poliovirus agents, antihepatitis agents, anti-arboroviral agents (anthropod-borne viruses such as dengue fever, yellow fever, and malaria), anti-rotavirus agents, anti-Ebola virus agents, anti-Marburg virus agents, anti-Lassa virus agents, and combinations thereof.
- Suitable antimicrobial agents include, but are not limited to, anti-cholera agents, anti E-coli agents, anti-tuberculosis agents, anti-leprosy agents, and combinations thereof.
- micronutrients include, but are not limited to, iron, cobalt, zinc, manganese, copper, iodine, selenium, molybdenum, chromium, vitamin A, beta carotene, vitamin Bl, vitamin B2, vitamin B3, vitamin B6, vitamin B9 (folic acid), vitamin B 12, vitamin C, vitamin D3, vitamin E, vitamin K, pantothenic acid, biotin, and combinations thereof.
- the required daily dosage of most micronutrients is less than 100 mg/day.
- Different agents, and different combinations of agents can be combined in the same particle, different particles, or combinations thereof. This can be done for reason of convenience, such as having separate particles for different agents for convenience in combimng or mixing different agents in different formulations, or in order to increase or optimize the stability or form of the agents based on the composition of the particle.
- biomaterials used for microorganism encapsulation include polymers, such as natural polymers and synthetic polymers (Gentile FT et al, React. Polym. 25:207-227(1995)).
- the terms biocompatible and biodegradable are associated with many of these biomaterials.
- Biomaterials for microorganism encapsulation are in direct contact with the living cells. Issues involved when selecting biomaterials for microorganism
- encapsulation are: (a) physicochemical properties (chemical composition, morphology, mechanical strength, stability in gastric and intestinal fluids); (b) toxicology assay; (c) manufacturing and sterilization processes.
- Biomaterials are inorganic or organic macromolecules, consisting of repeated chain of monomers linked by covalent bonds. Their chemical structure and the conformation of the monomer chains give them specific functionality such as ability to form gels.
- the most common biomaterial used for microorganism encapsulation is alginate.
- Other supporting biomaterials include carrageenan, gelatin, chitosan, whey proteins, cellulose acetate phthalate, locust bean gum and starches (Solanki HK, et ah, Biomed Res Int. 2013:620719 (2013)).
- Exemplary gastric resistant natural polymers include, but are not limited to, pectin and pectin-like polymers which typically consist mainly of galacturonic acid and galacturonic acid methyl ester units forming linear polysaccharide chains.
- these polysaccharides are rich in galacturonic acid, rhamnose, arabinose and galactose, for example the polygalacturonans, rhamnogalacturonans and some arabinans, galactans and arabinogalactans. These are normally classified according to the degree of esterification.
- HM high (methyl) ester
- a relatively high portion of the carboxyl groups occur as methyl esters, and the remaining carboxylic acid groups are in the form of the free acid or as its ammonium, potassium, calcium or sodium salt.
- Useful properties may vary with the degree of esterification and with the degree of polymerization.
- Pectin in which less than 50% of the carboxyl acid units occur as the methyl ester, is normally referred to as low (methyl) ester or LM-pectin.
- low ester pectin is obtained from high ester pectin by treatment at mild acidic or alkaline conditions.
- Amidated pectin is obtained from high ester pectin when ammonia is used in the alkaline deesterification process. In this type of pectin some of the remaining carboxylic acid groups have been transformed into the acid amide.
- the useful properties of amidated pectin may vary with the proportion of ester and amide units and with the degree of
- the gastric resistant natural polymer is pectin.
- the gastric resistant natural polymer is present in an amount less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
- mucoadhesive polymers into the structure of pharmaceutical products is to prolong their residence time in the targeted site and to allow the release of the drug cargo.
- Suitable polymers that can be used to form bioadhesive dosage include soluble and insoluble, non-biodegradable and biodegradable polymers. These can be hydrogels or thermoplastics, homopolymers, copolymers or blends, natural or synthetic. In preferred embodiments, the polymers have a bioadhesive force that can effectively and specifically target and bind the mucosal surface of the host.
- An exemplary bioadhesive polymer can bind to one or more mucosal surfaces of a host with a force of between 110 N/m 2 (11 mN/cm 2 ) and 100,000 N/m 2 .
- GI mucus is made of 95% water and 5% electrolytes, lipids, proteins and glycoproteins, as described by Spiro, R.G., "Glycoproteins," Annual Review of Biochemistry, 39, 599-638, 1970; Labat-Robert, J. & Decaeus, C, "Glycoproteins du Mucus Gastrique: Structure, Function, et Pathologie," Pathologie et Biologie (Paris), 24, 241 (1979).
- the composition of the latter fraction can vary greatly. Proteins, including the protein core of the glycoproteins, can made up anywhere from 60 to 80% of this fraction.
- glycoproteins typically have a molecular weight of approximately two million and consist of a protein core (approximately 18.6-25.6% by weight) with covalently attached
- Glycoproteins in Glycoproteins: Their Composition, Structure and Function (eds. A. Gottschalk), pp. 434-445 (Amsterdam: Elsevier Publishing
- the radius of the individual particles should be as thick as the thickness of the natural mucous layer. It has been shown that the gastric mucous layer thickness typically varies from 5 to 200 ⁇ in the rat and 10 to 400 ⁇ in man. Occasionally, however, it can reach thicknesses as great as 1000 ⁇ in man, as described by Spiro, R.G., "Glycoproteins,” Annual Review of Biochemistry, 39, 599-638, 1970; Labat-Robert, J.
- hydrophilic polymers Two classes of polymers appear to have potentially useful bioadhesive properties: hydrophilic polymers and hydrogels.
- hydrophilic polymers those containing carboxylic groups (e.g., polyfacrylic acid]) exhibit the best bioadhesive properties.
- carboxylic groups e.g., polyfacrylic acid
- polymers with the highest concentrations of carboxylic groups should be the materials of choice for bioadhesion on soft tissues.
- the most promising polymers were: sodium alginate, carboxymethylcellulose, hydroxymethylcellulose and methylcellulose. Some of these materials are water-soluble, while others are hydrogels.
- Hydrogels have often been used for bioadhesive drug delivery; however, one big drawback of using hydrogels is the lack of long-term stability during storage which is a problem for therapeutic applications.
- Rapidly bioerodible polymers such as poly[lactide-co-glycolide], polyanhydrides, polyorthoesters - which would expose carboxylic groups on the external surface as their smooth surface erodes - are excellent candidates for bioadhesive drug delivery systems in the gastrointestinal tract.
- Biodegradable polymers are more stable than hydrogels.
- polymers containing labile bonds such as polyanhydrides and polyesters, are well known for their hydrolytic reactivity. Their hydrolytic degradation rates can generally be altered by simple changes in the polymer backbone.
- Representative natural polymers are proteins, such as zein, serum albumin, or collagen, and polysaccharides, such as cellulose, dextrans, and alginic acid.
- Representative synthetic polymers include polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, polymers of acrylic and methacrylic esters, poly[lactide-co-glycolide], polyanhydrides,
- polyorthoestersblends and copolymers thereof include cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxymethyl cellulose, cellulose triacetate, cellulose sulphate, poly (methyl methacrylate), (poly (ethyl methacrylate), poly(butyl methacrylate), Poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), polyvinyl alcohols), polyvinyl acetate), poly(vinyl chloride), polys
- polymers can be obtained from sources such as Sigma Chemical Co., St. Louis, MO, Polysciences, Warrenton, PA, Aldrich, Milwaukee, WI, Fluka, Ronkonkoma, NY, and BioRad, Richmond, CA.
- milk proteins are natural vehicles for probiotic or other microorganism, and owing to their structural and physicochemical properties, they can be used as a delivery system (Livney YD, Current Opinion in Colloid and Interface Science, 15(l-2):73-83, (2010)).
- whey proteins are used for encapsulate microorganism in the current invention. Applications of whey proteins are also extended to other foods for protection during processing as well as stability during storage but also in nutraceutical for protection and soil release in the GI tract (Reid AA, et al, Journal of Food Science, 72(1) M31-M37 (2006)).
- positively-charged hydrogels such as chitosan
- negatively charged hydrogels such as alginate that exposes carboxylic groups on the surface.
- two sequential bilayers of alginate and chitosan are applied onto the microorganism for enhanced stability and adhesion.
- Poly anhydrides are good candidates for bioadhesive delivery systems since, as hydrolysis proceeds, more and more carboxylic groups are exposed to the external surface. Polylactides erode by bulk erosion;
- the erosion is slower.
- polymers that have high concentrations of carboxylic acid were preferred.
- biomaterials for encapsulating probiotic agents are listed below.
- Alginate is a naturally derived polysaccharide extracted from various species of algae and composed of two monosaccharide units: a-L-guluronic acid (G) and /?-D-mannuronic acid (M) linked from ⁇ (1-4) glycosidic bond (Formula I). M/G ratios determine the technological functionality of alginate. The gel strength depends upon high proportion block G. High temperature (60°C to 80°C) is needed to dissolve alginate in water. Alginate gels are insoluble in acidic media. Alginate is mostly used in concentration range of 0.5-4% (Sheu TY et al. Journal of Food Science, 54:557-561, (1993))
- Alginate can be purchased form commercially available sources such as Sigma Chemical Co. St. Louis, MO (#A7003).
- Chitosan is a linear polysaccharide with positive charge arising from its amine groups obtained by deacetylation of chitin. It can be isolated from crustacean shells, insect cuticles, and the membranes of fungi. It is a copolymer of two monomer residues anhydro-N-acetyl-D-glucosamine and anhydrous-D-glucosamine (Formula II). It is soluble at pH ⁇ 6 and forms gel structure by ionotropic gelation. Chitosan can further polymerize by means of cross- linking formation in the presence of anions and poly anions (Klein J et ah, European Journal of Applied Microbiology and Biotechnology, 18(2):86— 91, 1983). It is used for coating of gelatin capsules, because its efficiency for the increasing viability of probiotic cells is not satisfactory; it is most often used as coat/shell but not capsule.
- Chitosan can be purchased from commercially available sources such as Sigma Chemical Co., St. Louis, MO (#448877).
- Agarose is a polysaccharide derived from seaweed used for microencapsulation of cells and the cell/agarose suspension can be modified to form microbeads by reducing the temperature during preparation.
- microenvironments consisting of a defined mixture of collagen Type I and agarose polymers (Batorsky A et al., Biotechnol Bioeng. 92(4) :492- 500(2005)).
- Starch consists of D-glucose unit joint together with glycosidic bonds. It has been used as a material for coating of alginate capsules.
- High-amylose corn starch (HACS) can be applied for enhancing functions of capsule or shell/coat formation.
- Lyophilized corn starch (LCS) has been reported to be used as capsule-forming material; however, it decomposes after being subjected to pancreatic enzymes.
- Resistant starch (RS) is not degraded by the pancreatic amylase.
- Gellan gum is an anionic polysaccharide derived from Sphingomonas elodea which is constituted of a repeating unit of four monomers that are glucose, glucuronic acid, glucose, and rhamnose.
- Sphingomonas elodea which is constituted of a repeating unit of four monomers that are glucose, glucuronic acid, glucose, and rhamnose.
- Xanthan is an anionic polysaccharide derived from Sphingomonas elodea which is constituted of a repeating unit of four monomers that are glucose, glucuronic acid, glucose, and rhamnose.
- Xanthan is an anionic polysaccharide derived from Sphingomonas elodea which is constituted of a repeating unit of four monomers that are glucose, glucuronic acid, glucose, and rhamnose.
- Xanthan is an anionic polysaccharide derived from Sphingomonas
- exopoly saccharide derived from Xanthomonas campestris The optimum mixing proportion for xanthan-gellan gum is 1 : 0.75 (Borgogna M et ah, Food Chemistry, 122(2)416-423(2010)). This mixture is resistant to acidic conditions.
- Guar gum also called guaran, is a galactomannan. It is primarily the ground endosperm of guar beans. The guar seeds are dehusked, milled and screened to obtain the guar gum. Guar gum is a polysaccharide composed of the sugars galactose and mannose. The backbone is a linear chain of beta 1,4-linked mannose residues to which galactose residues are 1,6-Iinked at every second mannose, forming short side-branches.
- Guar gum is stable in solution over pH range 5-7. Strong acids cause hydrolysis and loss of viscosity, and alkalies in strong concentration also tend to reduce viscosity. It is insoluble in most hydrocarbon solvents. The viscosity attained is dependent on time, temperature, concentration, pH, rate of agitation and practical size of the powdered gum used. The lower the temperature lower the rate at which viscosity increases and the lower the final viscosity.
- Carrageenan is polymer having linear structure consisting of D- galactose units alternatively linked by a-(l-3) and ⁇ (1-4) bonds. Types of carrageenan are kappa ( ⁇ ), iota (i), and lambda ( ⁇ ). Monosulfated ⁇ - carrageenan and bisulfated i-carrageenan contain oxygen bridge between 3 and 6 of the D-galactose, which is responsible for the conformational transition and gelatin. The A-carrageenan is trisulfated and does not have this bridge required for gel formation. Carrageenan gelatin is induced by temperature changes.
- a rise in temperature (60-80°C) is required to dissolve it, and gelation occurs by cooling to room temperature, and then microparticles are stabilized by adding potassium ion.
- It is commonly used as a food additive; its safety has been approved by several government agencies including FDA, Codex Alimentarius, and the joint FAO/WHO food additive. It has good capacity to form gels that can entrap the cell.
- the cell slurry should be added to the heat sterilized suspension between 40- 45°C; otherwise the gel hardens at room temperature. Usually it is used in concentration such as 2—5% (Klien J et al., Comprehensive Biotechnology, M. Moo-Yong,C. L.Cooney, and A. E. Humphery, Eds., pp.
- Gelatin is used as a thermally reversible gelling agent for
- anionic gel-forming polysaccharides such as gellan gum. It is frequently used in food and pharmaceutical industries. It is a protein derived by partial hydrolysis of collagen of animal origin. It has versatile functional properties, and forms a solution of high viscosity in water which set to a gel on cooling.
- Hyaluronic acid is a non-sulphated glycosaminoglycan (GAG) in the extracellular matrix (ECM) of many soft connective tissues, composed of alternating units of D-glucuronic acid and N-acetyl-D-glucosamine, linked together via alternating ⁇ -1,4 and ⁇ -1,3 glycosidic bonds (Garg HG et al., Chemistiy and biology of hyaluronan. Elsevier Ltd.; Oxford: (2004)).
- GAG glycosaminoglycan
- ECM extracellular matrix
- HA is an attractive building block for the fabrication of artificial matrices for tissue engineering because it is biocompatible, biodegradable, bioactive, non- immunogenic and non-thrombogenic (Laurent TCE, The Chemistry, Biology, and Medical Applications of Hyaluronan and Its Derivatives.
- the pectins which are most abundant in the plant primary cell walls and the middle lamellae, are a class of molecules defined by the presence of galacturonic acid.
- the pectic polysaccharides include the galacturonans (homogalacturonan, substituted galacturonans, and RG-II) and
- Galacturonans have a backbone that consists of alpha- 1,4-linked galacturonic acid.
- Cellulose is the most abundant naturally occurring polymer of glucose, found as the main constituent of plants and natural fibers such as cotton and linen. Some bacteria (e.g., Acetobacter xylinum) are also able to synthesize cellulose. Most water-soluble cellulose derivatives are obtained via etherification of cellulose, which involves the reaction of the hydroxyl groups of cellulose with organic species, such as methyl and ethyl units. The degree of substitution, defined as the average number of etherified hydroxyl groups in a glucose unit, can be controlled to a certain extent, in order to obtain cellulose derivatives with given solubility and viscosity in water solutions.
- Cellulose-based hydrogels can be formed by properly crosslinking aqueous solutions of cellulose ethers, such as methylcellulose (MC), hydroxypropyl methylcellulose (HPMC), Hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxyethyl cellulose (HEC), carboxymethyl cellulose (CMC) and sodium carboxymethylcellulose (NaCMC), which are among the most widely used cellulose derivatives.
- MC methylcellulose
- HPMC Hydroxypropyl cellulose
- HPC Hydroxypropyl cellulose
- EC ethyl cellulose
- HEC hydroxyethyl cellulose
- CMC carboxymethyl cellulose
- NaCMC sodium carboxymethylcellulose
- the environmental conditions of each section along the GI tract can be exploited to design adequate delivery systems.
- the GI tract consists of esophagus, stomach, small intestine, and large intestine (colon). Stomach is where majority of digestion occurs.
- the small intestine comprised of duodenum, jejunum, and ileum and is where digestion and the majority of absorption of food/nutrients/vitamins take place.
- Colon is where water gets absorbed the rest is excreted as waste in the form of feces.
- the viable microbial populations in the digestive tract of normal humans are about 0- 10 3 for stomach, 0-10 4 for jejunum, 10 5 -10 8 for ileum and 10 10 - 10 12 for colon.
- the intraluminal pH is rapidly changed from highly acid in the stomach to about pH 6 in the duodenum.
- the pH around esophagus is about 7.0 and drops to 1-2.5 in the stomach.
- the pH gradually increases in the proximal small intestine from pH 6.2-7.4 to about pH 6.8-7.9 in the distal intestine.
- the pH drops to 5.2 to 6.7 in the ascending colon, but again gradually increases, reaching pH 5.2-7.0 in the descending colon
- the release of the encapsulated agent is triggered by a change in pH.
- pH-sensitive formulations e.g. formulations coated with enteric polymers that release drag when the pH move towards a more alkaline range, after passage through the stomach
- drugs coated with bioadhesive polymers that selectively provide adhesion to the colonic mucosa e.g. see US Patent 6,368,586)
- delivery systems that incorporate protease inhibitors to prevent proteolytic activity in the gastrointestinal tract from degrading biologic drug agents.
- polymeric delivery systems with a dissolution threshold in the range of 6.8 to 7.5 are used to exploit the natural shift towards a more alkaline pH in the distal sections of the gut for colonic delivery.
- Ionisable polymers with a pKa value between 3 and 10 are candidates for pH-responsive systems (R.A. Siegel, Adv. Polym. Sci. 109: 233(1993)).
- MAAc maleic anhydride
- DMAEMA N,N-dimethylaminoethyl methacrylate
- pH-responsive polymers include cationic polymers such as poly(ethylene imine) (PEI), PAMAM and other dendrimers, poly(N,N- dimethylaminoethyl methacrylate) (PDMAEMA), poly(amido amine)s, poly(L-lysine) (PLL) or modified chitosan.
- PEI poly(ethylene imine)
- PAMAM poly(N,N- dimethylaminoethyl methacrylate)
- PDMAEMA poly(amido amine)s
- PLL poly(L-lysine)
- modified chitosan modified chitosan.
- the pH-responsive polymer is hydroxypropyl- methylcellulosephthalate (HPMCP).
- non-pH responsive polymers are modified with pH responsive polymers for incorporating such properties in the coating material.
- chitosan is formulated by ionic cross-linking with HPMCPP for acid stability (Makhlof A et al, Eur JPharm Sci. 18;42(5):445-51(201 1)).
- the pH-responsive polymers are hydrazine, acetal, ortho-ester, and vinyl-ester functionalized polymers.
- EUDRAGIT® polymers are available from EVONIK. They are poly(methacrylate) polymers or copolymers. Examples include:
- Amino alkyl methacrylate copolymers R -CO-0-CH 2 -CH2N(CH3)2 for immediate release
- Methacrylic acid copolymers COOH for Delayed release
- Methacrylic ester copolymers R CO-OCH3 for Time-controlled release.
- EUDRAGIT® L and S polymers can be used for targeting specific areas of the intestine. These polymers include Eudragit® L 30 D-55, L 100-55, L 100 and L 12,5 as well as EUDRAGIT® S 100, S 12,5 and FS 30D. In addition, different grades can be combined with each other to adjust the dissolution pH in order to achieve the required GI targeting for the encapsulated content.
- EUDRAGIT® E polymers can also be used for pH sensitive release.
- Various cationic EUDRAGIT ® E grades with dimethyl- aminoethyl methacrylate as functional group can be used for protective coatings.
- Some examples are EUDRAGIT® E 100, E 12,5 and E PO.
- the probiotic organism is coated with multilayers of EUDRAGIT® E PO and alginate where the exposure to low pH triggers the dissolution of the outer coating of Eudragit® E PO.
- the probiotic organism is coated with multilayers of chitosan and Eudragit® L 100 where the exposure to neutral pH triggers the dissolution of the outer coating of Eudragit® L 100.
- CAP is used for controlling drug release in the intestine (Mortazavian A, et al., Egyptian Journal of Biotechnology, 5(1)1-18, 2007). It is not soluble at pH less than 5 but it is soluble at pH higher than 6. This property is essential for probiotic encapsulation because the bilateral must not dissolve in the stomach but only in the gut.
- the disadvantage of CAP is that it cannot form gel beads by ionotropic gelation so capsules have been developed by emulsification.
- CAP is widely used as a coating agent because it provides better protection for microorganisms in simulated GI conditions (F'avaro-Trindade CS, et ah, Journal of
- cellulose esters with similar properties include cellulose acetate and cellulose acetate butyrate and are widely used for preparing pH sensitive and semi-permeable microporous membranes.
- the encapsulated microorganism include one or more additional functional groups.
- One or more additional functional groups can be added to the polymeric coating, using any protocols known in the art, for example, covalent attachment (MacDonald C et ah, J R Soc Interface. 5(23): 663-669(2008)).
- the additional functional groups are attached to the surface of the encapsulated microorganism directly.
- Exemplary functional groups include targeting elements, immunomodulatory elements, chemical groups, biological macromolecules, and combinations thereof.
- the encapsulated microorganism can include targeting moieties that enhance attachment at targeted sites along the GI tract.
- exemplary targeting elements include proteins, peptides, nucleic acids, lipids, saccharides, or polysaccharides that bind to one or more targets associated with cell, or extracellular matrix, or specific type of tumor or infected cell.
- the degree of specificity with which the delivery vehicles are targeted can be modulated through the selection of a targeting molecule with the appropriate affinity and specificity. For example, antibodies, or antigen-binding fragments thereof are very specific.
- the targeting moieties exploit the surface-markers specific to a group of cells to be targeted.
- immunological components of the gut wall are targeted during gut inflammation under conditions such as neoplasia, IBD, infections, autoimmune diseases (e.g. celiac disease), ischaemia-reperfusion, intestinal hypoperfusion, and e.g. the use of non-steroidal anti-inflammatory drugs.
- calprotectin also known as MRP-8/MRP-14 or S100A8/A9 complex plays a regulatory role in the inflammatory process. It constitutes about 60% of the soluble proteins in human neutrophilic cytosol and is also found in monocytes, macrophages, and ileal tissue eosinophils.
- Antibody against calprotectin allows targeting of the encapsulated microorganism to the site of inflammation.
- the targeting domain can enhance site-specific delivery of the encapsulated microorganism to cancer cells in the GI tract.
- Antibodies that function by binding directly to one or more epitopes, other ligands or accessory molecules at the surface of the GI tract, are described.
- the antibody or antigen binding fragment thereof has affinity for a receptor at the surface of a specific cell type, such as a receptor expressed at the small intestine.
- antibodies can include an antigen binding site that binds to an epitope on the target cell. Binding of an antibody to a "target" cell can enhance site-specific attachment to the target cell protein via one or more distinct mechanisms.
- the antibody or antigen binding fragment binds specifically to an epitope.
- the epitope can be a linear epitope.
- the epitope can be specific to one cell type or can be expressed by multiple different cell types.
- the antibody or antigen binding fragment thereof can bind a conformational epitope that includes a 3-D surface feature, shape, or tertiary structure at the surface of the target cell.
- Some further non-limiting examples include targeting the disclosed composition to the disease sites for therapeutic and/or diagnostic purposes.
- Exemplary conditions within the GI tract include ulcer, inflammation, and cancers.
- a protein that is capable of specifically binding to receptors, either basally expressed or expressed on pathological cells, at the GI tract can be attached via covalent or non-covalent interactions to the surface of the encapsulated microorganism.
- ICAM-1 and VCAM-1 proteins can bind to ICAM and VCAM receptors, respectively. ICAM and VCAM receptors are overexpressed on the inflamed intestine tissues whereas an antibody such as IgG can be used to bind to basally expressed Fc-receptors on intestine tissues.
- Confirming the functionality of the incorporated protein/antibody can be done using ELISAs, or cell-binding assays (e.g. anti-ICAM functionalized bacteria can be tested for their binding ability to cells overexpressing ICAM receptor, such as LPS-stimulated HUVECS)
- anti-ICAM- 1 is incorporated onto the surface of the encapsulated microorganism for targeting ICAM receptor at inflammation sites of the intestine tissues.
- the protein ICAM is
- the engineered microorganisms carrying genes for fluorescent or bioluminescent proteins are used for detection.
- diagnostic markers such as fluorescent proteins are crossed- linked onto the encapsulated microorganism.
- anti- VCAM-1 is incorporated onto the encapsulated microorganism for targeting VCAM receptor at inflammation sites of the intestine tissues.
- Other examples include IgG for targeting basal Fc-neonatal receptors in intestine and anti-VPACl for targeting VPACl in the intestines.
- the target is ulcers in the stomach.
- microogranism can include immuno-modulatory factors.
- immunomodulatory factors include cytokines, xanthines, interleukins, interferons, oligodeoxynucleotides, glucans, growth factors (e.g., TNF, CSF, GM-CSF and G-CSF), hormones such as estrogens (diethylstilbestrol, estradiol), androgens (testosterone, HALOTESTIN® (fluoxymesterone)), progestins (MEGACE® (megestrol acetate), PRO VERA® (medroxyprogesterone acetate)), corticosteroids (prednisone,
- dexamethasone hydrocortisone
- CRM 197 diphtheria toxin
- outer membrane protein complex from Neisseria meningitides, as well as viral hemagglutinin and neuraminidase.
- the cationic polymers include immuno- stimulatory factors.
- immuno-stimulatory factors include, but are not limited to, TLR ligands, C-Type Lectin Receptor ligands, NOD-Like Receptor ligands, RLR ligands, and RAGE ligands.
- TLR ligands can include lipopolysaccharide (LPS) and derivatives thereof, as well as lipid A and derivatives there of including, but not limited to, monophosphoiyl lipid A (MPL), glycopyranosyl lipid A, PET-lipid A, and 3-0-desacyl-4' ⁇ monophosphoryl lipid A.
- Formulations are prepared using a pharmaceutically acceptable "carrier” composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions.
- the “carrier” is all components present in the pharmaceutical formulation other than the active ingredient or ingredients.
- carrier includes but is not limited to diluents, binders, lubricants, desintegrators, fillers, and coating compositions.
- Carrier also includes all components of the coating composition which may include plasticizers, pigments, colorants, stabilizing agents, and glidants.
- the delayed release dosage formulations may be prepared as described in references such as "Pharmaceutical dosage form tablets", eds. Liberman et al.
- suitable coating materials include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name Eudragit® (Roth Pharma, Westerstadt, Germany), Zein, shellac, and polysaccharides.
- cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate
- polyvinyl acetate phthalate acrylic acid polymers and copolymers
- methacrylic resins that are commercially available under the trade name Eudragit® (Roth Pharma, Westerstadt, Germany), Zein, shella
- the coating material may contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilization agents, pore formers and surfactants.
- Optional pharmaceutically acceptable excipients present in the drug- containing tablets, beads, granules or particles include, but are not limited to, diluents, binders, lubricants, disintegrants, colorants, stabilizers, and surfactants.
- Diluents also termed “fillers,” are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets or formation of beads and granules.
- Suitable diluents include, but are not limited to, dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose,
- microcrystalline cellulose kaolin, sodium chloride, dry starch, hydrolyzed starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and powder sugar.
- Binders are used to impart cohesive qualities to a solid dosage formulation, and thus ensure that a tablet or bead or granule remains intact after the formation of the dosage forms.
- Suitable binder materials include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums such as acacia, tragacanth, sodium alginate, cellulose,including hydorxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, and veegum, and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid/polymethacrylic acid and polyvinylpyrrolidone.
- Lubricants are used to facilitate tablet manufacture.
- suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc, and mineral oil.
- Disintegrants are used to facilitate dosage form disintegration or
- breakup after administration, and generally include, but are not limited to, starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross- linked PVP (Polyplasdone XL from GAF Chemical Corp).
- cross- linked PVP Polyplasdone XL from GAF Chemical Corp.
- Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions.
- Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
- Suitable anionic surfactants include, but are not limited to, those containing carboxyiate, sulfonate and sulfate ions.
- anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2- ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
- Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
- nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG- 150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG- 1000 cetyl ether, polyoxyethylene fridecyl ether, polypropylene glycol butyl ether, Poloxamer® 401, stearoyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide.
- amphoteric surfactants include sodium N-dodecyl-.beta.-alanine, sodium N-lauryl-.beta.-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
- the tablets, beads granules or particles may also contain minor amount of nontoxic auxiliary substances such as wetting or emulsifying agents, dyes, pH buffering agents, and preservatives.
- Such methods include, but are not limited to, the following: coating a drug or drug-containing composition with an appropriate coating material, typically although not necessarily incorporating a polymeric material, increasing drug particle size, placing the drug within a matrix, and forming complexes of the drug with a suitable complexing agent.
- the delayed release dosage units may be coated with the delayed release polymer coating using conventional techniques, e.g., using a conventional coating pan, an airless spray technique, fluidized bed coating equipment (with or without a Wurster insert), or the like.
- a conventional coating pan e.g., an airless spray technique, fluidized bed coating equipment (with or without a Wurster insert), or the like.
- Pharmaceutical Dosage Forms Tablets, eds. Lieberman et al. (New York: Marcel Dekker, Inc., 1989), and Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6.sup.th Ed. (Media, PA: Williams & Wilkins, 1995).
- a preferred method for preparing extended release tablets is by compressing a drug-containing blend, e.g., blend of granules, prepared using a direct blend, wet-granulation, or dry-granulation process.
- Extended release tablets may also be molded rather than compressed, starting with a moist material containing a suitable water-soluble lubricant. However, tablets are preferably manufactured using compression rather than molding.
- a preferred method for forming extended release drug-containing blend is to mix drug particles directly with one or more excipients such as diluents (or fillers), binders, disintegrants, lubricants, glidants, and colorants.
- a drug-containing blend may be prepared by using wet-granulation or dry-granulation processes.
- Beads containing the active agent may also be prepared by any one of a number of conventional techniques, typically starting from a fluid dispersion.
- a typical method for preparing drug-containing beads involves dispersing or dissolving the active agent in a coating suspension or solution containing pharmaceutical excipients such as polyvinylpyrrolidone, methylcellulose, talc, metallic stearates, silicone dioxide, plasticizers or the like.
- the admixture is used to coat a bead core such as a sugar sphere (or so-called "non-pareil”) having a size of approximately 60 to 20 mesh.
- An alternative procedure for preparing drug beads is by blending drug with one or more pharmaceutically acceptable excipients, such as microcrystalline cellulose, lactose, cellulose, polyvinyl pyrrolidone, talc, magnesium stearate, a disintegrant, etc., extruding the blend, spheronizing the extrudate, drying and optionally coating to form the immediate release beads.
- excipients such as microcrystalline cellulose, lactose, cellulose, polyvinyl pyrrolidone, talc, magnesium stearate, a disintegrant, etc.
- the particles can include excipients such as a sugar, such as lactose, a protein, such as albumin, and/or a surfactant.
- excipients such as a sugar, such as lactose, a protein, such as albumin, and/or a surfactant.
- compositions are generally formulated for oral delivery.
- Solid dosage forms are described generally in Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co. Easton Pa. 18042) at Chapter 89.
- Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes.
- Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present active compounds and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712.
- compositions may be prepared in liquid form, or may be in dried powder (e.g., lyophilized) form.
- Liposomal or proteinoid encapsulation may be used to formulate the compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673).
- Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556). See also Marshall, K. In: Modern Pharmaceutics Edited by G. S. Banker and C. T. Rhodes Chapter 10, 1979.
- liquid dosage forms for oral administration including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.
- pharmaceutically acceptable emulsions, solutions, suspensions, and syrups which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.
- compositions can be chemically modified so that oral delivery of the derivative is efficacious.
- the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of degradation; and (b) uptake into the blood stream from the stomach or intestine.
- PEGylation is a preferred chemical modification for pharmaceutical usage.
- moieties that can be used include: propylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, polyproline, poly-l,3-dioxolane and poly- 1,3,6- tioxocane (see, e.g., Abuchowski and Davis (1981) "Soluble Polymer- Enzyme Adducts," in Enzymes as Drugs. Hocenberg and Roberts, eds. (Wiley-Interscience: New York, N.Y.) pp. 367-383; and Newmark, et al. (1982) J. Appl. Biochem. 4:185-189).
- the microorganisms are encapsulated by extrusion, emulsion, and spray drying.
- microorganisms are entrapped in the gel matrix using different gel forming mechanisms (Champagene CP et al, Functional Dairy Products, 2:404-426, (2007)).
- the encapsulating conditions are designed to maintain cell viability, and solvents involved in the encapsulation technology must be nontoxic. The ability of microorganisms to survive and multiply in the host strongly influences their probiotic benefits.
- Microencapsulation techniques are achieved by encapsulation process or drying process.
- the encapsulation of the disclosed microorganisms is done by extrusion technique (King AH et al.,
- Extrusion method in the case of alginate capsule consists of the following stages: preparation of hydrocolloid solution and the addition of probiotic cell in hydrocolloid solution to form cell suspension. These cells suspension is passed through the syringe needle to form droplets which are directly dripped into the hardening solution containing cations like calcium.
- alginate polymers surround the core to form a three- dimensional lattice structure by cross-linking calcium ions (Kailasapathy K, CAB Reviews, 4(6) 1-19, (2009)), thereby entrapping the core material separated from liquid bath and is dried using a suitable technology.
- alginate Formation of gel by alginate solution (0.6%) would be possible if calcium ion (0.3 M) is present.
- alginate is used in the range of 1-2% and 0.005-1.5 M calcium chloride concentration.
- the diameter of forming beads in this method (2-5 mm) is larger than those formed in the emulsion method. Bead diameter is affected by concentration and viscosity of alginate solution and distance between the syringe and hardening solution, and diameter of extruder orifice affects the size of bead. Bead diameter decreases along with increasing concentration and viscosity of the encapsulation solution.
- alginate solution is dripped into the hardening batch containing calcium chloride and Chitosan. Soaking of alginate beads in the Chitosan solution (0.1%, pH 6.5) for 20 min gives rise to beads with good properties.
- the encapsulation of the disclosed microorganisms is carried out by emulsion technique, as demonstrated in the microencapsulation of lactic acid bacteria (Audet P et ah, Applied
- the encapsulation of the disclosed microorganisms is done by emulsification and ionic gelification.
- Emulsification is a chemical technique to encapsulate probiotic using alginate, carrageenan and pectin as an encapsulating material.
- water in oil (W/O) emulsion water soluble polymer becomes insoluble after addition of ions of calcium chloride, by means of cross-linking forming gel particles in the oil phase.
- the smallest particle of the aqueous phase in W/O phase emulsion will lead to the formation of beads with smaller diameters. Agitation rate and type of emulsifier also affects the diameter of the beads.
- Microbeads produced by this technique are recovered by membrane filtration technology (Krasaekoopt W et al., International Dairy Journal, 13(1), 3-13, 2003).
- the encapsulation of the microorganisms is carried out by emulsification and enzymatic gelification.
- Milk protein is used to encapsulate probiotics by means of an enzyme-induced gelation
- Milk proteins have excellent gelation properties and are a natural vehicle for probiotics.
- This method gives water insoluble and spherical particles.
- This method is an example of encapsulation by means of rennet gelation, which is based on the principle of using daily proteins which have been put in contact with rennet at low temperature. This allows keeping a liquid system where ⁇ - casein is cleaved by the enzyme. After that, dairy proteins are emulsified in a cold oil to form water in oil emulsion. Thermal induction of enzymatic coagulation allows protein flocculation and provides microparticles.
- the encapsulation of the disclosed microorganisms is carried out by emulsification and interfacial
- the process of making the novel compositions is similar to the polymer capsule preparation using immobilized particles described by Richardson JJ et al (Richardson JJ et al, Adv Mater. 25(47):6874-8(2013)).
- Drying improves stability of the encapsulated culture during prolonged storage. But the drying process causes some injuries to the microbeads, release of some cells, and reducing the viability of cells. Spray drying, freeze drying, and fluidized bed drying are used for the making of the current inventive compositions.
- the encapsulation of the disclosed microorganisms is carried out by spray drying.
- a solution containing probiotic living cells and the dissolved polymer matrix is prepared by using gum Arabic and starches because they tend to form a spherical microparticle during the drying process (de Vos P et al., International Dairy Journal, 20(4):292-302 (2010)).
- probiotic cell loses viability due to physical injury to microencapsulate and heat generation.
- the loss of probiotic cell can be reduced by using proper cryoprotectant during freeze drying, optimizing the inlet and outlet temperature for spray drying (Champagene CP et al., Functional Dairy Products, 2:404-426 (2007)).
- the encapsulation of the disclosed microorganisms is carried out by freeze drying.
- the solvent is frozen and removed via sublimation (Pikal MJ, PharmTech International, 1 :37-43 (1991)). Freezing causes damage to the cell membrane due to ice crystal formation and also imparts stress condition by high osmolarity. It has been traditionally used to stabilize probiotic bacteria, but the combination of freeze-drying and encapsulation is relatively new concept.
- Lactobacillus F19 and Bifidobacterium Bbl2 cells were first encapsulated into enzymatically gelled sodium caseinate, and gel particles were freeze- dried to study the storage stability (Heideback T et al, Journal of Food Engineering, 98(3): 309-316 (2010)). They reported better post-drying survival and storage viability for encapsulated cell compared to free cell.
- gelatinized starch and lecithin were incorporated into the alginate microcapsule containing probiotic organisms in encapsulated form, and beads were freeze-dried to evaluate the storage stability at different temperature. It was shown that encapsulated bacteria had much better stability at 23°C for 12 weeks, and lecithin helped in obtaining higher efficiency and more stability (Donthidi AR, et al., Journal of
- the encapsulation of the disclosed microorganisms is carried out by fluidized bed drying.
- cell suspension is sprayed and dried on inert carriers using a Wurster-based fluidized bed system (Huyghebaert N et al. European Journal of
- the encapsulation of the disclosed microorganisms is carried out by vacuum drying.
- Vacuum drying is suitable for heat sensitive probiotics because drying takes place at lower temperatures, and oxidation reaction can also be minimized, while disadvantage is batch operation and longer drying time which can be minimized by using a continuous vacuum dryer where cost is one-third of a freeze diyer, and the material can be dried at 1-4% moisture level at 40°C within 5-10 min (Hayashi H et al, Drying Technology, l(2):75-284, (1983)).
- spray freeze drying is sued to encapsulate.
- the probiotic cell solution is atomized into a cold vapor phase of a cryogenic liquid such as liquid nitrogen, which generates a dispersion of frozen droplets. These are dried in freeze dryer (Kailasapathy K, CAB Reviews, 4(6) 1-19, (2009)).
- the following microencapsulation techniques are used for making the formulation: a microencapsulation technique known as Probiocap (US Patent Publication No. 20030109025).
- Probiocap US Patent Publication No. 20030109025.
- the process is based on coating freeze-dried Lactobacillus with fatty acids. This technology allows strains to resist the harsh effect of temperature, gastric acidity, and compression.
- Danish-Korean Company patented a duel coating technology for Lactobacillus, which is marketed under the brand name Duaolac®.
- the first layer of coating is made of soy peptide
- the second layer is made of cellulose and gum.
- microencapsulated microorganisms are provided.
- compositions for enhancing gut microbiota can be administered in a number of ways depending on the conditions to be treated.
- the methods for administering the disclosed compositions are essentially the same, whether for prevention or treatment.
- the disclosed compositions are included in dairy products such as yogurt, mayonnaise, cheese, kefir, cream and ice cream. In some embodiments, the disclosed compositions are included in products such as lactic acid, frozen dessert, tea, coffee, soda drinks, energy drink, breakfast cereal and snack bars.
- the composition can be administered during a period before, during, or after onset of disease symptoms, or any combination of periods before, during or after onset of one or more disease symptoms.
- the subject can be administered one or more doses of the composition every 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48 days prior to onset of disease symptoms.
- the subject can be administered one or more doses of the composition every 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48 days after the onset of disease symptoms.
- the multiple doses of the compositions are administered before an improvement in disease condition is evident.
- the subject receives 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48, over a period of 1, 2, 3, 4, 5, 6 7, 14, 21, 28, 35, or 48 days or weeks before an improvement in the disease condition is evident.
- compositions can be administered alone, or in combination with a second active agent, as part of therapeutic regime for disease treatment.
- the composition can be administered on the first, second, third, or fourth day, or combinations thereof.
- the composition can be
- Disease states may exhibit either the presence of a novel microbe(s), absence of a normal microbe(s), or an alteration in the proportion of microbes.
- Segmented Filamentous Bacteria have been shown to play a critical role in prevention of infection and development of autoimmune diseases (Ivanov et al, Cell. 139(3):485-98, 2009).
- autoimmune diseases Ivanov et al, Cell. 139(3):485-98, 2009.
- a role for the indigenous microbiota in health and disease has been suggested in both infectious and noninfectious diseases and disorders, such as atopic dermatitis, eczema, rosacea, psoriasis, and acne (Holland et al. 1977 Br J Dermatol. 96(6):623-6; Thomsen et al. 1980 Arch. Dermatol. 116:1031- 1034; Till et al. 2000 Br. J. Dermatol.
- Bacterial vaginosis is caused by an imbalance of the naturally occurring vaginal microbiota. While the normal vaginal microbiota is dominated by Lactobacillus, in grade 2 (intermediate) bacterial vaginosis, Gardnerella and Mobiluncus spp. are also present, in addition to Lactobacilli. In grade 3 (bacterial vaginosis), Gardnerella and Mobiluncus spp. predominate, and Lactobacilli are few or absent (Hay et al., Br. Med. J., 308, 295-298, 1994)
- Parkinson's disease Alzheimer's disease, muscular dystrophy, fibromyalgia and cystic fibrosis.
- Some evidence also suggests the link between commensal gut microbiota and the central nervous system.
- Bravo et al showed that ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve (Bravo et al, Proc Natl Acad Sci USA. 108(38): 16050-5(2011)).
- the inhibition and treatment of the enteric pathogen diseases is accomplished by the probiotic composition through a competitive binding process.
- Probiotic bacteria Lactobacillus fermentum and Bifidobacterium lactis, appears to inhibit permeability caused by gliadin and therefore to reduce gliadin-induced cellular damage. Probiotic bacteria may reduce the damage caused by eating gluten-contaminated foods and may even accelerate mucosal healing after the initiation of a gluten-free diet (Lindfors K et al., Clin Exp Immunol. 152(3):552-8 (2008)). Lactobacillus fermentum and Bifidobacterium lactis are exemplary probiotic bacteria as a potential treatment for Celiac disease and gluten intolerance.
- the disclosed compositions are given to subjects with altered or non-optimal gut microbiota such as following a course of medical treatment that damages the healthy commensal microbiota.
- the compositions are given to subjects following a course of antibiotic treatment.
- the compositions are given to a subject following chemotherapy.
- compositions are given to babies or children after a course of antibiotics for ear infections or yeast infections. In some embodiments, the compositions are given to premature babies for populating their gut commensal microbiome.
- the compositions are for transferring vaginal microbial communities to confer stability and resistance to bacterial vaginosis (BV).
- the microbial populations are preferably obtained from women with Lactobacillus crispatus-dom ated (>50%) vaginal microbiota, who are healthy, free of sexually transmitted disease, and have a low pH in the secretions.
- the encapsulated microbial populations are administered to women with BV, as identified clinically with Amsel's criteria, and confirmed in the laboratory by Nugent scoring.
- the disease or disorder that can be prevented or treated by the disclosed methods and compositions are intestinal diseases and disorders, such as gastroenteritis and irritable bowel syndrome (IBS).
- IBS is characterized by symptoms such as abdominal cramp, discomfort, bloating and inflammation of the colon, rectum, and/or the distal small intestine.
- symptoms such as abdominal cramp, discomfort, bloating and inflammation of the colon, rectum, and/or the distal small intestine.
- exemplary diseases and disorders of the GI tract include diarrhea, dysentery, cholera, hemorrhagic colitis, peptic ulcer disease, gastritis, and enteric fever (e.g., typhoid fever).
- Exemplary invasive enteric bacteria strains that cause diseases and disorders of the GI tract include Salmonella spp (e.g., S. choleraesuis, S. paratyphi A, S. schottmuelleri and S. hirschfeldii), Shigella spy,
- Campylobacter sp . e.g., C. fetus, C. upsaliensis, C. lari, C. jejuni
- enterohepatic Helicobacter species e.g., H. cineadi, H. fennelliae
- Vibrio spp. Clostridium spp. (e.g., C. difficile)
- Pseudomonas spp. Enterobacter spp.
- Arcobacter spp. Yersinia spp.
- viruses that cause diseases and disorders of the GI tract include strains of adenoviruses, hepatitis E virus, astroviruses, noroviruses and other caliciviruses, reoviruses and rotaviruses.
- pH-responsive, mucoadhesive polymeric encapsulated compositions can also be administered to any animal in need of thereof including. Most common uses are in animals treated with antibiotics such as cats, dogs, horses and ruminants (sheep, cattle, goats, deer, llama) or newborns that did not get adequate colostrum and/or nurse their dams.
- the compositions e.g. containing probiotic can be used to inhibit or treat enteric pathogen-associated diseases when administered to an animal in need thereof using the methods described in the present specification.
- Enteric pathogen diseases include those diseases caused by pathogens such as diarrhea, irritable bowel syndrome and intestinal hemorrhages.
- enteric pathogens associated with these diseases include, but not limited to enteropathogenic Escherichia coli (EPEC), enterotoxigeneic E. coli (ETEC), Salmonella enteriditis, Yersina pseudotuberculosis and Listeria monocytogenes.
- the inhibition and treatment of the enteric pathogen diseases is accomplished by the probiotic composition through a competitive binding process.
- the probiotic lactohacilli compete with enteric pathogens for binding sites on the intestinal mucosa. Because the probiotic lactobacilli have a higher affinity and avidity for these binding sites than the enteric pathogens, the probiotic lactobacilli displace the enteric pathogens into the intestinal milieu where they are harmlessly flushed from the intestines by normal metabolic processes.
- this above described competitive binding and its efficacy in inhibiting and treating enteric pathogen diseases is provided in detailed examples below and in the accompanying figures.
- the compositions of encapsulated microorganisms are administered to a subject in a therapeutically effective amount.
- effective amount or “therapeutically effective amount” means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect.
- the precise dosage will vary according to a variety of factors such as subject-dependent variables ⁇ e.g., age, immune system health, etc), the disease or disorder, and the treatment being effected, the number of times daily and number of days or weeks of treatment, and whether the probiotics are administered concurrently with antibiotics.
- the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired.
- dosage levels are between 1-100 million colony forming units for human with a healthy digestive tract.
- the dosage level is about 1-100 billion colony forming units.
- the amount of encapsulated agents is effective to prevent or reduce the infection or onset of a disease or disorder in a subject compared to an untreated control.
- the encapsulated agents are in an amount effective to promote and encourage healthy commensal microbiota and decrease the amount of inflammation, pain or other symptoms associated with a disease or disorder in a subject.
- the effective amount of encapsulated agents does not induce significant cytotoxicity in the GI tract of a subject compared to an untreated control subject.
- the dosage levels for dogs and cats are about
- an animal is provided with a single dose containing from approximately 10 5 to 10 11 CFU of probiotic bacteria e.g. lactobacilli per gram of probiotic composition.
- the total amount consumed will depend on the individual needs of the animal and the weight and size of the animal.
- the preferred dosage for any given application can be easily determined by titration. Titration is accomplished by preparing a series of standard weight doses each containing from approximately 10 3 to 10 11 lactobacilli per gram. A series of doses are administered beginning at 0.5 grams and continuing up to a logical endpoint determined by the size of the animal and the dose form. The appropriate dose is reached when the minimal amount of lactobacilli composition required to achieve the desired results is administered.
- the appropriate dose is also known to those skilled in the ait as an "effective amount" of the pH-responsive, mucoadhesive polymeric encapsulated compositions.
- one measured dose as described above is administered daily, escalating the dose each successive day in 0.5 grams increments until symptoms subside.
- the preferred dose is between approximately 10 3 to 10 8 viable lactobacilli per kilogram of body weight (the weight of animal recipient) per day. This equates to approximately 10 billion viable Lactobacillus casei strain KE01 per day for the average healthy adult human.
- it is a simple matter to calculate the approximate dose appropriate for any animat of any weight It is understood that this is a non-limiting example that can be varied as appropriate by persons having skill in the art of prescribing probiotic compositions or by using the titration method provided above.
- pH-responsive, mucoadhesive polymeric encapsulated agent can be compared to a control.
- Suitable controls are known in the art and include, for example, an untreated subject.
- the control is untreated tissue from the subject that is treated, or from an untreated subject.
- an untreated control subject suffers from, or is at risk from the same disease or condition as the treated subject e.g. Crohn's disease.
- compositions for delivering encapsulated agent can be administered alone, or in combination with one or more additional active agent(s), as part of a therapeutic or prophylactic treatment regime.
- the pH-responsive, mucoadhesive polymeric encapsulated agent can be administered on the same day, or a different day than the second active agent.
- compositions including encapsulated agents can be administered on the first, second, third, or fourth day, or combinations thereof.
- the term “combination” or “combined” is used to refer to either concomitant, simultaneous, or sequential administration of two or more agents. Therefore, the combinations can be administered either concomitantly (e.g., as an admixture), separately but simultaneously (e.g., via separate intravenous lines into the same subject), or sequentially (e.g., one of the compounds or agents is given first followed by the second).
- the additional therapeutic agents can be administered locally or systemically to the subject, or coated or incorporated onto, or into a device.
- the additional agent or agents can modulate the local gut environment.
- the additional agent can act systemically in the host such as for relieving signs and symptoms related to the disease and conditions to be treated.
- Some non-limiting examples include anti-diarrheal medications, pain relievers, iron supplements, vitamin B-12 shots, calcium and vitamin D supplements and other supplemental nutrition given as enteral nutrition or parenteral nutrition.
- the additional agent could be antiinflammatory drugs such as aminosalicylates and corticosteroids.
- the additional agent could be immune suppressors such as azathioprine (Azasan, Imuran), mercaptopurine (Purinethol, Purixan), cyclosporine (Gengraf, Neoral, Sandimmune), infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), methotrexate (Rheumatrex), natalizumab (Tysabri), vedolizumab (Entyvio) and Ustekinumab (Stelara).
- the additional agent could be antibiotics such as Metronidazole (Flagyl) and Ciprofloxacin (Cipro).
- Example 1 Layer-by-Layer templating of Bacillus coagulans
- BC Bacillus coagulans
- BC either plain or encapsulated, were grown under shaking conditions (225 RPM) at 37°C using an I NOVA®44 incubating shaker. OD600 readings were obtained using a SPECTRAMAX® Plus 384 spectrophotometer with media-only backgrounds subtracted. In the case of pH-responsive growth, media was adjusted to be pH 4.5 for acidic conditions and used as made (pH 7.1) for neutral conditions.
- bacteria were fluorescently labeled with
- VIVOTAG-S® 750 (20 ⁇ of a 10 mg/ml VIVOTAG-S® 750 in DMSO with 5 mg of BC in 980 ⁇ of pH 8.5 210 mM bicarbonate buffer) under rotation at room temperature for 1 hour.
- Glycol chitosan and alginate (Sigma) were prepared as 2 mg/ml solutions in 0.5 M NaCl.
- EPO and L100 were prepared at 2 mg/ml in 0.5 M NaCl.
- the pH of chitosan and alginate solutions was 6.0 and 1 molar HCl and/or 1 molar NaOH were used to adjust pH as needed.
- EPO and LI 00 were prepared in 0.5 M NaCl by first dissolving EPO in pH 2 NaCl and L100 in pH 9 NaCl and titrating to a final pH of 6.0 NaCl for each. 5 mg/ml of bacteria were first suspended in 0.5 M NaCl and washed twice.
- Cationic polymers e.g.
- EPO or chitosan were first layered on plain bacteria using 1 ml of 2 mg/ml polymer solution as described above, for 30 minutes at room temperature. Bacteria were then washed 2x in 0.5 M NaCl and then coated identically with anionic polymers (e.g. LI 00 or alginate) for 30 minutes at room temperature. This process was repeated as necessary to synthesize LbL-probiotics of up to 3 bilayers (6 total layers).
- a Malvern zeta sizer was used to measure zeta potentials in either pH 1 or pH 7 pure water. Fluorescent chitosan and alginate polymers (PEGWorks) were coated identically to methods described above. A Tecan plate reader was used to measure fluorescent signals of the supernatant or templated probiotics in PBS, SIF, or SGF. A Carl Zeiss Axiovert 200M was used for taking brightfield images of probiotics and LbL-probiotics.
- Figure 1 illustrates a schematic presentation of Layer-by-Layer (LbL) templating of individual bacteria.
- a probiotic strain such as Bacillus coagulans can be templated with different polyelectrolytes, including polysaccharides chitosan, alginate and enteric pH responsive polymers such as EUDRAGIT® EPO and LI 00.
- CHI chitosan
- AAG alginate
- BC model probiotic Bacillus coagulans
- Example 2 Layer stability in simulated intestinal fluid and simulated gastric fluid
- Example 3 Layer-by-Layer templating protects encapsulated probiotics against biological insults
- Bacillus coagulans were subjected to either 4% bile salt solution (Sigma) or SGF (Bicca) in a water bath at 37C for up to 2 hours. After 2 hours, bacteria were pelleted at 3000g and resuspended and washed twice in PBS. Bacteria were plated in sequential dilutions of ten and allowed to grow for at least 48 hours at 37C, and counted as described in
- LbL-probiotics resisted acid and bile salt insults.
- Non-modified Bacillus coagulans exhibited rapid decrease in viability (colony forming units) in both simulated gastric fluid (SGF) and 4 % bile salts ( Figures 4A- 4B).
- 2-bilayers of chitosan and alginate protected against biological insults.
- LbL-coating of (CHI/ALG)2 provided protection to Bacillus coagulans against SGF and bile salts ( Figures 4C).
- LbL-formulated (CHI/ALG) 2 Bacillus coagidans were protected against both acidic and bile salt insults at 37C for at least 2 hours.
- Figure 4C shows the sequential LbL coating of cationic chitosan and anionic alginate on a model gram positive probiotic, Bacillus coagulans, facilitated over 6 orders of magnitude increase in survival in simulated gastric fluid and over 5 orders of magnitude increase in survival in bile salts, as compared to uncoated, non-layered Bacillus coagulans.
- Example 4 Layer-by-Layer enhances mucoadhesive capabilities of encapsulated probiotics
- Mucoadhesive LbL coating of (CHI/ALG)2 provided a 1.5-fold enhancement in mucoadhesion to ex vivo pig small intestine (Figure 5A).
- the 2-bilayer coating clearly enhanced mucoadhesive capabilities over non- formulated bacteria.
- Enteric polymer (EPO or LI 00) coated probiotics were subjected to pH treatments using either SGF or SIF for 1 hour at 37°C. Zeta potential measurements were taken at each layer coating and also following pH treatment. Results
- LbL-probiotics were constructed from enteric and FDA-approved pH responsive polymers such as EUDRAGIT® EPO for stimuli-responsive layer removal in specific areas of the GI tract ( Figures 6A and 6B).
- EUDRAGIT® EPO enteric and FDA-approved pH responsive polymers
- EUDRAGIT® LI 00 was included as the terminal layer, exposure to neutral solutions facilitated removal of LI 00, whereas continued exposure to acidic conditions did not.
- LbL-probiotics can be constructed from pH-responsive polymers for stimuli-responsive layer removal in specific areas of the GI tract. pH-responsive layer release can be integrated into LbL-probiotics via terminal coatings of enteric EPO and LI 00 EUDRAGIT® polymers. This offers a general approach to ensure stability and survival of bacteria/probiotics through the stomach for pH-mediated delivery and growth at the intestines or colon.
- a layer-by-layer (LbL) method for the single encapsulation of bacteria cells to directly modulate the microbiome can be achieved by: (i) protecting LbL-bacteria from harsh stomach conditions to circumvent acid- or bile salt-mediated bacteria death, (ii) facilitating mucoadhesion via inclusion of mucoadhesive polysaccharides (e.g. chitosan) in the terminal layer, and (iii) controlling layer release via pH sensitive polymers so as to facilitate growth in pH-regulated areas of GI tract.
- mucoadhesive polysaccharides e.g. chitosan
- Example 6 Number of bilayer modulates bacterial growth
- Figure 7 shows thaj as bilayer number increased from 0 to 3, growth rates of bacteria reduced accordingly. Therefore, the layer of bilayers can be designed as a way to modulate bacterial growth.
- LbL templating can be used to protect probiotics from harsh stomach conditions, to directly facilitate rnucoadhesion and control layer release via pH sensitive polymers. Furthermore, LbL templating can be used as a way to control rate and overall growth of bacteria. This technology offers a platform based approach to ensure stability and survival of probiotics through the stomach for pH- mediated delivery to, and growth in the intestines and colon.
- Example 7 pH-responsive polymeric encapsulation of multiple probiotic bacteria
- PH-responsive polymers such as EUDRAGIT® LI 00 can be used to encapsulate multiple bacteria within the same polymeric particle.
- the probiotic bacteria Bacillus coagulans (BC) were encapsulated in LI 00 at various probiotics :polymers ratios. Encapsulations with L100 lead to enhancement of probiotic survival following acidic insults. Subsequent exposure to neutral SIF conditions, under which the encapsulating LI 00 polymers dissolve, gave rise to a significant enhancement in the survival of encapsulated BC after acidic insults. In contrast, BC could not survive acidic conditions when the same mass of BC was first exposed to neutral SIF, followed by exposure to acidic SGF.
- the example demonstrates that the same polymer coating technique is applicable to encapsulate multiple microorganisms to be delivered to specific sites within the GI tract.
- Example 8 pH-responsive polymeric encapsulation of probiotic bacteria affects bacterial growth in conditions with neutral or acidic pH
- Figures 9A and 9B demonstrate the growth rate of the LbL-probiotics grown at different pH conditions.
- L100 is the terminal layer (closed circles)
- EPO is the terminal layer (open diamonds)
- exposure to neutral conditions prevents bacteria growth ( Figure 9A).
- EPO is the terminal layer (open diamonds)
- exposure to acidic conditions facilitates bacteria growth; however, when LI 00 is the terminal layer (closed circles), exposure to acidic conditions prevents bacteria growth ( Figure 9B).
- Example 9 LbL coating significantly enhances probiotic bacterial growth in a three-dimensional intestinal tissue model.
- EpilntestinalTM tissues were purchased from MatTek and used as recommended under antibiotic free conditions.
- Intestine-mimicking tissues from humans were used to compare the growth of plain and LbL-probiotics on live mammalian intestine tissues.
- the EpilntestinalTM system is an intestinal model proven to recreate physiological intestine structures (Jirova et al., International Conference on Chemical, Civil and Environmental
- Bioluminescent plain and (CHI/ALG) 2 LbL-probiotics were placed in direct contact with EpilntestinalTM tissue for 1 hour, washed, imaged, and analyzed for total emitted radiance to track and compare their adhesion and growth kinetics (Figure 10A, 10B). Since unbound BC would pass through the GI tract in physiological situations, unbound BC were washed from the EpilntestinalTM surface at each timepoint.
- the LbL-probiotic bacteria showed significantly faster growth at 1, 2, and 6 hours after plating when compared to the growth of plain bacteria (Figure 10A). Fold-enhancement of LbL-probiotics' growth over that of plain, uncoated, probiotics at each timepoint is shown in Figure 10B.
- the LbL coating enhanced the growth rate of (CHI/ALG) 2 -coated LbL-probiotics by more than two-fold at these time points.
- Example 10 LbL coating significantly enhances probiotic bacterial delivery to the to the GI tract.
- LbL-coatings were investigated using freshly isolated pig intestines and intestine-mimicking tissues from humans. After 1 hour incubation at 37°C and subsequent washes, (CHI/ALG)2 LbL-probiotics adhered to the mucosal surface of freshly isolated pig intestine nearly 1.5- fold higher as compared to plain-probiotics ( Figure 1 IB). LbL coatings enhanced mucoadhesion to pig intestine at 1 hour.
- Example 11 Encapsulation of Type II oral poliovirus
- Figure 9 shows the survival of OPV after 4 days at 37°C with a normalizing control of identical Type II OPV from a fresh stock. MgCl 2 .6H 2 0 was used as a comparison with standard salt buffer.
Abstract
Methods of encapsulating microorganisms, or components thereof, for targeted enteric delivery to an animal host have been developed. In particular, the encapsulation provides a prolonged survival, extended retention and a pH-sensitive release of the encapsulated microorganisms or antigenic components thereof at targeted sites within the gastrointestinal tract. The formulations are useful for diagnostic, therapeutic and prophylactic purposes and can alter a host's microbial composition associated with a condition or a disease state.
Description
PH-RESPONSrVE MUCOADHESIVE POLYMERIC
ENCAPSULATED MICROORGANISMS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit of U.S. Provisional Application No.
62/267,121, filed December 14, 2015 and U.S. Provisional Application No. 62/333,570, filed May 9, 2016, which are hereby incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
The invention relates generally to microencapsulation delivery systems and in particular to the enhancement of site-specific delivery of microorganisms within the gastrointestinal tract to treat or prevent diseases and/or conditions.
BACKGROUND OF THE INVENTION
The gastrointestinal (GI) microbiome has been widely investigated for its role in many diseases, ranging from diabetes to depression to cancer. The roles of specific GI microorganisms in regulation and progression of these diseases have recently been defined and described, and as such, efforts to modulate the microbiome (e.g., decreasing disease-causing bacterial populations and increasing probiotic populations) are of particular interest. Unfortunately, technologies facilitating the controlled and direct modulation of the GI microbiome are lacking, mostly due to the challenges arising from the delivery of microbes through the stomach (e.g., low pH and high bile salt concentration) to target areas in the GI tract (e.g., intestines and colon).
WO2009070012 discloses protein-based probiotic encapsulates to enhance the survival of the probiotics. Cook, et al. used a model probiotic, Bifidobacterium breve, encapsulated into an alginate matrix before coating in multilayers of alternating alginate and chitosan (Cook MT et al, J. Mater. Chem. B, 2013,1, 52-60). A significantly improved viability of the probiotics targeted to the intestine was observed when encapsulated.
However, Cook et al encapsulated cell aggregates rather than single cells. Quorum sensing has been implicated where specific gene expressions under
acidic conditions in several probiotics were observed (Koponen J et ah, J. Proteomics 75(4):1357-1374 (2012)).
Furthermore, Cook et al developed the probiotic delivery system mainly to overcome the challenges of survival through the gastric insults of low pH and enzymatic activity. However, these systems have been relatively crude at ensuring delivery to the desired anatomical region. There exists a need for effective compositions to maintain viability of microorganisms following ingestion as well as the abilities to adhere to the target tissue(s) so that its contents will be delivered to targeted tissues as a function of proximity and duration of the contact.
Therefore, it is an objective of the current invention to provide compositions for targeting encapsulated microorganism to a specific site within the GI tract.
It is also an objective of the current invention to provide compositions of encapsulated microorganism with an improved survival and retention.
It is a further objective to control the growth of the microorganism for the intended purpose.
SUMMARY OF THE INVENTION
Compositions and methods of use for preferentially targeting therapeutic, prophylactic or diagnostic microorganisms, or antigenic components thereof, with prolonged survival to select sites within the gastrointestinal tract have been developed. The compositions may also include therapeutic, prophylactic and/or diagnostic agents.
Compositions for selectively targeting microorganisms with prolonged survival include encapsulated single-cell microorganisms, encapsulated in one or more layers of mucoadhesive polymers, coated with an outer layer of pH-responsive polymers. The pH-responsive polymers dissolve at a specific pH or range of pHs. For example, the pH or range of pH can correspond with the local pH of a specific target site which allows the release of the encapsulated microorganism at the site. Further, the layer- by-layer mucoadhesive polymeric coating prolongs viability and enhances
the retention of the encapsulated microorganism so that it will not be eliminated before it has had a chance to exert an effect. In a preferred embodiment, the layer-by-layer encapsulating polymers include one or two bilayers of chitosan and/or alginate, and a pH-responsive polymer outer layer. Exemplary pH-responsive polymers include EUDRAGIT® E PO and EUDRAGIT®L 100.
Methods for targeting the encapsulated microorganisms to specific locations within the GI tract are provided. Generally, the methods include administering single-cell microorganisms encapsulated in one or more layers of mucoadhesive polymers, and further coated with an outer layer of pH- responsive polymers to a subject. In some embodiments the subject is suffering from a condition associated with alteration in the gut microbiota. Such conditions include Crohn's disease, ulcerative colitis, diverticulitis, irritable bowel syndrome, gluten insensitivity, lactose intolerance, obesity, asthma, allergies, metabolic syndrome, diabetes, psoriasis, eczema, rosacea, atopic dermatitis, gastrointestinal reflux disease, cancers of the
gastrointestinal tract, bacterial vaginosis, neurodevelopmental conditions and general lowered immunity following a course of antibiotics or chemotherapy. Typically, an effective dosage is administered in one or more doses, over a time period of once a day, once every other day, once a week, biweekly, etc. until one or more symptoms of the condition or disease status is improved.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic showing layer-by-layer templating of polymeric materials onto a bacterial cell.
Figures 2A-2B are line diagrams showing layer characterization for chitosan (CHI) and alginate (ALG) coatings on model probiotic organism Bacillus coagulans (BC). Figure 2A shows zeta potential for each sequential layer of chitosan and alginate, and for two chitosan and alginate bilayers, (CHI/ALG)2, at pH 1 and 7. Figure 2B shows relative fluorescence of Bacillus coagulans coated with 2, 4 or 6 layers of fluorescent chitosan or alginate.
Figures 3A-3B are graphs showing fold enhancement of polymer release from 2-bilayer templating on Bacillus coagulans over time (hours) in either simulated intestinal fluid (SIF/PBS) or simulated gastric fluid (SGF/PBS) relative to their release in PBS. Figure 3A shows the polymer release kinetics of chitosan from (CHI/ALG)2 coated Bacillus coagulans, and Figure 3B with shows the polymer release kinetics of alginate from
(CHI/ALG)2 coated Bacillus coagulans, with both cases being normalized to neutral PBS conditions.
Figures 4A-4C are bar graphs showing the survival rate of non- formulated Bacillus coagulans (plain) and Layer-by-Layer (LbL) coated
Bacillus coagulans under simulated gastric fluid (SGF) insult or bile insult at 37°C over time of hours. The survival rate is measured in colony forming unit per ml of culture (CFU/ml). Figure 4A shows the survival rate of plain Bacillus coagulans under SGF insult for 30min, lhr and 2hr. Figure 4B shows the survival rate of unmodified Bacillus coagulans under 4% bile insult for each of 30min, lhr and 2hr, respectively. Figure 4C shows the survival rate of plain or LbL-formulated (CHI/ALG)2 Bacillus coagulans in PBS, SGF and 4% bile after 2 hours incubation.
Figure 5 is a bar graph showing mucoadhesive capabilities (measured in total radiant efficiency) of non-formulated Bacillus coagulans (plain), chitosan coated Bacillus coagulans (Chitosan) and 2-bilayers of chitosan and alginate coated Bacillus coagulans (Chitosan/Alginate)2.
Figures 6A-6B are line graphs showing layer characterization for enteric pH-responsive polymers EUDRAGIT® EPO (EPO) and
EUDRAGIT® LI 00 coatings onto the probiotic Bacillus coagulans. (Figure 6A) Zeta potential for non-formulated Bacillus coagulans (BC), BC with sequential layer(s) of EPO and ALG including BC(EPO), BC(EPO/ALG)j and BC(EPO/ALG)i.5 in simulated intestinal fluid (SIF). In addition, zeta potential is also shown for BC(EPO/ALG)i.5 after exposure to simulated gastric fluid (SGF, black circle) or remaining in SIF (open squares and black diamond). (Figure 6B) Zeta potential for non-formulated Bacillus coagulans (BC), BC with sequential layer(s) of LI 00 and chitosan (CHI) including
BC(CHI), BC(CHI/L100)i. In addition, zeta potential is also shown for after exposure to SGF (black diamond) or SIF (open square and black circle).
Figure 7 is a line graph showing growth of bacteria with 0, 1, 2, or 3 bilayers of coating over time (hours) estimated by the absorbance at 600 run (OD 600). (CHI/ALG), (CHI/ALG)2 , and (CHI/ALG)3 on Bacillus coagulans, was used as the layer formulation for 1, 2 and 3 bilayers, respectively. Plain was used to describe 0-bilayer Bacillus coagulans.
Figure 8 is a bar graph showing viability of model probiotics Bacillus coagulans (BC) at different probiotic to EUDRAGIT® LI 00 emulsion ratio. Hatched bars show EUDRAGIT® L 100 microencapsulated BC exposed directly to simulated intestinal fluid (SIF) and then plate counted. Black bars show the same mass of particles first exposed to acidic simulated gastric fluid (SGF) and then to neutral SIF. White bars show the same mass of particles first exposed to neutral SIF, followed by exposure to acidic SGF.
Figures 9A and 9B are line graphs showing the growth (measured in
OD 600) of unencapsulated bacterial cells ("BC") (plain, open squares), pH- responsive polymer encapsulated BC with LI 00 as the terminal layer ((CHI/L 100)3, closed circles), and pH-responsive polymer encapsulated BC with EPO is the terminal layer ((EPO/ALG)3, open diamonds) over time (hours) in neutral pH 7 (Figure 9A) and acidic pH (Figure 9B).
Figure 1 OA is a line graph showing the growth rate (measured in Radiance (p/sec/cm2/sr)xl05) of plain, uncoated, bacteria (closed circles) and (CHI/ALG)2-coated LbL-probiotics over time (hours) in Epilntestinal® 3D tissue model at 37°C (* p < 0.05). Figure 10B is a line graph showing the fold-enhancement of LbL-probiotics' growth over that of plain, uncoated, probiotics at each time point.
Figure 11A is a bar graph showing fold signal increase over background of bioluminescent plain (hatched bar) and LbL-(CHI/ALG)2- encapsulated (black bar) BC bound to mouse GI tract. Fold-signal increase between plain and LbL Be 1 hour after oral gavage of an identical number of BC showed statistical difference. Error bars represent standard deviation (n = 4), (*P < 0.05) using Student's t-test between plain and LbL groups. Figure
1 IB is a bar graph showing total radiant efficiency as measured by IVIS of plain (hatched) and LbL (black) BC at 1 hour following mucoadhesion to pig intestine. Error bars represent standard deviation (n = 3). * denotes statistical difference (P < 0.05) using Student's t-test between plain and LbL groups.
Figure 12 is a bar graph showing the recovery of Type II oral polio virus (OPV) after 4 days at 37°C when encapsulated in a single layer of EPO, a single layer of Glycol Chitosan, or a single layer of 50:50 mixture of EPO and glycol chitosan compared to a standard salt buffer of Μ¾θ2.6¾0.
DETAILED DESCRIPTION OF THE INVENTION
An optimal controlled release system designed to administer beneficial microorganisms in specific areas of the gastrointestinal tract requires three critical areas of consideration: (1) protecting the beneficial microorganisms from harsh conditions such as stomach acid or bile salt to enhance their survival; (2) facilitating mucoadhesion to the lining of the appropriate viscus so that the probiotic microorganisms will not be entrained beyond the desired site of action and eliminated before it has had a chance to exert a topical effect; and (3) controlling release, for example via pH sensitive polymers so as to facilitate growth in pH-regulated areas of the GI tract.
Cell encapsulation technology has the potential to protect microorganisms and to deliver them into the gut. However, there are still many challenges to overcome with respect to the microencapsulation process and the conditions prevailing in the gut. Single cell encapsulation offers advantages such as increasing surface area for attachment at target sites as well as avoiding quorum sensing which could have negative effects on the encapsulated cells.
I. Definitions
The term "mucoadhesive" is a property of a material (e.g. a polymer or a protein) that has the ability to adhere to mucosal membranes in the aqueous environment of the gastrointestinal tract.
The term "enteric" refers to a polymer/protein coating on bacteria that facilitates safe transit (e.g. avoiding acidic or bile salt mediated death)
tlirough stomach for delivery to the small intestine and/or the colon. This can be tested by subjecting different coating formulations against specific biological insults. For example, incubating coated bacteria in acidic or bile- salt solutions at 37°C and compaiing their survival to non-coated bacteria, either by direct counting or colorimetric methods. The result will capture the enteric potential of the coating formulation.
The term "pH responsive" generally refers to a polymer/protein coating that degrades or dissolves in response to changes in the pH of its immediate surrounding. Of particular interest are coatings that are stable in acidic conditions (pH < 5), but degrade in neutral conditions (pH > 7) since these coatings will facilitate stability in the stomach and dissolve in the small intestines and/or colon. This can be tested by subjecting different coating formulations to solutions of vaiying pHs. Confirmation of layer removal can be performed by testing for surface charges (if the coated polymers are of opposite or distinct charge) or by testing the solution for labeled (e.g.
fluorescent or radiolabeled) polymer that had been removed due to changes in the pH.
The terms "microbiome" or "microbiota" are used interchangeably, and refer to collectively, to the entirety of microbes found in association with a higher organism, such as a human. Organisms belonging to a human's microbiota may generally be categorized as bacteria, archaea, yeasts, and single-celled eukaryotes, as wells as various viruses and parasites such as Helminths.
The term "probiotic" utilizes the World Health Organization's 2001 definition of "live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host". Probiotics must be alive when administered, have viability and reproducibility based on in vivo results, and during use and storage.
The terms "biocompatible" and "biologically compatible" generally refer to materials that are, along with any metabolites or degradation products thereof, generally non-toxic to the recipient, and do not cause any significant adverse effects to the recipient. Generally speaking,
biocompatible materials are materials which do not elicit a significant inflammatory or immune response when administered to a patient.
The term "biodegradable", generally refers to a polymer that will degrade or erode by enzymatic action and/or hydrolysis under physiologic conditions to smaller units or chemical species that are capable of being metabolized, eliminated, or excreted by the subject. The degradation time is a function of polymer composition, morphology, such as porosity, particle dimensions, and environment.
The term "effective amount" or "therapeutically effective amount" means a dosage sufficient to alleviate one or more symptom of the disease or disorder state being treated or to otherwise provide a desired pharmacologic and/or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected.
The terms "treat", "treatment" and "treating" refer to the reduction or amelioration of the progression, severity and/or duration of a disease or disorder, delay of the onset of a disease or disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of a disease or disorder, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents). The terms "treat",
"treatment" and "treating" also encompass the reduction of the risk of developing a disease or disorder, and the delay or inhibition of the recurrence of a disease or disorder.
The term "enteral administration" means administration via absorption through the gastrointestinal tract. Enteral administration can include oral and sublingual administration, gastric administration, or rectal administration.
The terms "enhance", "increase", "stimulate", "promote", "decrease", "inhibit" or "reduce" are used relative to a control. Controls are known in the art. For example, an increase response in a subject or cell treated with a compound is compared to a response in subject or cell that is not treated with the compound.
The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" means one or more carrier ingredients approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, mammals, and more particularly in humans. .
The term "in combination" refers to the use of more than one therapeutic agent. The use of the term "in combination" does not restrict the order in which said therapeutic agents are administered to a subject.
II. Compositions
Compositions for preferentially targeting microorganisms with prolonged survival to select sites along the gastrointestinal tract generally include a beneficial microorganism associated encapsulated in one or multilayers of polymer(s). In some embodiments, the compositions are targeted to the small intestine of a subject. In other embodiments, the compositions are targeted to the colon of a subject.
Typically the composition includes encapsulating polymers that resist the physiological conditions present within the mammalian digestive tract, such as gastric acids and bile salts, to enhance the survival of the encapsulated microorganisms. A preferred agent is an organism that is non- pathogenic in humans, such as probiotic bacteria. In a preferred embodiment, the compositions include pH-responsive polymers that adhere and dissolve at targeted site within the GI tract to allow the attachment and proliferation (growth) of the encapsulated organism at the site. In further embodiments, the compositions contain encapsulating polymers that regulate the growth of the probiotic agent at the target site.
In some embodiments, multiple microorganisms are encapsulated within the same polymeric particle. In another embodiment, the encapsulated agents are live attenuated vaccines such as Type II oral poliovirus.
A. Agents to be Encapsulated
Agents to be encapsulated include probiotic microorganisms, such as bacteria and yeast, genetically transformed prokaryotic or eukaryotic cells, as well as viruses.
1. Probiotic Microorganisms
Probiotic is a term that means "for life" and defined as "live microorganisms that beneficially affect the host's health by improving its microbial balance". Lactobacillus and Bifidobacteria are the two most common types of microorganisms which are extensively used as probiotics in humans. Probiotics are different based on the species. For examples, in dogs and cats the most common probiotic organism is Enterococcus faecium. In ruminants, Lactobacillus pentosus WE7 is useful for the prevention and treatment of enteric disease in horses. The use of probiotic bacterial culture stimulates the growth of preferred microorganisms, crowds out potentially harmful bacteria, and reinforces the body's natural defense mechanisms. A non-limiting list of exemplary probiotic microorganisms includes Lactic acid bacteria (LAB), such as Lactobacillus spp., Leuconostoc spp., Pediococcus spp., Lactococcus spp., Bifidobacterium spp. and Streptococcus spp., as well as certain yeasts and bacilli. In young pre-ruminants, probiotics such as LAB or Bacillus species generally target the lower intestine and represent an interesting means to stabilize the gut microbiota and decrease the risk of pathogen colonization. Probiotics for adult ruminants have mainly been selected to improve fiber digestion by rumen microorganisms. Such probiotics have positive effects on various digestive processes, especially cellulolysis and the synthesis of microbial proteins. The main form of probiotic commonly used in dairy cows is various strains of yeast (mostly Saccharomyces cerevisiae). Regarding bacterial probiotics for adult ruminants, lactate-producing bacteria {Enterococcus, Lactobacillus), which sustain lactic acids are a more constant level than Streptococcus bovis, may represent a possible means of limiting acidosis in high-concentrate-fed animals, especially feedlot cattle. Megasphaella elsdenii or
Propionibacterium species, which utilize lactate, have also been
administered as direct fed microbials to avoid the accumulation of ruminal lactate.
Some bacterial strains have been widely discussed in the literature and clinical studies have demonstrated their therapeutic effect in a human subject (Solanki HK, et ah, BiomedRes Int. 2013:620719 (2013)). Examples of probiotic strains and their intended therapeutic applications include Lactobacillus plantarum 299v, Bacillus coagulans ATCC no. 31284, and Lactobacillus acidophilus LI for hypercholesterolemia and cardiovascular disease; Lactobacillus rhamnosus GG for prevention of atopy; Lactobacillus rhamnosus GG, Bifidobacterium lactis, and Lactobacillus paracaseifor eczema; Lactobacillus rhamnosus GG, Bifidobacterium lactis, and
Lactobacillus paracasei for food allergies; Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus johnsonii, Lactobacillus rhamnosus, and Lactobacillus acidophilus for lowered immunity; Lactobacillus rhamnosus GG, Saccharomyces cerevisiae, Lactobacillus acidophilus, and Lactobacillus plantarum 299v for antibiotic use (during and after);
Lactobacillus rhamnosus GG for nonsteroidal anti-inflammatory drug; Lactobacillus rhamnosus GG, Saccharomyces cerevisiae for intestinal hyperpermeability; Lactobacillus rhamnosus GG, Lactobacillus reuteri MM53, Lactobacillus paracasei CRL431, Lactobacillus acidophilus CRL730, Lactobacillus johnsonii Lai, Bifidobacterium lactis Bbl2, Lactobacillus plantarum 299v, and Lactobacillus paracasei for
gastroenteritis; Lactobacillus johnsonii Lai a, Lactobacillus plantarum 299v, and Lactobacillus rhamnosus GG for giardia infection; Lactobacillus rhamnosus GG, Lactobacillus johnsonii Lai, Lactobacillus plantarum 299v, Lactobacillus paracasei, and propionibacterium freudenreichii HA-101 and HA- 102 for intestinal dysbiosis; Lactobacillus acidophilus, Lactobacillus johnsonii Lai for lactose intolerance; Lactobacillus johnsonii Lai,
Lactobacillus acidophilus, and Lactobacillus rhamnosus for GG for peptic ulcer disease & nonerosive gastritis; Lactobacillus plantarum 299v, VSL no. 3β for irritable bowel syndrome; Lactobacillus acidophilus NCFB 1748, VSL no. 3a for radiation- induced diarrhea; Lactobacillus rhamnosus GG,
Bifidobacterium lactis Bbl2, Lactobacillus acidophilus, Saccharomyces • cerevisiae, and Lactobacillus plantarum 299v for traveller's diarrhea;
Lactobacillus rhamnosus GG, Saccharomyces cerevisiae for Crohn's disease; Escherichia coli Nissle 1917, VSL no. 3β, Lactobacillus plantarum 299 for ulcerative colitis; Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus acidophilus, and Lactobacillus delbrueckii ssp. bulgaricus strain LB-51 for prevention of colon cancer; Lactobacillus rhamnosus GR-1, Lactobacillus fermentumB-54, Lactobacillus fermentum RC-14, and Lactobacillus acidophilus for urinary tract infection; Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus GR-1, and Lactobacillus fermentum RC-14 for vaginal candidiasis (thrush).
In some embodiments, the microorganisms to be delivered in a subject for general health or for helping recovery after a course of antibiotics or chemotherapy include Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum, Lactobacillus fermentum, and
Lactobacillus rhamnosus, Streptococcus fhermophiles, Bifidobacterium breve and Bacillus coagula s. Total weight of microbial populations occupying different regions in the digestive tract at different pH is presented in Table 1.
Table 1. Microbial populations in the digestive tract of normal humans.
In some embodiments, the microorganisms to be delivered in a subject for diarrhea treatment are Lactobacillus rhamnosus, Lactobacillus reiiteri, and Saccharomyces boulardii.
In some embodiments, the microorganism to be delivered in a subject for stomach ulcer is Bifidobacterium bifidum.
In some embodiments, the microorganisms to be delivered in a subject for gluten insensitivity include Lactobacillus casei, Lactobacillus fermentum, Lactobacillus parcasei, Lactobacillus bifidus, and
Saccharomyces boulardii.
In some embodiments, the microorganisms to be delivered to preterm babies include Bifidobacterium breve, Saecharaomyces boulardii,
Bifidobacteria infantis, Streptococcus thermophiles, Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus sporogenes, Lactobacillus planatarum, Lactobacillus rhamnosus, and Bifidobacterium lactis.
In some embodiments, the compositions contain probiotics for dogs. Some exemplary microorganisms include Inter ococcus faecium, and Bacillus coagulans for general health; Lactobacillus acidophilus, and Lactobacillus rhamnosus for treating diarrhea. Further non-limiting examples include Bifidobacterium animalis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus fermentum, and
Lactobacillus reuteri.
In some embodiments, the disclose composition contain probiotics for horses. Some exemplary microorganisms include Lactobacillus plantaruin, Enterococcus faecium, Lactobacillus casei, and Lactobacillus acidophilus as well as Saccharomyces boulardii, and Lactobacillus reuteri.
In some embodiments, the disclose composition contain probiotics for cattle. Some exemplary microorganisms include Lactobacillus fermentum, Enterococcus faecium, Lactobacillus acidophilus, and
Lactobacillus casei.
In some embodiments, the disclosed composition contain probiotics for cats. Some exemplary microorganisms include Enterococcus faecium and Lactobacillus acidophilus.
Most probiotic formulations contain a mixture of one or more types of organisms. The bacteria may be in diy or lyophilized form, or sporulated.
2. Transformed or Genetically Engineered
Microorganisms
Typically, the encapsulated microorganisms are live prokaryotic or eukaryotic cells. In some embodiments, the cells are a transformed or modified form of a naturally occurring strain. Methods for transforming cells are known in the art. In other embodiments, the microorganisms are bacterial spores or other senescent forms of the bacteria. When bacterial spores are used, the spores can be dormant spores. In one embodiment the spores are spores of Bacillus subtilis. In other embodiments, the bacteria are attenuated or otherwise non- viable bacteria, such as killed bacteria. In some embodiments the bacteria are selected for a property associated with the genotype or phenotype of the specific genus, strain or sub-strain. Exemplaiy characteristics include antibiotic resistance.
In some embodiments, these probiotic microorganisms are genetically engineered to be resistant to common antibiotics such as penicillins, cephaolsporins, tetracyclines, aminoglycosides, and macrolides. These can be used to complement antibiotic treatment to restore healthy microbiota.
In some embodiments, microorganisms are genetically engineered to include a reporter system. Some exemplary reporter systems include bioluminescent and fluorescent proteins such as green fluorescent proteins from jellyfish. These bacteria can be used as a diagnostic tool to detect pathological conditions within the GI tract including inflammation and ulcer.
In some embodiments, microorganisms are genetically engineered to secrete therapeutic, prophylactic or diagnostic products. For example, microorganisms are engineered to secret insulin for treating diabetes to act as living "drug factories"; or bacteria are engineered to secret fluorescent proteins for detection of defined conditions within the GI tract.
3. Vaccines
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains the same antigens (or parts of antigents) from a microorganism that causes disease.
For example, measles vaccine contains measles virus. However, the antigens in vaccines are either killed, or weakened to the point that the do not cause disease but they are strong enough to stimulate the body's immune system so that the immune system can readily recognize and kill any of
microorganisms that it later encounters (immunity).
An antigen can include any protein or peptide that is foreign to the subject organism. Preferred antigens can be presented at the surface of antigen presenting cells (APC) of a subject for surveillance by immune effector cells, such as leucocytes expressing the CD4 receptor (CD4 T cells) and Natural Killer (NK) cells. Typically, the antigen is of viral, bacterial, protozoan, fungal, or animal origin. In some embodiments the antigen is a cancer antigen. Cancer antigens can be antigens expressed only on tumor cells and/or required for tumor cell survival.
Instead of the entire organism, one can encapsulate one or more antigenic protein, lipid, sugar, nucleic acid, or combination thereof\, for use as a vaccine. As used herein, "antigenic" refers to the ability of the molecule to elicit a B or T cell mediated response, which may be humoral (resulting in antibody) or cell mediated (resulting in activation of dendritic cells, macrophages, T cells or the pathway resulting in activation thereof).
Certain antigens are recognized by those skilled in the art as immuno- stimulatory (i.e., stimulate effective immune recognition) and provide effective immunity to the organism or molecule from which they derive. Antigens can be peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof. The antigen can be derived from a virus, bacterium, parasite, plant, protozoan, fungus, tissue or transformed cell such as a cancer or leukemic cell and can be a whole cell or immunogenic component thereof, e.g., cell wall components or molecular components thereof. Suitable antigens are known in the art and are available from commercial government and scientific sources. The antigens may be purified or partially purified polypeptides derived from tumors or viral or bacterial sources. The antigens can be recombinant polypeptides produced by expressing DNA encoding the polypeptide antigen in a heterologous
expression system. The antigens can be DNA encoding all or part of an antigenic protein. Antigens may be provided as single antigens or may be provided in combination. Antigens may also be provided as complex mixtures of polypeptides or nucleic acids.
In some embodiments, live attenuated or inactivated vaccines are incorporated within the pH-responsive mucoadhesive polymeric encapsulation. Exemplary vaccines include live, attenuated viral vaccines, such as the cold-adapted, recombinant nasal influenza and oral rotavirus vaccines, and adenovirus-based vaccine as well as the poliovirus and Salmonella typhi vaccines. The vaccine can include live, attenuated or inactivated microorganisms or a protein, DNA or lipid component thereof.
Suitable vaccines for encapsulation include, but are not limited to, vaccines against anthrax, chickenpox, diphtheria, hepatitis A, hepatitis B, HIB, HPV, influenza, Japanese encephalitis, measles, viral meningitis, mumps, whooping cough, pneumonia, polio, rabies, ritavirus, rubella, shingles, smallpox, tetanus, tuberculosis, typhoid, and yellow fever. These are typically in the form of attenuated organisms, although isolated proteins can also be incorporated.
Antigenic molecules can be encapsulated alone, or in combination with microorganisms, which may be present in an amount effective as an adjuvant to enhance the immune response, or to broaden the response.
4. Therapeutic, Prophylactic and Diagnostic Agents Other agents may also be incorporated with the microorganisms and/or components thereof. Representative agents may be proteins, lipids, sugars, nucleic acid molecules, or combinations thereof, small molecule drugs (typically less than 1000 Da although some may be higher), or radiopaque, radionuclide, or magnetic imaging agents.
Other therapeutic, nutritional, prophylactic or diagnostic agents can also be included. In one embodiment, anti-parasitic agents are incorporated into the particles. Anti-parasitic agents, such as anti-protozoa agents, antihelminthics, and combinations thereof, include, but are not limited to,
antinematodes, anticestodes, antitrematodes, antiamoebics, antiprotozoals, and combinations thereof.
Suitable antinematodal drugs include, but are not limited to, benzimiadazoles (e.g., mebendazole, thiabendazole), avermectins (e.g., ivermectin), pyrantel pamoate, diethylcarbamazine, and combinations thereof.
Suitable anticestodes include, but are not limited to, niclosamine, praziquantel, albendazole, and combinations thereof.
Suitable antitrematodes include, but are not limited to, praziquantel. Suitable antiamoebics include, but are not limited to, rifampin, amphotericin B, and combinations thereof.
Suitable antiprotozoals include, but are not limited to, melarsoprol, eflornithine, metronidazole, tinidazole, miltefosine, and combinations thereof.
The particles can contain one or more antiviral and/or antimicrobial agents. Suitable agents include anti-influenza agents, anti-poliovirus agents, antihepatitis agents, anti-arboroviral agents (anthropod-borne viruses such as dengue fever, yellow fever, and malaria), anti-rotavirus agents, anti-Ebola virus agents, anti-Marburg virus agents, anti-Lassa virus agents, and combinations thereof. Suitable antimicrobial agents include, but are not limited to, anti-cholera agents, anti E-coli agents, anti-tuberculosis agents, anti-leprosy agents, and combinations thereof.
Exemplary micronutrients include, but are not limited to, iron, cobalt, zinc, manganese, copper, iodine, selenium, molybdenum, chromium, vitamin A, beta carotene, vitamin Bl, vitamin B2, vitamin B3, vitamin B6, vitamin B9 (folic acid), vitamin B 12, vitamin C, vitamin D3, vitamin E, vitamin K, pantothenic acid, biotin, and combinations thereof. The required daily dosage of most micronutrients is less than 100 mg/day.
Different agents, and different combinations of agents, can be combined in the same particle, different particles, or combinations thereof. This can be done for reason of convenience, such as having separate particles for different agents for convenience in combimng or mixing different agents
in different formulations, or in order to increase or optimize the stability or form of the agents based on the composition of the particle.
B. Biomaterials for Microencapsulation
The biomaterials used for microorganism encapsulation include polymers, such as natural polymers and synthetic polymers (Gentile FT et al, React. Polym. 25:207-227(1995)). The terms biocompatible and biodegradable are associated with many of these biomaterials. Biomaterials for microorganism encapsulation are in direct contact with the living cells. Issues involved when selecting biomaterials for microorganism
encapsulation are: (a) physicochemical properties (chemical composition, morphology, mechanical strength, stability in gastric and intestinal fluids); (b) toxicology assay; (c) manufacturing and sterilization processes.
Biomaterials are inorganic or organic macromolecules, consisting of repeated chain of monomers linked by covalent bonds. Their chemical structure and the conformation of the monomer chains give them specific functionality such as ability to form gels. The most common biomaterial used for microorganism encapsulation is alginate. Other supporting biomaterials include carrageenan, gelatin, chitosan, whey proteins, cellulose acetate phthalate, locust bean gum and starches (Solanki HK, et ah, Biomed Res Int. 2013:620719 (2013)).
Exemplary gastric resistant natural polymers include, but are not limited to, pectin and pectin-like polymers which typically consist mainly of galacturonic acid and galacturonic acid methyl ester units forming linear polysaccharide chains. Typically these polysaccharides are rich in galacturonic acid, rhamnose, arabinose and galactose, for example the polygalacturonans, rhamnogalacturonans and some arabinans, galactans and arabinogalactans. These are normally classified according to the degree of esterification.
In high (methyl) ester ("HM") pectin, a relatively high portion of the carboxyl groups occur as methyl esters, and the remaining carboxylic acid groups are in the form of the free acid or as its ammonium, potassium, calcium or sodium salt. Useful properties may vary with the degree of
esterification and with the degree of polymerization. Pectin, in which less than 50% of the carboxyl acid units occur as the methyl ester, is normally referred to as low (methyl) ester or LM-pectin. In general, low ester pectin is obtained from high ester pectin by treatment at mild acidic or alkaline conditions. Amidated pectin is obtained from high ester pectin when ammonia is used in the alkaline deesterification process. In this type of pectin some of the remaining carboxylic acid groups have been transformed into the acid amide. The useful properties of amidated pectin may vary with the proportion of ester and amide units and with the degree of
polymerization.
In one embodiment, the gastric resistant natural polymer is pectin. The gastric resistant natural polymer is present in an amount less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
1. Mucoadhesive polymers
The presence of a mucus layer that covers the surface of a variety of organs has been capitalized to develop mucoadhesive, or bioadhesive dosage forms that remain in the administration site for prolonged times, increasing the local and/or systemic bioavailability of the administered drug. The benefit of the incorporation of mucoadhesive polymers into the structure of pharmaceutical products is to prolong their residence time in the targeted site and to allow the release of the drug cargo.
Suitable polymers that can be used to form bioadhesive dosage include soluble and insoluble, non-biodegradable and biodegradable polymers. These can be hydrogels or thermoplastics, homopolymers, copolymers or blends, natural or synthetic. In preferred embodiments, the polymers have a bioadhesive force that can effectively and specifically target and bind the mucosal surface of the host. An exemplary bioadhesive polymer can bind to one or more mucosal surfaces of a host with a force of between 110 N/m2 (11 mN/cm2) and 100,000 N/m2.
The mucosal surface layer of the host varies from species to species and even amongst different animals due to differences arising from
variations in diet, location, GI activity, sex and state of health. In general, GI mucus is made of 95% water and 5% electrolytes, lipids, proteins and glycoproteins, as described by Spiro, R.G., "Glycoproteins," Annual Review of Biochemistry, 39, 599-638, 1970; Labat-Robert, J. & Decaeus, C, "Glycoproteins du Mucus Gastrique: Structure, Function, et Pathologie," Pathologie et Biologie (Paris), 24, 241 (1979). However, the composition of the latter fraction can vary greatly. Proteins, including the protein core of the glycoproteins, can made up anywhere from 60 to 80% of this fraction.
Horowitz, M.I., "Mucopolysaccharides and Glycoproteins of the Alimentary Tract" in Alimentary Canal (eds. C. F. Code), pp. 1063-1085 (Washington: American Physiological Society, 1967). The glycoproteins typically have a molecular weight of approximately two million and consist of a protein core (approximately 18.6-25.6% by weight) with covalently attached
carbohydrate side chains (approximately 81.4-74.4% by weight) terminating in either L-fucose or sialic acid residues. Spiro, R.G., "Glycoproteins,"
Annual Review of Biochemistry, 39, 599-638, 1970; Scawen, M. & Allen, A., "The Action of Proteolytic Enzymes on the Glycoprotein from Pig Gastric Mucus," Biochemical Journal, 163, 363-368, 1977; Horowitz, M.I. & Pigman, W., The Glycoconjugates, pp. 560 (New York: Academic Press, Inc., 1977); Pigman, W. & Gottschalk, A., "Submaxillary Gland
Glycoproteins" in Glycoproteins: Their Composition, Structure and Function (eds. A. Gottschalk), pp. 434-445 (Amsterdam: Elsevier Publishing
Company, Inc., 1966). Species and location differences in the composition of these glycoproteins have been reported by Horowitz, M.I.,
"Mucopolysaccharides and Glycoproteins of the Alimentary Tract" in
Alimentary Canal (eds. C. F. Code), pp. 1063-1085 (Washington: American Physiological Society, 1967).
In order for bioadhesive particles to embed themselves in the mucus lining the GI tract, the radius of the individual particles should be as thick as the thickness of the natural mucous layer. It has been shown that the gastric mucous layer thickness typically varies from 5 to 200 μπι in the rat and 10 to 400 μιη in man. Occasionally, however, it can reach thicknesses as great as
1000 μπι in man, as described by Spiro, R.G., "Glycoproteins," Annual Review of Biochemistry, 39, 599-638, 1970; Labat-Robert, J. & Decaeus, C, "Glycoproteins du Mucus Gastrique: Structure, Fonction, et Pathologie," Pathologie et Biologie (Paris), 24, 241, 1979; Allen, A., Hutton, D.A., Pearson, J.P., & Sellers, L.A., "Mucus Glycoprotein Structure, Gel
Formation and Gastrointestinal Mucus Function" in Mucus and Mucosa, Ciba Foundation Symposium 109 (eds. J. Nugent & M. O'Connor), pp. 137 (London: Pitman, 1984). Obvious physical differences in the mucus thickness were observed in the studies described herein. For example, the mucous layers in the rat and monkey were substantially thinner than those observed in the pig and sheep. Although the general order of adhesiveness was maintained throughout the studies, it must be noted that the tenacity of adhesion was dependent on the abundance of mucus.
Two classes of polymers appear to have potentially useful bioadhesive properties: hydrophilic polymers and hydrogels. In the large class of hydrophilic polymers, those containing carboxylic groups (e.g., polyfacrylic acid]) exhibit the best bioadhesive properties. One could infer that polymers with the highest concentrations of carboxylic groups should be the materials of choice for bioadhesion on soft tissues. In other studies, the most promising polymers were: sodium alginate, carboxymethylcellulose, hydroxymethylcellulose and methylcellulose. Some of these materials are water-soluble, while others are hydrogels. Hydrogels have often been used for bioadhesive drug delivery; however, one big drawback of using hydrogels is the lack of long-term stability during storage which is a problem for therapeutic applications.
Rapidly bioerodible polymers such as poly[lactide-co-glycolide], polyanhydrides, polyorthoesters - which would expose carboxylic groups on the external surface as their smooth surface erodes - are excellent candidates for bioadhesive drug delivery systems in the gastrointestinal tract.
Biodegradable polymers are more stable than hydrogels. In addition, polymers containing labile bonds, such as polyanhydrides and polyesters, are
well known for their hydrolytic reactivity. Their hydrolytic degradation rates can generally be altered by simple changes in the polymer backbone.
Representative natural polymers are proteins, such as zein, serum albumin, or collagen, and polysaccharides, such as cellulose, dextrans, and alginic acid. Representative synthetic polymers include polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, polymers of acrylic and methacrylic esters, poly[lactide-co-glycolide], polyanhydrides,
polyorthoestersblends and copolymers thereof. Specific examples of these polymers include cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxymethyl cellulose, cellulose triacetate, cellulose sulphate, poly (methyl methacrylate), (poly (ethyl methacrylate), poly(butyl methacrylate), Poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), polyvinyl alcohols), polyvinyl acetate), poly(vinyl chloride), polystyrene and polyvinylpyrrolidone, polyurethane, polylactides, poly(butyric acid), poly(valeric acid), poly[lactide-co- glycolide], polyanhydrides, polyorthoesters, poly(fumaric acid), and poly(maleic acid).
These polymers can be obtained from sources such as Sigma Chemical Co., St. Louis, MO, Polysciences, Warrenton, PA, Aldrich, Milwaukee, WI, Fluka, Ronkonkoma, NY, and BioRad, Richmond, CA.
In some embodiments, milk proteins are natural vehicles for probiotic or other microorganism, and owing to their structural and physicochemical properties, they can be used as a delivery system (Livney YD, Current Opinion in Colloid and Interface Science, 15(l-2):73-83, (2010)). In other
embodiments, whey proteins are used for encapsulate microorganism in the current invention. Applications of whey proteins are also extended to other foods for protection during processing as well as stability during storage but also in nutraceutical for protection and soil release in the GI tract (Reid AA, et al, Journal of Food Science, 72(1) M31-M37 (2006)).
In a particular embodiment, positively-charged hydrogels, such as chitosan, are first applied onto the microorganism, followed by negatively charged hydrogels, such as alginate that exposes carboxylic groups on the surface. The rationale behind this choice is the fact that most cell membranes are actually negatively charged and there is still no definite conclusion as to what the most important property is in obtaining good bioadhesion to the wall of the gastrointestinal tract.
In a further embodiment, two sequential bilayers of alginate and chitosan are applied onto the microorganism for enhanced stability and adhesion. Poly anhydrides are good candidates for bioadhesive delivery systems since, as hydrolysis proceeds, more and more carboxylic groups are exposed to the external surface. Polylactides erode by bulk erosion;
furthermore, the erosion is slower. In designing these systems as bioadhesive polymers, polymers that have high concentrations of carboxylic acid were preferred.
Some non-limiting exemplary biomaterials for encapsulating probiotic agents are listed below.
i. Alginate
Alginate is a naturally derived polysaccharide extracted from various species of algae and composed of two monosaccharide units: a-L-guluronic acid (G) and /?-D-mannuronic acid (M) linked from β (1-4) glycosidic bond (Formula I). M/G ratios determine the technological functionality of alginate. The gel strength depends upon high proportion block G. High temperature (60°C to 80°C) is needed to dissolve alginate in water. Alginate gels are insoluble in acidic media. Alginate is mostly used in concentration range of 0.5-4% (Sheu TY et al. Journal of Food Science, 54:557-561, (1993))
Alginate can be purchased form commercially available sources such as Sigma Chemical Co. St. Louis, MO (#A7003).
Formula I
ii. Chitosan
Chitosan is a linear polysaccharide with positive charge arising from its amine groups obtained by deacetylation of chitin. It can be isolated from crustacean shells, insect cuticles, and the membranes of fungi. It is a copolymer of two monomer residues anhydro-N-acetyl-D-glucosamine and anhydrous-D-glucosamine (Formula II). It is soluble at pH< 6 and forms gel structure by ionotropic gelation. Chitosan can further polymerize by means of cross- linking formation in the presence of anions and poly anions (Klein J et ah, European Journal of Applied Microbiology and Biotechnology, 18(2):86— 91, 1983). It is used for coating of gelatin capsules, because its efficiency for the increasing viability of probiotic cells is not satisfactory; it is most often used as coat/shell but not capsule.
Chitosan can be purchased from commercially available sources such as Sigma Chemical Co., St. Louis, MO (#448877).
Formula II
iii. Agarose
Agarose is a polysaccharide derived from seaweed used for microencapsulation of cells and the cell/agarose suspension can be modified to form microbeads by reducing the temperature during preparation.
Batorsky A et al reported a system to encapsulate adult human mesenchymal stem cells (hMSC) within spherical three-dimensional (3D)
microenvironments consisting of a defined mixture of collagen Type I and agarose polymers (Batorsky A et al., Biotechnol Bioeng. 92(4) :492- 500(2005)).
iv. Starch
Starch consists of D-glucose unit joint together with glycosidic bonds. It has been used as a material for coating of alginate capsules. High-amylose corn starch (HACS) can be applied for enhancing functions of capsule or shell/coat formation. Lyophilized corn starch (LCS) has been reported to be used as capsule-forming material; however, it decomposes after being subjected to pancreatic enzymes. Resistant starch (RS) is not degraded by the pancreatic amylase. His specification apart from giving the microbeads good enteric delivery characteristic also gives them probiotic functionality as they can be used by the probiotic bacteria in the intestine (Haralampu SG et al, Carbohydrate Polymers, 41(3):285-292, (2000)). The incorporation of Hi- Maize starch improved the encapsulation of viable bacteria compared with the bacteria encapsulated without starch (Malm CJ et al., Journal of the American Pharmaceutical Association, 40(10): 520-525, (1951)).
v. Xanthan-Gellan Gum
Gellan gum is an anionic polysaccharide derived from Sphingomonas elodea which is constituted of a repeating unit of four monomers that are glucose, glucuronic acid, glucose, and rhamnose. Xanthan is an
exopoly saccharide derived from Xanthomonas campestris. The optimum mixing proportion for xanthan-gellan gum is 1 : 0.75 (Borgogna M et ah, Food Chemistry, 122(2)416-423(2010)). This mixture is resistant to acidic conditions.
vi. Guar Gum
Guar gum, also called guaran, is a galactomannan. It is primarily the ground endosperm of guar beans. The guar seeds are dehusked, milled and screened to obtain the guar gum. Guar gum is a polysaccharide composed of the sugars galactose and mannose. The backbone is a linear chain of beta 1,4-linked mannose residues to which galactose residues are 1,6-Iinked at every second mannose, forming short side-branches.
Guar gum is stable in solution over pH range 5-7. Strong acids cause hydrolysis and loss of viscosity, and alkalies in strong concentration also tend to reduce viscosity. It is insoluble in most hydrocarbon solvents. The viscosity attained is dependent on time, temperature, concentration, pH, rate of agitation and practical size of the powdered gum used. The lower the temperature lower the rate at which viscosity increases and the lower the final viscosity.
vii. -Carrageenan
Carrageenan is polymer having linear structure consisting of D- galactose units alternatively linked by a-(l-3) and β (1-4) bonds. Types of carrageenan are kappa (κ), iota (i), and lambda (λ). Monosulfated κ- carrageenan and bisulfated i-carrageenan contain oxygen bridge between 3 and 6 of the D-galactose, which is responsible for the conformational transition and gelatin. The A-carrageenan is trisulfated and does not have this bridge required for gel formation. Carrageenan gelatin is induced by temperature changes. A rise in temperature (60-80°C) is required to dissolve it, and gelation occurs by cooling to room temperature, and then
microparticles are stabilized by adding potassium ion. It is commonly used as a food additive; its safety has been approved by several government agencies including FDA, Codex Alimentarius, and the joint FAO/WHO food additive. It has good capacity to form gels that can entrap the cell. However, the cell slurry should be added to the heat sterilized suspension between 40- 45°C; otherwise the gel hardens at room temperature. Usually it is used in concentration such as 2—5% (Klien J et al., Comprehensive Biotechnology, M. Moo-Yong,C. L.Cooney, and A. E. Humphery, Eds., pp. 542-550, Pergamon Press, Oxford, UK, 1985.). The encapsulation of probiotic cell in κ- carrageenan beads keeps the bacteria in a viable state [169], but the produced gels are brittle and do not withstand stresses (Chen MJ, et al., Encapsulation and Controlled Release Technologies in Food Systems, J. M. Lakkis, Ed., pp. 83-107,Wiley-Blackwell, New York, NY, USA, 2007).
viii. Gelatin
Gelatin is used as a thermally reversible gelling agent for
encapsulation. Because of its amphoteric nature, it is an excellent candidate to incorporate with anionic gel-forming polysaccharides, such as gellan gum. It is frequently used in food and pharmaceutical industries. It is a protein derived by partial hydrolysis of collagen of animal origin. It has versatile functional properties, and forms a solution of high viscosity in water which set to a gel on cooling.
ix. Hyaluronic acid
Hyaluronic acid (HA) is a non-sulphated glycosaminoglycan (GAG) in the extracellular matrix (ECM) of many soft connective tissues, composed of alternating units of D-glucuronic acid and N-acetyl-D-glucosamine, linked together via alternating β-1,4 and β-1,3 glycosidic bonds (Garg HG et al., Chemistiy and biology of hyaluronan. Elsevier Ltd.; Oxford: (2004)). HA is an attractive building block for the fabrication of artificial matrices for tissue engineering because it is biocompatible, biodegradable, bioactive, non- immunogenic and non-thrombogenic (Laurent TCE, The Chemistry, Biology, and Medical Applications of Hyaluronan and Its Derivatives.
Portland Press; Miami: 1998). Efficient, biocompatible and chemo-selective
crosslinking chemistries have enabled the encapsulation of cells during gelation, giving rise to three dimensional (3D) cell/gel constructs with intimate cell-matrix interactions (Allison DD, et al., Tissue Eng. 12:2131— 2140(2006)).
x. Pectin
The pectins, which are most abundant in the plant primary cell walls and the middle lamellae, are a class of molecules defined by the presence of galacturonic acid. The pectic polysaccharides include the galacturonans (homogalacturonan, substituted galacturonans, and RG-II) and
rhamnogalacturonan-I. Galacturonans have a backbone that consists of alpha- 1,4-linked galacturonic acid.
xi. Cellulose and cellulose derivatives
Cellulose is the most abundant naturally occurring polymer of glucose, found as the main constituent of plants and natural fibers such as cotton and linen. Some bacteria (e.g., Acetobacter xylinum) are also able to synthesize cellulose. Most water-soluble cellulose derivatives are obtained via etherification of cellulose, which involves the reaction of the hydroxyl groups of cellulose with organic species, such as methyl and ethyl units. The degree of substitution, defined as the average number of etherified hydroxyl groups in a glucose unit, can be controlled to a certain extent, in order to obtain cellulose derivatives with given solubility and viscosity in water solutions. Cellulose-based hydrogels, either reversible or stable, can be formed by properly crosslinking aqueous solutions of cellulose ethers, such as methylcellulose (MC), hydroxypropyl methylcellulose (HPMC), Hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxyethyl cellulose (HEC), carboxymethyl cellulose (CMC) and sodium carboxymethylcellulose (NaCMC), which are among the most widely used cellulose derivatives. The excellent biocompatibility of cellulose and cellulose derivatives has prompted the large use of cellulose-based devices in biomedical applications.
2. Enteric/pH-response polymers
The environmental conditions of each section along the GI tract can be exploited to design adequate delivery systems. The GI tract consists of
esophagus, stomach, small intestine, and large intestine (colon). Stomach is where majority of digestion occurs. The small intestine comprised of duodenum, jejunum, and ileum and is where digestion and the majority of absorption of food/nutrients/vitamins take place. Colon is where water gets absorbed the rest is excreted as waste in the form of feces. The viable microbial populations in the digestive tract of normal humans are about 0- 103 for stomach, 0-104 for jejunum, 105-108 for ileum and 1010- 1012 for colon.
The intraluminal pH is rapidly changed from highly acid in the stomach to about pH 6 in the duodenum. The pH around esophagus is about 7.0 and drops to 1-2.5 in the stomach. The pH gradually increases in the proximal small intestine from pH 6.2-7.4 to about pH 6.8-7.9 in the distal intestine. The pH drops to 5.2 to 6.7 in the ascending colon, but again gradually increases, reaching pH 5.2-7.0 in the descending colon
(Fallingborg J, Dan Med Bull.46(3): 183-96 (1999)). Physiology of the GI tract is an important consideration in the probiotic encapsulation process.
In some embodiments the release of the encapsulated agent is triggered by a change in pH. Numerous methods have been described in the art to enable general delivery of drugs to the colon, and any of them can be combined to improve delivery to a niche in the colon. Such methods include pH-sensitive formulations (e.g. formulations coated with enteric polymers that release drag when the pH move towards a more alkaline range, after passage through the stomach), formulations that delay the release of the drug for a lag time of 3-5 hours, roughly equivalent to small intestinal transit time, thereby securing delivery to the colon, drugs coated with bioadhesive polymers that selectively provide adhesion to the colonic mucosa (e.g. see US Patent 6,368,586), and delivery systems that incorporate protease inhibitors to prevent proteolytic activity in the gastrointestinal tract from degrading biologic drug agents.
In some embodiments, polymeric delivery systems with a dissolution threshold in the range of 6.8 to 7.5 are used to exploit the natural shift
towards a more alkaline pH in the distal sections of the gut for colonic delivery.
Ionisable polymers with a pKa value between 3 and 10 are candidates for pH-responsive systems (R.A. Siegel, Adv. Polym. Sci. 109: 233(1993)). Weak acids and bases like carboxylic acids, phosporic acid and amines, respectively, exhibit a change in the ionisation state upon variation of the pH. This leads to a conformational change for the soluble polymers and a change in the swelling behaviour of the hydrogels when these ionisable groups are linked to the polymer structure.
Classical monomers are acrylic acid (AAc), methacrylic acid
(MAAc), maleic anhydride (MA), and N,N-dimethylaminoethyl methacrylate (DMAEMA). But also polymers containing phosphoric acid derivatives have been reported (Nakamae K, et al, C em.193:983(1992); Miyata T, et al, Chem. Phys. 195:1111 (1994)).
Some pH-responsive polymers include cationic polymers such as poly(ethylene imine) (PEI), PAMAM and other dendrimers, poly(N,N- dimethylaminoethyl methacrylate) (PDMAEMA), poly(amido amine)s, poly(L-lysine) (PLL) or modified chitosan.
In some embodiments, the pH-responsive polymer is hydroxypropyl- methylcellulosephthalate (HPMCP). In some embodiments, non-pH responsive polymers are modified with pH responsive polymers for incorporating such properties in the coating material. For example, chitosan is formulated by ionic cross-linking with HPMCPP for acid stability (Makhlof A et al, Eur JPharm Sci. 18;42(5):445-51(201 1)).
In some embodiments, the pH-responsive polymers are hydrazine, acetal, ortho-ester, and vinyl-ester functionalized polymers.
Some further exemplary pH responsive polymers are listed below.
i. EUDRAGIT® polymers
EUDRAGIT® polymers are available from EVONIK. They are poly(methacrylate) polymers or copolymers. Examples include:
Amino alkyl methacrylate copolymers R= -CO-0-CH2-CH2N(CH3)2 for immediate release
Methacrylic acid copolymers R = COOH for Delayed release Ammonioalkyl methacrylate copolymers R= CO-OCH2-CH2N(CH3)3 + CI - for Time-controlled release
Methacrylic ester copolymers R= CO-OCH3 for Time-controlled release. EUDRAGIT® L and S polymers can be used for targeting specific areas of the intestine. These polymers include Eudragit® L 30 D-55, L 100-55, L 100 and L 12,5 as well as EUDRAGIT® S 100, S 12,5 and FS 30D. In addition, different grades can be combined with each other to adjust the dissolution pH in order to achieve the required GI targeting for the encapsulated content.
EUDRAGIT® E polymers can also be used for pH sensitive release. Various cationic EUDRAGIT® E grades with dimethyl- aminoethyl methacrylate as functional group can be used for protective coatings. Some examples are EUDRAGIT® E 100, E 12,5 and E PO.
In one embodiment, the probiotic organism is coated with multilayers of EUDRAGIT® E PO and alginate where the exposure to low pH triggers the dissolution of the outer coating of Eudragit® E PO.
In another embodiment, the probiotic organism is coated with multilayers of chitosan and Eudragit® L 100 where the exposure to neutral pH triggers the dissolution of the outer coating of Eudragit® L 100.
ii. Cellulose Acetate Phthalate (CAP)
Because of its safe nature, CAP is used for controlling drug release in the intestine (Mortazavian A, et al., Iranian Journal of Biotechnology, 5(1)1-18, 2007). It is not soluble at pH less than 5 but it is soluble at pH higher than 6. This property is essential for probiotic encapsulation because the bilateral must not dissolve in the stomach but only in the gut. The disadvantage of CAP is that it cannot form gel beads by ionotropic gelation
so capsules have been developed by emulsification. CAP is widely used as a coating agent because it provides better protection for microorganisms in simulated GI conditions (F'avaro-Trindade CS, et ah, Journal of
Microencapsulation, 19(4):485- 94, (2002)). Other cellulose esters with similar properties include cellulose acetate and cellulose acetate butyrate and are widely used for preparing pH sensitive and semi-permeable microporous membranes.
C. Additional Functional Groups
In some embodiments, the encapsulated microorganism include one or more additional functional groups. One or more additional functional groups can be added to the polymeric coating, using any protocols known in the art, for example, covalent attachment (MacDonald C et ah, J R Soc Interface. 5(23): 663-669(2008)). In some embodiments, the additional functional groups are attached to the surface of the encapsulated microorganism directly. Exemplary functional groups include targeting elements, immunomodulatory elements, chemical groups, biological macromolecules, and combinations thereof.
1. Targeting Elements
The encapsulated microorganism can include targeting moieties that enhance attachment at targeted sites along the GI tract. Exemplary targeting elements include proteins, peptides, nucleic acids, lipids, saccharides, or polysaccharides that bind to one or more targets associated with cell, or extracellular matrix, or specific type of tumor or infected cell. The degree of specificity with which the delivery vehicles are targeted can be modulated through the selection of a targeting molecule with the appropriate affinity and specificity. For example, antibodies, or antigen-binding fragments thereof are very specific.
Typically, the targeting moieties exploit the surface-markers specific to a group of cells to be targeted. In some embodiments, immunological components of the gut wall are targeted during gut inflammation under conditions such as neoplasia, IBD, infections, autoimmune diseases (e.g. celiac disease), ischaemia-reperfusion, intestinal hypoperfusion, and e.g. the
use of non-steroidal anti-inflammatory drugs. For example, calprotectin, also known as MRP-8/MRP-14 or S100A8/A9 complex plays a regulatory role in the inflammatory process. It constitutes about 60% of the soluble proteins in human neutrophilic cytosol and is also found in monocytes, macrophages, and ileal tissue eosinophils. Antibody against calprotectin allows targeting of the encapsulated microorganism to the site of inflammation.
In some embodiments the targeting domain can enhance site-specific delivery of the encapsulated microorganism to cancer cells in the GI tract.
Antibodies that function by binding directly to one or more epitopes, other ligands or accessory molecules at the surface of the GI tract, are described. Typically, the antibody or antigen binding fragment thereof has affinity for a receptor at the surface of a specific cell type, such as a receptor expressed at the small intestine.
Any specific antibody can be used in the methods and compositions provided herein. For example, antibodies can include an antigen binding site that binds to an epitope on the target cell. Binding of an antibody to a "target" cell can enhance site-specific attachment to the target cell protein via one or more distinct mechanisms.
In some embodiments, the antibody or antigen binding fragment binds specifically to an epitope. The epitope can be a linear epitope. The epitope can be specific to one cell type or can be expressed by multiple different cell types. In other embodiments, the antibody or antigen binding fragment thereof can bind a conformational epitope that includes a 3-D surface feature, shape, or tertiary structure at the surface of the target cell.
Some further non-limiting examples include targeting the disclosed composition to the disease sites for therapeutic and/or diagnostic purposes. Exemplary conditions within the GI tract include ulcer, inflammation, and cancers.
In some embodiments, a protein that is capable of specifically binding to receptors, either basally expressed or expressed on pathological cells, at the GI tract can be attached via covalent or non-covalent interactions to the surface of the encapsulated microorganism. For example, ICAM-1 and
VCAM-1 proteins can bind to ICAM and VCAM receptors, respectively. ICAM and VCAM receptors are overexpressed on the inflamed intestine tissues whereas an antibody such as IgG can be used to bind to basally expressed Fc-receptors on intestine tissues.
Confirming the functionality of the incorporated protein/antibody can be done using ELISAs, or cell-binding assays (e.g. anti-ICAM functionalized bacteria can be tested for their binding ability to cells overexpressing ICAM receptor, such as LPS-stimulated HUVECS)
In some embodiments, anti-ICAM- 1 is incorporated onto the surface of the encapsulated microorganism for targeting ICAM receptor at inflammation sites of the intestine tissues. The protein ICAM is
overexpressed on inflamed tissues on the intestine. By including anti-icam- l antibody at the terminal layer in the encapsulated microorganism
formulation, it provides a direct means to target to the inflammation site. In some embodiments, the engineered microorganisms carrying genes for fluorescent or bioluminescent proteins are used for detection. In other embodiments, diagnostic markers such as fluorescent proteins are crossed- linked onto the encapsulated microorganism.
In some embodiments, anti- VCAM-1 is incorporated onto the encapsulated microorganism for targeting VCAM receptor at inflammation sites of the intestine tissues. Other examples include IgG for targeting basal Fc-neonatal receptors in intestine and anti-VPACl for targeting VPACl in the intestines.
In some embodiments, the target is ulcers in the stomach.
2. ImmunoModulatory elements
Cationic polymers for use in formation of encapsulated
microogranism can include immuno-modulatory factors. Exemplary immunomodulatory factors include cytokines, xanthines, interleukins, interferons, oligodeoxynucleotides, glucans, growth factors (e.g., TNF, CSF, GM-CSF and G-CSF), hormones such as estrogens (diethylstilbestrol, estradiol), androgens (testosterone, HALOTESTIN® (fluoxymesterone)), progestins (MEGACE® (megestrol acetate), PRO VERA®
(medroxyprogesterone acetate)), corticosteroids (prednisone,
dexamethasone, hydrocortisone), CRM 197 (diphtheria toxin), outer membrane protein complex from Neisseria meningitides, as well as viral hemagglutinin and neuraminidase.
In certain embodiments, the cationic polymers include immuno- stimulatory factors. Exemplary immuno-stimulatory factors include, but are not limited to, TLR ligands, C-Type Lectin Receptor ligands, NOD-Like Receptor ligands, RLR ligands, and RAGE ligands. TLR ligands can include lipopolysaccharide (LPS) and derivatives thereof, as well as lipid A and derivatives there of including, but not limited to, monophosphoiyl lipid A (MPL), glycopyranosyl lipid A, PET-lipid A, and 3-0-desacyl-4'~ monophosphoryl lipid A.
D. Formulations
Formulations are prepared using a pharmaceutically acceptable "carrier" composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions. The "carrier" is all components present in the pharmaceutical formulation other than the active ingredient or ingredients. The term "carrier" includes but is not limited to diluents, binders, lubricants, desintegrators, fillers, and coating compositions.
"Carrier" also includes all components of the coating composition which may include plasticizers, pigments, colorants, stabilizing agents, and glidants. The delayed release dosage formulations may be prepared as described in references such as "Pharmaceutical dosage form tablets", eds. Liberman et al. (New York, Marcel Dekker, Inc., 1989), "Remington - The science and practice of pharmacy", 20th ed., Lippincott Williams & Wilkins, Baltimore, MD, 2000, and "Pharmaceutical dosage forms and drug delivery systems", 6th Edition, Ansel et.al., (Media, PA: Williams and Wilkins, 1995) which provides information on carriers, materials, equipment and process for preparing tablets and capsules and delayed release dosage forms of tablets, capsules, and granules.
Examples of suitable coating materials include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name Eudragit® (Roth Pharma, Westerstadt, Germany), Zein, shellac, and polysaccharides.
Additionally, the coating material may contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilization agents, pore formers and surfactants.
Optional pharmaceutically acceptable excipients present in the drug- containing tablets, beads, granules or particles include, but are not limited to, diluents, binders, lubricants, disintegrants, colorants, stabilizers, and surfactants. Diluents, also termed "fillers," are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets or formation of beads and granules. Suitable diluents include, but are not limited to, dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose,
microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and powder sugar.
Binders are used to impart cohesive qualities to a solid dosage formulation, and thus ensure that a tablet or bead or granule remains intact after the formation of the dosage forms. Suitable binder materials include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums such as acacia, tragacanth, sodium alginate, cellulose,including hydorxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, and veegum, and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid/polymethacrylic acid and polyvinylpyrrolidone.
Lubricants are used to facilitate tablet manufacture. Examples of suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc, and mineral oil.
Disintegrants are used to facilitate dosage form disintegration or
"breakup" after administration, and generally include, but are not limited to, starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross- linked PVP (Polyplasdone XL from GAF Chemical Corp).
Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions.
Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents. Suitable anionic surfactants include, but are not limited to, those containing carboxyiate, sulfonate and sulfate ions. Examples of anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2- ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate. Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine. Examples of nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG- 150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG- 1000 cetyl ether, polyoxyethylene fridecyl ether, polypropylene glycol butyl ether, Poloxamer® 401, stearoyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide. Examples of amphoteric surfactants include
sodium N-dodecyl-.beta.-alanine, sodium N-lauryl-.beta.-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
If desired, the tablets, beads granules or particles may also contain minor amount of nontoxic auxiliary substances such as wetting or emulsifying agents, dyes, pH buffering agents, and preservatives.
As will be appreciated by those skilled in the art and as described in the pertinent texts and literature, a number of methods are available for preparing drug-containing tablets, beads, granules or particles that provide a variety of drug release profiles. Such methods include, but are not limited to, the following: coating a drug or drug-containing composition with an appropriate coating material, typically although not necessarily incorporating a polymeric material, increasing drug particle size, placing the drug within a matrix, and forming complexes of the drug with a suitable complexing agent.
The delayed release dosage units may be coated with the delayed release polymer coating using conventional techniques, e.g., using a conventional coating pan, an airless spray technique, fluidized bed coating equipment (with or without a Wurster insert), or the like. For detailed information concerning materials, equipment and processes for preparing tablets and delayed release dosage forms, see Pharmaceutical Dosage Forms: Tablets, eds. Lieberman et al. (New York: Marcel Dekker, Inc., 1989), and Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6.sup.th Ed. (Media, PA: Williams & Wilkins, 1995).
A preferred method for preparing extended release tablets is by compressing a drug-containing blend, e.g., blend of granules, prepared using a direct blend, wet-granulation, or dry-granulation process. Extended release tablets may also be molded rather than compressed, starting with a moist material containing a suitable water-soluble lubricant. However, tablets are preferably manufactured using compression rather than molding. A preferred method for forming extended release drug-containing blend is to mix drug particles directly with one or more excipients such as diluents (or fillers), binders, disintegrants, lubricants, glidants, and colorants. As an alternative to direct blending, a drug-containing blend may be prepared by
using wet-granulation or dry-granulation processes. Beads containing the active agent may also be prepared by any one of a number of conventional techniques, typically starting from a fluid dispersion. For example, a typical method for preparing drug-containing beads involves dispersing or dissolving the active agent in a coating suspension or solution containing pharmaceutical excipients such as polyvinylpyrrolidone, methylcellulose, talc, metallic stearates, silicone dioxide, plasticizers or the like. The admixture is used to coat a bead core such as a sugar sphere (or so-called "non-pareil") having a size of approximately 60 to 20 mesh.
An alternative procedure for preparing drug beads is by blending drug with one or more pharmaceutically acceptable excipients, such as microcrystalline cellulose, lactose, cellulose, polyvinyl pyrrolidone, talc, magnesium stearate, a disintegrant, etc., extruding the blend, spheronizing the extrudate, drying and optionally coating to form the immediate release beads.
1. Excipients
In addition to a therapeutic or prophylactic agent (or possibly other desired molecules for delivery), the particles can include excipients such as a sugar, such as lactose, a protein, such as albumin, and/or a surfactant.
E. Enteral Administration
The compositions are generally formulated for oral delivery.
1. Additives for Oral Administration
Oral solid dosage forms are described generally in Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co. Easton Pa. 18042) at Chapter 89. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present active compounds and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712. The compositions may be prepared in
liquid form, or may be in dried powder (e.g., lyophilized) form. Liposomal or proteinoid encapsulation may be used to formulate the compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556). See also Marshall, K. In: Modern Pharmaceutics Edited by G. S. Banker and C. T. Rhodes Chapter 10, 1979.
Another embodiment provides liquid dosage forms for oral administration, including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.
2. Chemically Modified Forms for Oral Dosage The disclosed compositions can be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of degradation; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the component or components and increase in circulation time in the body. PEGylation is a preferred chemical modification for pharmaceutical usage. Other moieties that can be used include: propylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, polyproline, poly-l,3-dioxolane and poly- 1,3,6- tioxocane (see, e.g., Abuchowski and Davis (1981) "Soluble Polymer- Enzyme Adducts," in Enzymes as Drugs. Hocenberg and Roberts, eds. (Wiley-Interscience: New York, N.Y.) pp. 367-383; and Newmark, et al. (1982) J. Appl. Biochem. 4:185-189).
III. Methods of Making
In some embodiments, the microorganisms are encapsulated by extrusion, emulsion, and spray drying. In these methods, microorganisms are entrapped in the gel matrix using different gel forming mechanisms
(Champagene CP et al, Functional Dairy Products, 2:404-426, (2007)). The encapsulating conditions are designed to maintain cell viability, and solvents involved in the encapsulation technology must be nontoxic. The ability of microorganisms to survive and multiply in the host strongly influences their probiotic benefits.
Microencapsulation techniques are achieved by encapsulation process or drying process.
A. Microencapsulation Process.
In some embodiments, the encapsulation of the disclosed microorganisms is done by extrusion technique (King AH et al.,
Encapsulation and Controlled Release of Food Ingredients, Sara JR and Gary AR, Eds., vol. 590 of ACS Symposium Series, 26-39, American Chemical Society, Washington, DC, USA.). Extrusion method in the case of alginate capsule consists of the following stages: preparation of hydrocolloid solution and the addition of probiotic cell in hydrocolloid solution to form cell suspension. These cells suspension is passed through the syringe needle to form droplets which are directly dripped into the hardening solution containing cations like calcium. When the droplets come in contact with hardening solution, alginate polymers surround the core to form a three- dimensional lattice structure by cross-linking calcium ions (Kailasapathy K, CAB Reviews, 4(6) 1-19, (2009)), thereby entrapping the core material separated from liquid bath and is dried using a suitable technology.
Formation of gel by alginate solution (0.6%) would be possible if calcium ion (0.3 M) is present. Usually, alginate is used in the range of 1-2% and 0.005-1.5 M calcium chloride concentration. Generally ¾ the diameter of forming beads in this method (2-5 mm) is larger than those formed in the emulsion method. Bead diameter is affected by concentration and viscosity of alginate solution and distance between the syringe and hardening solution, and diameter of extruder orifice affects the size of bead. Bead diameter decreases along with increasing concentration and viscosity of the encapsulation solution. Using low glucuronic alginate, formation of beads with smaller diameter is possible (Smidsrod O et al., Trends in
Biotechnology, 8(3):71-75 (1990)). For production of alginate capsule with Chitosan coat, alginate solution is dripped into the hardening batch containing calcium chloride and Chitosan. Soaking of alginate beads in the Chitosan solution (0.1%, pH 6.5) for 20 min gives rise to beads with good properties.
In some embodiments, the encapsulation of the disclosed microorganisms is carried out by emulsion technique, as demonstrated in the microencapsulation of lactic acid bacteria (Audet P et ah, Applied
Microbiology and Biotechnology, 29(1):11-18,(1988)). In this method, small volume of cell/polymer slurry (dispersed phase) is added to the large volume of vegetable oil (as a continuous phase) such as soy oil, sunflower, corn, and light paraffin oil. After the formation of emulsion, cross-linking is required to form gels. Geliiication is done by different mechanisms like ionic, enzymatic, and interfacial polymerization as discussed next. It can be easily scaled up, and the diameter of producing beads is considerably smaller (25 μιη-2 mm).
In some embodiments, the encapsulation of the disclosed microorganisms is done by emulsification and ionic gelification.
Emulsification is a chemical technique to encapsulate probiotic using alginate, carrageenan and pectin as an encapsulating material. Once water in oil (W/O) emulsion is formed, water soluble polymer becomes insoluble after addition of ions of calcium chloride, by means of cross-linking forming gel particles in the oil phase. The smallest particle of the aqueous phase in W/O phase emulsion will lead to the formation of beads with smaller diameters. Agitation rate and type of emulsifier also affects the diameter of the beads. Microbeads produced by this technique are recovered by membrane filtration technology (Krasaekoopt W et al., International Dairy Journal, 13(1), 3-13, 2003).
In some embodiments, the encapsulation of the microorganisms is carried out by emulsification and enzymatic gelification. Milk protein is used to encapsulate probiotics by means of an enzyme-induced gelation
(Heidebach T et al, Food Hydrocolloids, 23( 7):1670-1677 (2009)). Milk
proteins have excellent gelation properties and are a natural vehicle for probiotics. This method gives water insoluble and spherical particles. This method is an example of encapsulation by means of rennet gelation, which is based on the principle of using daily proteins which have been put in contact with rennet at low temperature. This allows keeping a liquid system where κ- casein is cleaved by the enzyme. After that, dairy proteins are emulsified in a cold oil to form water in oil emulsion. Thermal induction of enzymatic coagulation allows protein flocculation and provides microparticles.
In some embodiments, the encapsulation of the disclosed microorganisms is carried out by emulsification and interfacial
polymerization. This technique requires formation of an emulsion in which discontinuous phase contains an aqueous suspension of the cell and continuous phase contains organic solvent. To initiate the polymerization reaction, biocompatible agent which is soluble in the continuous phase is added. The drops of probiotic cell are coated to form thin and strong membrane (Kailasapathy K et al, Current Issues in Intestinal Microbiology, 3(2):39-48 (2002)).
In a preferred embodiment, the process of making the novel compositions is similar to the polymer capsule preparation using immobilized particles described by Richardson JJ et al (Richardson JJ et al, Adv Mater. 25(47):6874-8(2013)).
B. Drying Process for Microencapsulation.
Drying improves stability of the encapsulated culture during prolonged storage. But the drying process causes some injuries to the microbeads, release of some cells, and reducing the viability of cells. Spray drying, freeze drying, and fluidized bed drying are used for the making of the current inventive compositions.
In some embodiments, the encapsulation of the disclosed microorganisms is carried out by spray drying. A solution containing probiotic living cells and the dissolved polymer matrix is prepared by using gum Arabic and starches because they tend to form a spherical microparticle during the drying process (de Vos P et al., International Dairy Journal,
20(4):292-302 (2010)). In drying process, probiotic cell loses viability due to physical injury to microencapsulate and heat generation. However, the loss of probiotic cell can be reduced by using proper cryoprotectant during freeze drying, optimizing the inlet and outlet temperature for spray drying (Champagene CP et al., Functional Dairy Products, 2:404-426 (2007)).
In some embodiments, the encapsulation of the disclosed microorganisms is carried out by freeze drying. In this technique, the solvent is frozen and removed via sublimation (Pikal MJ, PharmTech International, 1 :37-43 (1991)). Freezing causes damage to the cell membrane due to ice crystal formation and also imparts stress condition by high osmolarity. It has been traditionally used to stabilize probiotic bacteria, but the combination of freeze-drying and encapsulation is relatively new concept. Recently, Lactobacillus F19 and Bifidobacterium Bbl2 cells were first encapsulated into enzymatically gelled sodium caseinate, and gel particles were freeze- dried to study the storage stability (Heideback T et al, Journal of Food Engineering, 98(3): 309-316 (2010)). They reported better post-drying survival and storage viability for encapsulated cell compared to free cell. In other recent work, gelatinized starch and lecithin were incorporated into the alginate microcapsule containing probiotic organisms in encapsulated form, and beads were freeze-dried to evaluate the storage stability at different temperature. It was shown that encapsulated bacteria had much better stability at 23°C for 12 weeks, and lecithin helped in obtaining higher efficiency and more stability (Donthidi AR, et al., Journal of
Microencapsulation, 27(l):67-77, (2010)).
In some embodiments, the encapsulation of the disclosed microorganisms is carried out by fluidized bed drying. In this process, cell suspension is sprayed and dried on inert carriers using a Wurster-based fluidized bed system (Huyghebaert N et al. European Journal of
Pharmaceutics and Biopharmaceutics, 61(3): 134— 141 , (2005)).
In some embodiments, the encapsulation of the disclosed microorganisms is carried out by vacuum drying. Vacuum drying is suitable for heat sensitive probiotics because drying takes place at lower
temperatures, and oxidation reaction can also be minimized, while disadvantage is batch operation and longer drying time which can be minimized by using a continuous vacuum dryer where cost is one-third of a freeze diyer, and the material can be dried at 1-4% moisture level at 40°C within 5-10 min (Hayashi H et al, Drying Technology, l(2):75-284, (1983)).
In some embodiments, spray freeze drying is sued to encapsulate. In this technique, the probiotic cell solution is atomized into a cold vapor phase of a cryogenic liquid such as liquid nitrogen, which generates a dispersion of frozen droplets. These are dried in freeze dryer (Kailasapathy K, CAB Reviews, 4(6) 1-19, (2009)).
In some embodiments, the following microencapsulation techniques are used for making the formulation: a microencapsulation technique known as Probiocap (US Patent Publication No. 20030109025). The process is based on coating freeze-dried Lactobacillus with fatty acids. This technology allows strains to resist the harsh effect of temperature, gastric acidity, and compression. Danish-Korean Company patented a duel coating technology for Lactobacillus, which is marketed under the brand name Duaolac®. The first layer of coating is made of soy peptide, and the second layer is made of cellulose and gum.
TV. Methods of Use
Methods of using the pH responsive, mucoadhesive
microencapsulated microorganisms are provided.
A. Therapeutic and Prophylactic Administration
Pharmaceutical compositions for enhancing gut microbiota can be administered in a number of ways depending on the conditions to be treated. The methods for administering the disclosed compositions are essentially the same, whether for prevention or treatment.
In some embodiments, the disclosed compositions are included in dairy products such as yogurt, mayonnaise, cheese, kefir, cream and ice cream. In some embodiments, the disclosed compositions are included in products such as lactic acid, frozen dessert, tea, coffee, soda drinks, energy drink, breakfast cereal and snack bars.
The composition can be administered during a period before, during, or after onset of disease symptoms, or any combination of periods before, during or after onset of one or more disease symptoms. For example, the subject can be administered one or more doses of the composition every 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48 days prior to onset of disease symptoms. The subject can be administered one or more doses of the composition every 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48 days after the onset of disease symptoms. In some embodiments, the multiple doses of the compositions are administered before an improvement in disease condition is evident. For example, in some embodiments, the subject receives 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48, over a period of 1, 2, 3, 4, 5, 6 7, 14, 21, 28, 35, or 48 days or weeks before an improvement in the disease condition is evident.
The compositions can be administered alone, or in combination with a second active agent, as part of therapeutic regime for disease treatment. For example, the composition can be administered on the first, second, third, or fourth day, or combinations thereof. The composition can be
administered on the same day, or a different day than the second active agent.
B. Microbiota-Associated Diseases and Conditions
Disease states may exhibit either the presence of a novel microbe(s), absence of a normal microbe(s), or an alteration in the proportion of microbes.
Work in recent years has implicated and described mechanistic explanations of how the microbiota is related to or causes specific disease states. Recent research has established that disruption of the normal equilibrium between a host and its microbiota, generally manifested as a microbial imbalance, is associated with, and may lead to, a number of conditions and diseases. These include Crohn's disease, ulcerative colitis, obesity, asthma, allergies, metabolic syndrome, diabetes, psoriasis, eczema, rosacea, atopic dermatitis, gastrointestinal reflux disease, cancers of the gastrointestinal tract, bacterial vaginosis, neurodevelopmental conditions such as autism spectrum disorders, and numerous infections, among others.
For example, in Crohn's disease, concentrations of Bacterioides, Eubacteria and Peptostreptococcus are increased whereas Bifidobacteria numbers are reduced (Linskens et al., Scand J Gastroenterol Suppl. 2001;(234):29-40 ); in ulcerative colitis, the number of facultative anaerobes is increased. In these inflammatory bowel diseases, such microbial imbalances cause increased immune stimulation, and enhanced mucosal permeability (Sartor, Proc Natl Acad Sci U S A. 2008 Oct 28; 105(43): 16413-4). In obese subjects, the relative proportion of Bacteroidetes has been shown to be decreased relative to lean people (Ley et al., Nature. 2006 Dec 21;444(7122): 1022-3), and possible links of microbial imbalances with the development of diabetes have also been discussed (Cani et al, Pathol Biol (Paris). 2008
Jul;56(5):305-9). Segmented Filamentous Bacteria have been shown to play a critical role in prevention of infection and development of autoimmune diseases (Ivanov et al, Cell. 139(3):485-98, 2009). In the skin, a role for the indigenous microbiota in health and disease has been suggested in both infectious and noninfectious diseases and disorders, such as atopic dermatitis, eczema, rosacea, psoriasis, and acne (Holland et al. 1977 Br J Dermatol. 96(6):623-6; Thomsen et al. 1980 Arch. Dermatol. 116:1031- 1034; Till et al. 2000 Br. J. Dermatol. 142:885-892; Paulino et al. 2006 J. Clin. Microbiol 44:2933-2941). Furthermore, the resident microbiota may also become pathogenic in response to an impaired skin barrier (Roth and James 1988 Annu. Rev. Microbiol. 42:441-464). Bacterial vaginosis is caused by an imbalance of the naturally occurring vaginal microbiota. While the normal vaginal microbiota is dominated by Lactobacillus, in grade 2 (intermediate) bacterial vaginosis, Gardnerella and Mobiluncus spp. are also present, in addition to Lactobacilli. In grade 3 (bacterial vaginosis), Gardnerella and Mobiluncus spp. predominate, and Lactobacilli are few or absent (Hay et al., Br. Med. J., 308, 295-298, 1994)
Other conditions where a microbial link is suspected based on preliminary evidence include rheumatoid arthritis, multiple sclerosis,
Parkinson's disease, Alzheimer's disease, muscular dystrophy, fibromyalgia and cystic fibrosis. Some evidence also suggests the link between
commensal gut microbiota and the central nervous system. Bravo et al showed that ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve (Bravo et al, Proc Natl Acad Sci USA. 108(38): 16050-5(2011)). In some embodiments, the inhibition and treatment of the enteric pathogen diseases is accomplished by the probiotic composition through a competitive binding process.
Probiotic bacteria, Lactobacillus fermentum and Bifidobacterium lactis, appears to inhibit permeability caused by gliadin and therefore to reduce gliadin-induced cellular damage. Probiotic bacteria may reduce the damage caused by eating gluten-contaminated foods and may even accelerate mucosal healing after the initiation of a gluten-free diet (Lindfors K et al., Clin Exp Immunol. 152(3):552-8 (2008)). Lactobacillus fermentum and Bifidobacterium lactis are exemplary probiotic bacteria as a potential treatment for Celiac disease and gluten intolerance.
In some embodiments, the disclosed compositions are given to subjects with altered or non-optimal gut microbiota such as following a course of medical treatment that damages the healthy commensal microbiota. In some embodiments, the compositions are given to subjects following a course of antibiotic treatment. In some embodiments, the compositions are given to a subject following chemotherapy.
In some embodiments, the compositions are given to babies or children after a course of antibiotics for ear infections or yeast infections. In some embodiments, the compositions are given to premature babies for populating their gut commensal microbiome.
In some embodiments, the compositions are for transferring vaginal microbial communities to confer stability and resistance to bacterial vaginosis (BV). The microbial populations are preferably obtained from women with Lactobacillus crispatus-dom ated (>50%) vaginal microbiota, who are healthy, free of sexually transmitted disease, and have a low pH in the secretions. The encapsulated microbial populations are administered to women with BV, as identified clinically with Amsel's criteria, and confirmed
in the laboratory by Nugent scoring. Transplantation of more beneficial lactobacillus types, including the vaginal microbial community and the mucus environment in which they live, is a promising method for reestablishing healthy bacterial communities that do not compromise the structural and adhesive properties of cervicovaginal secretions in the vaginas of women with recurrent BV.
1. Intestinal Disorders
In some embodiments the disease or disorder that can be prevented or treated by the disclosed methods and compositions are intestinal diseases and disorders, such as gastroenteritis and irritable bowel syndrome (IBS). IBS is characterized by symptoms such as abdominal cramp, discomfort, bloating and inflammation of the colon, rectum, and/or the distal small intestine. Although the exact causes of IBS remains poorly understood, several of its pathologic features suggest that the disease derives in part from dysregulated control of bacterial interactions with the mucosal surface.
Other exemplary diseases and disorders of the GI tract include diarrhea, dysentery, cholera, hemorrhagic colitis, peptic ulcer disease, gastritis, and enteric fever (e.g., typhoid fever).
Exemplary invasive enteric bacteria strains that cause diseases and disorders of the GI tract include Salmonella spp (e.g., S. choleraesuis, S. paratyphi A, S. schottmuelleri and S. hirschfeldii), Shigella spy,
Campylobacter sp . (e.g., C. fetus, C. upsaliensis, C. lari, C. jejuni ), enterohepatic Helicobacter species (e.g., H. cineadi, H. fennelliae), Vibrio spp., Clostridium spp. (e.g., C. difficile), Pseudomonas spp., Enterobacter spp., Arcobacter spp., Yersinia spp., Aeromonas spp. and Escherichia spp.
Exemplary viruses that cause diseases and disorders of the GI tract include strains of adenoviruses, hepatitis E virus, astroviruses, noroviruses and other caliciviruses, reoviruses and rotaviruses.
C. Treating Conditions in Animals
The pH-responsive, mucoadhesive polymeric encapsulated compositions can also be administered to any animal in need of thereof including. Most common uses are in animals treated with antibiotics such as
cats, dogs, horses and ruminants (sheep, cattle, goats, deer, llama) or newborns that did not get adequate colostrum and/or nurse their dams.
Specifically, the compositions e.g. containing probiotic, can be used to inhibit or treat enteric pathogen-associated diseases when administered to an animal in need thereof using the methods described in the present specification. Enteric pathogen diseases include those diseases caused by pathogens such as diarrhea, irritable bowel syndrome and intestinal hemorrhages. Examples of enteric pathogens associated with these diseases include, but not limited to enteropathogenic Escherichia coli (EPEC), enterotoxigeneic E. coli (ETEC), Salmonella enteriditis, Yersina pseudotuberculosis and Listeria monocytogenes. In some embodiments, the inhibition and treatment of the enteric pathogen diseases is accomplished by the probiotic composition through a competitive binding process. For example, the probiotic lactohacilli compete with enteric pathogens for binding sites on the intestinal mucosa. Because the probiotic lactobacilli have a higher affinity and avidity for these binding sites than the enteric pathogens, the probiotic lactobacilli displace the enteric pathogens into the intestinal milieu where they are harmlessly flushed from the intestines by normal metabolic processes. In vivo examples of this above described competitive binding and its efficacy in inhibiting and treating enteric pathogen diseases is provided in detailed examples below and in the accompanying figures.
D. Dosages and Effective Amounts
In some in vivo approaches, the compositions of encapsulated microorganisms are administered to a subject in a therapeutically effective amount. As used herein the term "effective amount" or "therapeutically effective amount" means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables {e.g., age, immune system health, etc), the disease or disorder, and the treatment being effected, the number of times daily and number of days or
weeks of treatment, and whether the probiotics are administered concurrently with antibiotics.
The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired.
Generally dosage levels are between 1-100 million colony forming units for human with a healthy digestive tract. For restoring microbiome after treatments that eliminate most gut microbiome for example, in case of antibiotic treatment or chemotherapy, the dosage level is about 1-100 billion colony forming units.
Preferably, the amount of encapsulated agents is effective to prevent or reduce the infection or onset of a disease or disorder in a subject compared to an untreated control.
In another embodiment, the encapsulated agents are in an amount effective to promote and encourage healthy commensal microbiota and decrease the amount of inflammation, pain or other symptoms associated with a disease or disorder in a subject.
In a preferred embodiment the effective amount of encapsulated agents does not induce significant cytotoxicity in the GI tract of a subject compared to an untreated control subject.
In some embodiments, the dosage levels for dogs and cats are about
500 million to 50 billion CFUs; for horses and cattle are about 1 billion to 100 billion CFUs.
In one embodiment, an animal is provided with a single dose containing from approximately 105 to 1011 CFU of probiotic bacteria e.g. lactobacilli per gram of probiotic composition. The total amount consumed will depend on the individual needs of the animal and the weight and size of the animal. The preferred dosage for any given application can be easily determined by titration. Titration is accomplished by preparing a series of standard weight doses each containing from approximately 103 to 1011 lactobacilli per gram. A series of doses are administered beginning at 0.5 grams and continuing up to a logical endpoint determined by the size of the animal and the dose form. The appropriate dose is reached when the minimal
amount of lactobacilli composition required to achieve the desired results is administered. The appropriate dose is also known to those skilled in the ait as an "effective amount" of the pH-responsive, mucoadhesive polymeric encapsulated compositions.
For example, if it is desired to reduce the symptoms associated with irritable bowel syndrome in an animal, one measured dose as described above is administered daily, escalating the dose each successive day in 0.5 grams increments until symptoms subside. In one embodiment the preferred dose is between approximately 103 to 108 viable lactobacilli per kilogram of body weight (the weight of animal recipient) per day. This equates to approximately 10 billion viable Lactobacillus casei strain KE01 per day for the average healthy adult human. By extrapolation, it is a simple matter to calculate the approximate dose appropriate for any animat of any weight. It is understood that this is a non-limiting example that can be varied as appropriate by persons having skill in the art of prescribing probiotic compositions or by using the titration method provided above.
E. Controls
The effect of pH-responsive, mucoadhesive polymeric encapsulated agent can be compared to a control. Suitable controls are known in the art and include, for example, an untreated subject. In some embodiments, the control is untreated tissue from the subject that is treated, or from an untreated subject. In some embodiments, an untreated control subject suffers from, or is at risk from the same disease or condition as the treated subject e.g. Crohn's disease.
F. Combination Therapy
The disclosed methods and compositions for delivering encapsulated agent can be administered alone, or in combination with one or more additional active agent(s), as part of a therapeutic or prophylactic treatment regime. The pH-responsive, mucoadhesive polymeric encapsulated agent can be administered on the same day, or a different day than the second active agent. For example, compositions including encapsulated agents can
be administered on the first, second, third, or fourth day, or combinations thereof.
The term "combination" or "combined" is used to refer to either concomitant, simultaneous, or sequential administration of two or more agents. Therefore, the combinations can be administered either concomitantly (e.g., as an admixture), separately but simultaneously (e.g., via separate intravenous lines into the same subject), or sequentially (e.g., one of the compounds or agents is given first followed by the second). The additional therapeutic agents can be administered locally or systemically to the subject, or coated or incorporated onto, or into a device.
In some embodiments, the additional agent or agents can modulate the local gut environment. In some embodiments, the additional agent can act systemically in the host such as for relieving signs and symptoms related to the disease and conditions to be treated. Some non-limiting examples include anti-diarrheal medications, pain relievers, iron supplements, vitamin B-12 shots, calcium and vitamin D supplements and other supplemental nutrition given as enteral nutrition or parenteral nutrition.
In some embodiments, the additional agent could be antiinflammatory drugs such as aminosalicylates and corticosteroids. In some embodiments, the additional agent could be immune suppressors such as azathioprine (Azasan, Imuran), mercaptopurine (Purinethol, Purixan), cyclosporine (Gengraf, Neoral, Sandimmune), infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), methotrexate (Rheumatrex), natalizumab (Tysabri), vedolizumab (Entyvio) and Ustekinumab (Stelara). In some embodiments, the additional agent could be antibiotics such as Metronidazole (Flagyl) and Ciprofloxacin (Cipro).
The present invention will be further understood by reference to the following non-limiting examples.
Examples
Example 1: Layer-by-Layer templating of Bacillus coagulans
Methods and Materials
Bacteria Growth
Bacillus coagulans (ATCC #7050) ("BC") were grown at 37C in
Difco nutrient broth and on Difco nutrient agar (VWR) and used for all experiments and stored while in the exponential phase. Counting of bacteria was performed using the standard plate counting method streaked with glass beads, where all plates had between 30-100 colonies. Prior to plating, all formulations were first resuspended and washed twice in PBS. For IVIS experiments, bacteria were stained with vivotag-S 750 (20 μΐ of a 10 mg/ml vivotag-S 750 in DMSO in 5 mg of bacteria in 980 μΐ of pH 8.5 210 mM bicarbonate buffer) under rotation at room temperature for 1 hour.
BC, either plain or encapsulated, were grown under shaking conditions (225 RPM) at 37°C using an I NOVA®44 incubating shaker. OD600 readings were obtained using a SPECTRAMAX® Plus 384 spectrophotometer with media-only backgrounds subtracted. In the case of pH-responsive growth, media was adjusted to be pH 4.5 for acidic conditions and used as made (pH 7.1) for neutral conditions.
For IVIS experiments, bacteria were fluorescently labeled with
VIVOTAG-S® 750 (20 μΐ of a 10 mg/ml VIVOTAG-S® 750 in DMSO with 5 mg of BC in 980 μΐ of pH 8.5 210 mM bicarbonate buffer) under rotation at room temperature for 1 hour.
Transformation of BC with pGEN-luxCDABE (Lane et al., Proceedings of the National Academy of Sciences, 104:16669-74 (2007)) was performed following a standard heat-shock protocol. Briefly, 150 μΐ of bacteria were incubated on ice with 5 ng of pure plasmid DNA for 30 minutes, heat-shocked for 45 seconds at 42°C, and placed back on ice for 2 minutes. 800 μΐ of SOC medium was added to the tubes and incubated for 1 hour at 37°C. 50 μΐ of this suspension was plated on LB agar plates with ampicillin and incubated over night at 37°C. Individual colonies were selected, and luminescence was verified using IVIS imaging.
Layer-by-layer Synthesis
Glycol chitosan and alginate (Sigma) were prepared as 2 mg/ml solutions in 0.5 M NaCl. EPO and L100 were prepared at 2 mg/ml in 0.5 M NaCl. The pH of chitosan and alginate solutions was 6.0 and 1 molar HCl and/or 1 molar NaOH were used to adjust pH as needed. EPO and LI 00 were prepared in 0.5 M NaCl by first dissolving EPO in pH 2 NaCl and L100 in pH 9 NaCl and titrating to a final pH of 6.0 NaCl for each. 5 mg/ml of bacteria were first suspended in 0.5 M NaCl and washed twice. Cationic polymers (e.g. EPO or chitosan) were first layered on plain bacteria using 1 ml of 2 mg/ml polymer solution as described above, for 30 minutes at room temperature. Bacteria were then washed 2x in 0.5 M NaCl and then coated identically with anionic polymers (e.g. LI 00 or alginate) for 30 minutes at room temperature. This process was repeated as necessary to synthesize LbL-probiotics of up to 3 bilayers (6 total layers).
Characterization of Layers
A Malvern zeta sizer was used to measure zeta potentials in either pH 1 or pH 7 pure water. Fluorescent chitosan and alginate polymers (PEGWorks) were coated identically to methods described above. A Tecan plate reader was used to measure fluorescent signals of the supernatant or templated probiotics in PBS, SIF, or SGF. A Carl Zeiss Axiovert 200M was used for taking brightfield images of probiotics and LbL-probiotics.
Results
Figure 1 illustrates a schematic presentation of Layer-by-Layer (LbL) templating of individual bacteria. For example, a probiotic strain such as Bacillus coagulans can be templated with different polyelectrolytes, including polysaccharides chitosan, alginate and enteric pH responsive polymers such as EUDRAGIT® EPO and LI 00.
Layer characterization for chitosan (CHI) and alginate (ALG) coatings on model probiotic Bacillus coagulans (BC) was carried out by measuring the zeta potential (Figure 2A). Zeta potential was measured for each sequential layer of coating, up to two bilayers of chitosan and alginate,
(CHI/ALG)2, at pH 1 and 7.
Uniform layer templating for up to 3 bilayers of chitosan and alginate was confirmed using fluorescent chitosan and alginate (Figure 2B). Linear increases in fluorescent intensity imply uniform layer buildup for both polysaccharides.
Bright field imaging revealed that LbL-templating was achieved on single cells although the LbL-probiotics tend to aggregate once coated with 2 bilayers of chitosan and alginate (CHI/ALG)2 (data not shown).
Example 2: Layer stability in simulated intestinal fluid and simulated gastric fluid
Methods and Materials
As described in Example 1.
Results
2-bilayer of chitosan and alginate templated on Bacillus coagulans remained stable under physiologically relevant conditions (Figures 3A and 3B). This result suggests that layers will not be readily removed or destroyed due to conditions typically encountered in the GI tract.
Example 3: Layer-by-Layer templating protects encapsulated probiotics against biological insults
Methods and Materials
Probiotic Response to Insults
Plain or LbL-coated Bacillus coagulans were subjected to either 4% bile salt solution (Sigma) or SGF (Bicca) in a water bath at 37C for up to 2 hours. After 2 hours, bacteria were pelleted at 3000g and resuspended and washed twice in PBS. Bacteria were plated in sequential dilutions of ten and allowed to grow for at least 48 hours at 37C, and counted as described in
Example 1.
Results
LbL-probiotics resisted acid and bile salt insults. Non-modified Bacillus coagulans exhibited rapid decrease in viability (colony forming units) in both simulated gastric fluid (SGF) and 4 % bile salts (Figures 4A- 4B). 2-bilayers of chitosan and alginate protected against biological insults. LbL-coating of (CHI/ALG)2 provided protection to Bacillus coagulans
against SGF and bile salts (Figures 4C). LbL-formulated (CHI/ALG)2 Bacillus coagidans were protected against both acidic and bile salt insults at 37C for at least 2 hours.
Figure 4C shows the sequential LbL coating of cationic chitosan and anionic alginate on a model gram positive probiotic, Bacillus coagulans, facilitated over 6 orders of magnitude increase in survival in simulated gastric fluid and over 5 orders of magnitude increase in survival in bile salts, as compared to uncoated, non-layered Bacillus coagulans.
Example 4: Layer-by-Layer enhances mucoadhesive capabilities of encapsulated probiotics
Methods and Materials
Mucoadhesive Assay
Freshly isolated small intestine from porcine were cleaned and sectioned. 100 μΐ of a 5 mg/ml solution of vivotag-S 750 stained probiotics, including plain, chitosan coated, and (CHI/ALG)2 formulations, were pipetted directly onto the inner wall of the small intestines. Samples were then incubated for 1 hour at 37C before immediately imaged using an IVIS Spectrum-bioluminescent and fluorescent imaging system (Xenogen). Analysis and spectral unmixing was performed using Living Image Software (PerkinElmer).
Results
Mucoadhesive LbL coating of (CHI/ALG)2 provided a 1.5-fold enhancement in mucoadhesion to ex vivo pig small intestine (Figure 5A). The 2-bilayer coating clearly enhanced mucoadhesive capabilities over non- formulated bacteria.
Example 5: pH-responsive layer removal
Methods and Materials
pH-Responsive Layer Removal
Enteric polymer (EPO or LI 00) coated probiotics were subjected to pH treatments using either SGF or SIF for 1 hour at 37°C. Zeta potential measurements were taken at each layer coating and also following pH treatment.
Results
LbL-probiotics were constructed from enteric and FDA-approved pH responsive polymers such as EUDRAGIT® EPO for stimuli-responsive layer removal in specific areas of the GI tract (Figures 6A and 6B). When EPO was included as the terminal layer, exposure to acidic solutions facilitated removal of EPO, whereas continued exposure to neutral conditions did not. When EUDRAGIT® LI 00 was included as the terminal layer, exposure to neutral solutions facilitated removal of LI 00, whereas continued exposure to acidic conditions did not.
This proof-of-principle example illustrates that LbL-probiotics can be constructed from pH-responsive polymers for stimuli-responsive layer removal in specific areas of the GI tract. pH-responsive layer release can be integrated into LbL-probiotics via terminal coatings of enteric EPO and LI 00 EUDRAGIT® polymers. This offers a general approach to ensure stability and survival of bacteria/probiotics through the stomach for pH-mediated delivery and growth at the intestines or colon.
In summary, a layer-by-layer (LbL) method for the single encapsulation of bacteria cells to directly modulate the microbiome can be achieved by: (i) protecting LbL-bacteria from harsh stomach conditions to circumvent acid- or bile salt-mediated bacteria death, (ii) facilitating mucoadhesion via inclusion of mucoadhesive polysaccharides (e.g. chitosan) in the terminal layer, and (iii) controlling layer release via pH sensitive polymers so as to facilitate growth in pH-regulated areas of GI tract.
Example 6: Number of bilayer modulates bacterial growth
Methods and Materials
As described in Example 1.
Results
Figure 7 shows thaj as bilayer number increased from 0 to 3, growth rates of bacteria reduced accordingly. Therefore, the layer of bilayers can be designed as a way to modulate bacterial growth.
In summary, the above examples showed that LbL templating can be used to protect probiotics from harsh stomach conditions, to directly
facilitate rnucoadhesion and control layer release via pH sensitive polymers. Furthermore, LbL templating can be used as a way to control rate and overall growth of bacteria. This technology offers a platform based approach to ensure stability and survival of probiotics through the stomach for pH- mediated delivery to, and growth in the intestines and colon.
Example 7: pH-responsive polymeric encapsulation of multiple probiotic bacteria
Methods and Materials
As described in Example 1.
Results
PH-responsive polymers such as EUDRAGIT® LI 00 can be used to encapsulate multiple bacteria within the same polymeric particle. In Figure 8, the probiotic bacteria Bacillus coagulans (BC) were encapsulated in LI 00 at various probiotics :polymers ratios. Encapsulations with L100 lead to enhancement of probiotic survival following acidic insults. Subsequent exposure to neutral SIF conditions, under which the encapsulating LI 00 polymers dissolve, gave rise to a significant enhancement in the survival of encapsulated BC after acidic insults. In contrast, BC could not survive acidic conditions when the same mass of BC was first exposed to neutral SIF, followed by exposure to acidic SGF.
In addition, higher LI 00 polymer content resulted in probiotics with further enhanced viability after acidic insults. This suggests a better protection through acidic insults can be achieved with increased amount of coating polymers.
The example demonstrates that the same polymer coating technique is applicable to encapsulate multiple microorganisms to be delivered to specific sites within the GI tract.
Example 8: pH-responsive polymeric encapsulation of probiotic bacteria affects bacterial growth in conditions with neutral or acidic pH
Methods and Materials
As described in Example 1
Results
Figures 9A and 9B demonstrate the growth rate of the LbL-probiotics grown at different pH conditions. When L100 is the terminal layer (closed circles), exposure to neutral conditions facilitates bacteria growth; however, when EPO is the terminal layer (open diamonds), exposure to neutral conditions prevents bacteria growth (Figure 9A). When EPO is the terminal layer (open diamonds), exposure to acidic conditions facilitates bacteria growth; however, when LI 00 is the terminal layer (closed circles), exposure to acidic conditions prevents bacteria growth (Figure 9B).
This data demonstrates that LbL-probiotics constructed from enteric and FDA-approved pH-responsive polymers can be selectively grown in different pH conditions.
Example 9: LbL coating significantly enhances probiotic bacterial growth in a three-dimensional intestinal tissue model.
Methods and Materials
Epilntestinal™ tissues were purchased from MatTek and used as recommended under antibiotic free conditions. For growth experiments, lxl07BC were applied to the apical side of the Epilntestinal tissue (n = 3 per group) in 50% nutrient broth and 50% maintenance medium (MatTek). After 1 hour of incubation at 37°C and 5% C(¾ , non-adhered BC were washed 3x using sterile PBS. IVIS images of MatTek tissues with BC were taken at specific time points. TEM, confocal, and histology images were provided by
MatTek.
Results
Intestine-mimicking tissues from humans (MatTek Epilntestinal) were used to compare the growth of plain and LbL-probiotics on live mammalian intestine tissues. The Epilntestinal™ system is an intestinal model proven to recreate physiological intestine structures (Jirova et al.,
International Conference on Chemical, Civil and Environmental
Engineering, June 5-6:66-68 (2015)) such as the columnar growth of intestinal epithelial cells, tight junctions, and brush borders (images taken but not shown). Bioluminescent plain and (CHI/ALG)2 LbL-probiotics were placed in direct contact with Epilntestinal™ tissue for 1 hour, washed, imaged, and analyzed for total emitted radiance to track and compare their adhesion and growth kinetics (Figure 10A, 10B). Since unbound BC would pass through the GI tract in physiological situations, unbound BC were washed from the Epilntestinal™ surface at each timepoint. At 1, 2, and 6 hours, adherence and growth of (CHI/ALG)2 LbL-probiotics outperformed plain-probiotics, sometimes by as much as 2-fold (6 hours) (Figure 10A, 10B). However, at 12 hours, these differences diminished as the intestinal surface begun to saturate.
The LbL-probiotic bacteria showed significantly faster growth at 1, 2, and 6 hours after plating when compared to the growth of plain bacteria (Figure 10A). Fold-enhancement of LbL-probiotics' growth over that of plain, uncoated, probiotics at each timepoint is shown in Figure 10B. The LbL coating enhanced the growth rate of (CHI/ALG)2-coated LbL-probiotics by more than two-fold at these time points.
Histology (hematoxylin and eosin stain) of EPIINTESTINAL™ tissue highlighted the columnar growth of intestinal cells at 50x
magnification. TEM imaging of EPIINTESTINAL™ tissue highlighted the presence of tight junctions and brush borders at 12,000x. Confocal imaging of EPIINTESTINAL™ tissue highlighted the presence of brush borders and columnar epithelium.
Example 10: LbL coating significantly enhances probiotic bacterial delivery to the to the GI tract.
Methods and Materials
8-10 week old female BALB/c mice were oral gavaged 5x108 plain or LbL Bacillus coagulans (n = 4 mice per group). After 1 hour, mice were sacrificed via CO2 overdose and the GI tract (stomach to colon) was harvested. The GI tract was then opened with a razor blade to expose the
gavaged BC to oxygen for bioluminescent imaging. All animal procedures were performed according to MIT Animal Care and Use Committee approved protocols.
Results
The role of LbL coatings on survival and delivery of probiotics in vivo was investigated by orally gavaging an identical number of bioluminescent plain and (CHI/ALG)2 LbL-probiotics. 1 hour after oral gavage, bioluminescent (CHI/ALG)2 LbL-probiotics emitted over 5-fold enhanced signal over background in the GI tract as compared to plain- probiotics (Figure 11A). Representative images (not shown) highlighted how the GI tract distribution between plain-probiotics and (CHI/ALG)2 LbL- probiotics were similar; however, unlike plain-probiotics, (CHI/ALG)2 LbL- probiotics were capable of surviving harsh stomach conditions to arrive at the intestine in a viable state. The impact of LbL-coatings on probiotic mucoadhesion and growth on intestinal tissues was investigated using freshly isolated pig intestines and intestine-mimicking tissues from humans. After 1 hour incubation at 37°C and subsequent washes, (CHI/ALG)2 LbL-probiotics adhered to the mucosal surface of freshly isolated pig intestine nearly 1.5- fold higher as compared to plain-probiotics (Figure 1 IB). LbL coatings enhanced mucoadhesion to pig intestine at 1 hour.
Collectively, these results demonstrate that the enhanced mucoadhesion provided by LbL-probiotics leads to growth advantages at later timepoints. Since more bacteria adhere directly to the intestine tissue at short timepoints, they replicate and reach the exponential growth phase faster. In vivo, LbL probiotics outperformed plain probiotics in terms of survival (Figure 11 A), likely due to an interplay occurring between resistance against acid/bile salts, intestinal adhesion, and subsequent growth.
Example 11: Encapsulation of Type II oral poliovirus
Methods and Materials
As described in Example 1.
Results
In another example, encapsulation of Type II oral poliovirus (OPV) in a single layer of EPO, a single layer of Glycol Chitosan, or a single layer of 50:50 mixture of EPO and glycol chitosan was achieved (Figure 9). Figure 9 shows the survival of OPV after 4 days at 37°C with a normalizing control of identical Type II OPV from a fresh stock. MgCl2.6H20 was used as a comparison with standard salt buffer.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.
Claims
1. A formulation of mucoadhesive polymeric encapsulated microorganisms or antigenic components thereof comprising
a) a single-cell microorganism selected from the group consisting of yeast and bacteria, or viral particle, or antigenic component thereof,
b) one or more mucoadhesive polymers,
wherein the microorganisms or components thereof is encapsulated within the one or more polymers and
wherein the encapsulated microorganisms or components thereof is released upon exposure to one or more physiological conditions within the gastrointestinal tract.
2. The formulation of claim 1, wherein the one or more mucoadhesive polymers comprises an outer layer of pH-responsive polymers.
3. The formulation of claim 1 or 2, wherein the one or more mucoadhesive polymers are applied sequentially layer-by-layer onto the microorganism.
4. The formulation of any of claims 1-3, wherein the one or more mucoadhesive polymers are selected from the group consisting of chitosan, alginate, agarose, gelatin, hyaluronic acid, xanthan gum, guar gum, pectin, cellulose and cellulose derivatives.
5. The formulation of claim 4, wherein the one or more mucoadhesive polymers include chitosan and alginate.
6. The formulation of any of claims 1-5, wherein the one or more mucoadhesive polymers are selected from the group consisting of polyacrylic acids, poly(methacrylic acids), polymethacrylates, hydroxypropyl-methylcellulosephthalate (HPMC), and hydrazine, acetal, ortho-ester-, and vinyl-ester functionalized polymers.
7. The formulation of claim 6, wherein the pH-responsive polymers are polymethacrylate polymers sold as EUDRAGIT® E PO or
EUDRAGIT®L 100.
8. The formulation of any of claims 1-7, wherein the one or more physiological conditions are pH.
9. The formulation of claim 8, wherein the pH is within a range selected from the group consisting of from about 1 to about 2.5 inclusive, from about
6.1 to about 7.4 inclusive, from about 6.8 to about 7.9 inclusive, from about
5.2 to about 6.7 inclusive and from about 5.2 to about 7.0 inclusive.
10. The formulation of any of claims 1-9, wherein the microorganism is a probiotic microorganism.
11. The formulation of claim 10, wherein the microorganism is selected from the group consisting of Bacillus coagulans, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum, Lactobacillus fermentum, Lactobacillus rhamnosus, Streptococcus thermophiles, Bifidobacterium breve, Lactobacillus reuteri, and Saccharomyces boulardii and any genetically-modified variants thereof.
12. The formulation of claim 11 , wherein the probiotic bacteria are genetically engineered to express one or more recombinant proteins.
13. The formulation of claim 12, wherein recombinant proteins are selected from the group consisting of diagnostic, prophylactic and therapeutic proteins.
14. The formulation of any of claims 1-13, wherein the microorganism is a live attenuated vaccine.
15. The formulation of any of claims 1-14, wherein the microorganism is lyophilized.
16. The formulation of claim 1 for use as a vaccine, the formulation comprising antigens.
17. The formulation of any of claims 1-16, wherein the polymer protects the microorganism during storage or delivery or enhances the function of the microorganism in the gastrointestinal tract.
18. The formulation of any of claims 1-17, wherein the microorganism is administered in a dosage unit for replacement of microorganism in the gastrointestinal tract.
19. The formulation of any of claims 1-18 is formulated in a pharmaceutical composition for enteral administration.
20. The formulation of any of claims 1-19 further comprising therapeutic, prophylactic or diagnostic agents.
21. A method for the treatment or prevention of one or more diseases or conditions associated with an alteration in the gut microbiota, comprising administering to the subject an effective amount of the formulation of claim 19 or 20.
22. The method of claim 21 , wherein the one or more diseases or conditions are selected from the group consisting of Crohn's disease, ulcerative colitis, gluten insensitivity, lactose intolerance, obesity, asthma, allergies, metabolic syndrome, diabetes, psoriasis, eczema, rosacea, atopic dermatitis, gastrointestinal reflux disease, cancers of the gastrointestinal tract, bacterial vaginosis, neurodevelopmental conditions and general lowered immunity following a course of antibiotics or chemotherapy.
23. The method of claim 21 or 22 comprising repeating the
administration of the formulation of claim 19 for a time and in an amount effective to alleviate one or more symptoms of a disease or condition.
24. The method of claim 21 wherein the formulation comprising antigenic components of the microorganisms.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267121P | 2015-12-14 | 2015-12-14 | |
US62/267,121 | 2015-12-14 | ||
US201662333570P | 2016-05-09 | 2016-05-09 | |
US62/333,570 | 2016-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017105990A1 true WO2017105990A1 (en) | 2017-06-22 |
Family
ID=57681752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/065535 WO2017105990A1 (en) | 2015-12-14 | 2016-12-08 | Ph-responsive mucoadhesive polymeric encapsulated microorganisms |
Country Status (2)
Country | Link |
---|---|
US (1) | US10548844B2 (en) |
WO (1) | WO2017105990A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020245341A1 (en) * | 2019-06-06 | 2020-12-10 | University Of Vienna | Delivering viable microorganisms |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10406336B2 (en) | 2016-08-03 | 2019-09-10 | Neil S. Davey | Adjustable rate drug delivery implantable device |
JP2020532515A (en) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス, インコーポレイテッド | Methods and compositions for the treatment of microbiome-related disorders |
US10849938B2 (en) | 2017-09-13 | 2020-12-01 | ZBiotics Company | Gene expression system for probiotic microorganisms |
KR102424237B1 (en) * | 2018-10-30 | 2022-07-21 | 비타볼러스 인크. | Oral Delivery of Mammalian Cells for Therapeutic Use |
CN111280449B (en) * | 2020-02-11 | 2022-11-11 | 浙江华康药业股份有限公司 | Intestinal slow-release sugar alcohol additive and preparation method and application thereof |
KR20220146577A (en) * | 2020-02-26 | 2022-11-01 | 시에이치알. 한센 에이/에스 | Spray Freeze Drying of Complete Anaerobic Bacteria |
US11426353B2 (en) * | 2020-06-24 | 2022-08-30 | 13400719 Canada Inc. | Composite coating for an active agent |
CN111925971A (en) * | 2020-09-07 | 2020-11-13 | 江西华威科技有限公司 | Environment-responsive bacillus emulsion and preparation method thereof |
CN112522160B (en) * | 2020-12-24 | 2022-05-10 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Lactobacillus fermentum PV22 with antiviral ability and application thereof |
WO2022249194A1 (en) * | 2021-05-27 | 2022-12-01 | Tagra Biotechnologies Ltd. | Encapsulation of live microorganisms |
CN114917259B (en) * | 2022-02-15 | 2023-10-13 | 中国科学院上海硅酸盐研究所 | Two-dimensional hydrosilylene-microorganism composite material and preparation method and application thereof |
WO2023237672A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Vitamin b1 for use in improving gut health |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US20030109025A1 (en) | 2000-03-16 | 2003-06-12 | Henri Durand | Particles containing coated living micro-organisms, and method for producing same |
WO2009070012A1 (en) | 2007-11-29 | 2009-06-04 | Nizo Food Research B.V. | Protein-based probiotic encapsulates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2517245C (en) * | 2003-02-28 | 2009-01-20 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
US7238677B2 (en) * | 2003-03-28 | 2007-07-03 | Kimberly-Clark Worldwide, Inc. | Prevention of urogenital infections |
CA2781712A1 (en) * | 2009-11-25 | 2011-06-03 | Captozyme, Llc | Methods and compositions for treating oxalate-related conditions |
EP2643057A4 (en) * | 2010-11-26 | 2014-05-21 | Univ Witwatersrand Jhb | An implant for the controlled release of pharmaceutically active agents |
GB201115143D0 (en) | 2011-09-02 | 2011-10-19 | Univ Wolverhampton | Improved viablity of probiotic microorganisms |
-
2016
- 2016-12-08 US US15/372,703 patent/US10548844B2/en active Active
- 2016-12-08 WO PCT/US2016/065535 patent/WO2017105990A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US20030109025A1 (en) | 2000-03-16 | 2003-06-12 | Henri Durand | Particles containing coated living micro-organisms, and method for producing same |
WO2009070012A1 (en) | 2007-11-29 | 2009-06-04 | Nizo Food Research B.V. | Protein-based probiotic encapsulates |
Non-Patent Citations (78)
Title |
---|
"Pharmaceutical dosage form tablets", 1989, MARCEL DEKKER, INC. |
"Pharmaceutical Dosage Forms: Tablets", 1989, MARCEL DEKKER, INC |
"Remington - The science and practice of pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO., pages: 1435 - 1712 |
ABUCHOWSKI; DAVIS: "Enzymes as Drugs", 1981, WILEY-INTERSCIENCE, article "Soluble Polymer-Enzyme Adducts", pages: 367 - 383 |
ALLEN, A.; HUTTON, D.A.; PEARSON, J.P.; SELLERS, L.A.: "Mucus and Mucosa, Ciba Foundation Symposium", vol. 109, 1984, article "Mucus Glycoprotein Structure, Gel Formation and Gastrointestinal Mucus Function", pages: 137 |
ALLISON DD ET AL., TISSUE ENG., vol. 12, 2006, pages 2131 - 2140 |
ANGEL J. PRIYA ET AL: "Enhanced Survival of Probiotic Lactobacillus acidophilus by Encapsulation with Nanostructured Polyelectrolyte Layers through Layer-by-Layer Approach", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 59, no. 21, 9 November 2011 (2011-11-09), US, pages 11838 - 11845, XP055351072, ISSN: 0021-8561, DOI: 10.1021/jf203378s * |
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995, WILLIAMS & WILKINS |
ANSEL: "Pharmaceutical dosage forms and drug delivery systems", 1995, WILLIAMS AND WILKINS |
AUDET P ET AL., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 29, no. 1, 1988, pages 11 - 18 |
BATORSKY A ET AL., BIOTECHNOL BIOENG., vol. 92, no. 4, 2005, pages 492 - 500 |
BORGOGNA M ET AL., FOOD CHEMISTRY, vol. 122, no. 2, 2010, pages 416 - 423 |
BRAVO ET AL., PROC NATL ACAD SCI USA., vol. 108, no. 38, 2011, pages 16050 - 5 |
CANI ET AL., PATHOL BIOL, vol. 56, no. 5, July 2008 (2008-07-01), pages 305 - 9 |
CHAMPAGENE CP ET AL., FUNCTIONAL DAIRY PRODUCTS, vol. 2, 2007, pages 404 - 426 |
CHEN MJ ET AL.: "Encapsulation and Controlled Release Technologies in Food Systems", 2007, WILEY-BLACKWELL, pages: 83 - 107 |
COOK MT ET AL., J. MATER. CHEM. B, vol. 1, 2013, pages 52 - 60 |
DE VOS P ET AL., INTERNATIONAL DAIRY JOURNAL, vol. 20, no. 4, 2010, pages 292 - 302 |
DONTHIDI AR ET AL., JOURNAL OF MICROENCAPSULATION, vol. 27, no. 1, 2010, pages 67 - 77 |
FALLINGBORG J, DAN MED BULL, vol. 46, no. 3, 1999, pages 183 - 96 |
F'AVARO-TRINDADE CS ET AL., JOURNAL OF MICROENCAPSULATION, vol. 19, no. 4, 2002, pages 485 - 494 |
GARG HG ET AL.: "Chemistry and biology of hyaluronan", 2004, ELSEVIER LTD. |
GENTILE FT, REACT. POLYM., vol. 25, 1995, pages 207 - 227 |
HARALAMPU SG ET AL., CARBOHYDRATE POLYMERS, vol. 41, no. 3, 2000, pages 285 - 292 |
HAY ET AL., BR. MED. J., vol. 308, 1994, pages 295 - 298 |
HAYASHI H, DRYING TECHNOLOGY, vol. 1, no. 2, 1983, pages 75 - 284 |
HEIDEBACH T ET AL., FOOD HYDROCOLLOIDS, vol. 23, no. 7, 2009, pages 1670 - 1677 |
HEIDEBACK T ET AL., JOURNAL OF FOOD ENGINEERING, vol. 98, no. 3, 2010, pages 309 - 316 |
HOLLAND ET AL., BR J DERMATOL., vol. 96, no. 6, 1977, pages 623 - 6 |
HOROWITZ, M.I.: "Alimentary Canal", 1967, AMERICAN PHYSIOLOGICAL SOCIETY, article "Mucopolysaccharides and Glycoproteins of the Alimentary Tract", pages: 1063 - 1085 |
HOROWITZ, M.I.; PIGMAN, W.: "The Glycoconjugates", 1977, ACADEMIC PRESS, INC., pages: 560 |
HOROWITZ, M.I: "Alimentary Canal", 1967, AMERICAN PHYSIOLOGICAL SOCIETY, article "Mucopolysaccharides and Glycoproteins of the Alimentary Tract", pages: 1063 - 1085 |
HUYGHEBAERT N ET AL., EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 61, no. 3, 2005, pages 134 - 141 |
IVANOV ET AL., CELL, vol. 139, no. 3, 2009, pages 485 - 98 |
JIROVA ET AL., INTERNATIONAL CONFERENCE ON CHEMICAL, CIVIL AND ENVIRONMENTAL ENGINEERING, 5 June 2015 (2015-06-05), pages 66 - 68 |
JOÃO M.S. DE BARROS ET AL: "Enteric coated spheres produced by extrusion/spheronization provide effective gastric protection and efficient release of live therapeutic bacteria", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 493, no. 1-2, 1 September 2015 (2015-09-01), AMSTERDAM, NL, pages 483 - 494, XP055280455, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2015.06.051 * |
KAILASAPATHY K ET AL., CURRENT ISSUES IN INTESTINAL MICROBIOLOGY, vol. 3, no. 2, 2002, pages 39 - 48 |
KAILASAPATHY K, CAB REVIEWS, vol. 4, no. 6, 2009, pages 1 - 19 |
KING AH ET AL.: "Encapsulation and Controlled Release of Food Ingredients", vol. 590, AMERICAN CHEMICAL SOCIETY, pages: 26 - 39 |
KLEIN J ET AL., EUROPEAN JOURNAL OF APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 18, no. 2, 1983, pages 86,91 |
KLIEN J ET AL.: "Comprehensive Biotechnology", 1985, PERGAMON PRESS, pages: 542 - 550 |
KOPONEN J ET AL., J. PROTEOMICS, vol. 75, no. 4, 2012, pages 1357 - 1374 |
KRASAEKOOPT W ET AL., INTERNATIONAL DAIRY JOURNAL, vol. 13, no. 1, 2003, pages 3 - 13 |
LABAT-ROBEIT, J.; DECAEUS, C.: "Glycoproteins du Mucus Gastrique: Structure, Function, et Pathologie", PATHOLOGIE ETBIOLOGIE, vol. 24, 1979, pages 241 |
LABAT-ROBERT, J.; DECAEUS, C.: "Glycoproteins du Mucus Gastrique: Structure, Fonction, et Pathologie", PATHOLOGIE ET BIOLOGIE (PARIS, vol. 24, 1979, pages 241 |
LANE ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, 2007, pages 16669 - 74 |
LAURENT TCE: "The Chemistry, Biology, and Medical Applications of Hyaluronan and Its Derivatives", 1998, PORTLAND PRESS |
LEY ET AL., NATURE, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1022 - 3 |
LINDFORS K ET AL., CLIN EXP IMMUNOL., vol. 152, no. 3, 2008, pages 552 - 8 |
LINSKENS ET AL., SCAND J GASTROENTEROL SUPPL., 2001, pages 29 - 40 |
LIVNEY YD, CURRENT OPINION IN COLLOID AND INTERFACE SCIENCE, vol. 15, no. 1-2, 2010, pages 73 - 83 |
MACDONALD C, JR SOC INTERFACE., vol. 5, no. 23, 2008, pages 663 - 669 |
MAKHLOF A ET AL., EUR JPHARM SCI., vol. 42, no. 5, 18 December 2010 (2010-12-18), pages 445 - 51 |
MALM CJ ET AL., JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, vol. 40, no. 10, 1951, pages 520 - 525 |
MARSHALL, K.: "Modern Pharmaceutics", 1979 |
MICHAEL T. COOK ET AL: "Layer-by-layer coating of alginate matrices with chitosan-alginate for the improved survival and targeted delivery of probiotic bacteria after oral administration", JOURNAL OF MATERIALS CHEMISTRY B, vol. 1, no. 1, 1 January 2013 (2013-01-01), GB, pages 52 - 60, XP055351008, ISSN: 2050-750X, DOI: 10.1039/C2TB00126H * |
MIDHUN BEN THOMAS ET AL: "Enhanced viability of probiotic Saccharomyces boulardii encapsulated by layer-by-layer approach in pH responsive chitosan-dextran sulfate polyelectrolytes", JOURNAL OF FOOD ENGINEERING, vol. 136, 1 September 2014 (2014-09-01), GB, pages 1 - 8, XP055351154, ISSN: 0260-8774, DOI: 10.1016/j.jfoodeng.2014.03.015 * |
MIYATA T ET AL., CHEM. PHYS., vol. 195, 1994, pages 1111 |
MORTAZAVIAN A ET AL., IRANIAN JOURNAL OF BIOTECHNOLOGY, vol. 5, no. 1, 2007, pages 1 - 18 |
NAKAMAE K ET AL., CHEM, vol. 193, 1992, pages 983 |
NEWMARK ET AL., J. APPL. BIOCHEM., vol. 4, 1982, pages 185 - 189 |
PAULINO ET AL., J. CLIN. MICROBIOL., vol. 44, 2006, pages 2933 - 2941 |
PIGMAN, W.; GOTTSCHALK, A.: "Glycoproteins: Their Composition, Structure and Function", 1966, ELSEVIER PUBLISHING COMPANY, INC., article "Submaxillary Gland Glycoproteins", pages: 434 - 445 |
PIKAL MJ, PHARMTECH INTERNATIONAL, vol. 1, 1991, pages 37 - 43 |
R.A. SIEGEL, ADV. POLYM. SCI., vol. 109, 1993, pages 233 |
REID AA ET AL., JOURNAL OF FOOD SCIENCE, vol. 72, no. 1, 2006, pages M31 - M37 |
RICHARDSON JJ ET AL., ADV MATER., vol. 25, no. 47, 2013, pages 6874 - 8 |
ROTH; JAMES, ANNU. REV. MICROBIOL., vol. 42, 1988, pages 441 - 464 |
SARTOR, PROC NATL ACAD SCI USA., vol. 105, no. 43, 28 October 2008 (2008-10-28), pages 16413 - 4 |
SCAWEN, M.; ALLEN, A.: "The Action of Proteolytic Enzymes on the Glycoprotein from Pig Gastric Mucus", BIOCHEMICAL JOURNAL, vol. 163, 1977, pages 363 - 368 |
SHEU TY ET AL., JOURNAL OF FOOD SCIENCE, vol. 54, 1993, pages 557 - 561 |
SMIDSROD O ET AL., TRENDS IN BIOTECHNOLOGY, vol. 8, no. 3, 1990, pages 71 - 75 |
SOLANKI HK ET AL., BIOMED RES INT., 2013, pages 620719 |
SPIRO, R.G.: "Glycoproteins", ANNUAL REVIEW OF BIOCHEMISTRY, vol. 39, 1970, pages 599 - 638 |
THOMSEN ET AL., ARCH. DERMATOL., vol. 116, 1980, pages 1031 - 1034 |
TILL ET AL., BR. J. DERMATOL., vol. 142, 2000, pages 885 - 892 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020245341A1 (en) * | 2019-06-06 | 2020-12-10 | University Of Vienna | Delivering viable microorganisms |
Also Published As
Publication number | Publication date |
---|---|
US20170165201A1 (en) | 2017-06-15 |
US10548844B2 (en) | 2020-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10548844B2 (en) | pH-responsive mucoadhesive polymeric encapsulated microorganisms | |
Asgari et al. | Polymeric carriers for enhanced delivery of probiotics | |
DK1667696T3 (en) | PROBIOTIC STORAGE AND SUBMISSION | |
Solanki et al. | Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent | |
US10369176B2 (en) | Probiotic formulations and methods for use | |
Cook et al. | Microencapsulation of a synbiotic into PLGA/alginate multiparticulate gels | |
CA2825473C (en) | Protection of microbial cells from acidic degradation | |
KR101353692B1 (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
JP2019189609A (en) | Disease treatment composition comprising combination of microbiota-derived bioactive molecules | |
Khan et al. | Development of extrusion-based legume protein isolate–alginate capsules for the protection and delivery of the acid sensitive probiotic, Bifidobacterium adolescentis | |
AU2003274229B2 (en) | Galenic formulation for colon targeted delivery of active ingredients | |
WO1999064023A1 (en) | Lactic acid bacterium-containing compositions, drugs and foods | |
Khorasani et al. | Starch-and carboxymethylcellulose-coated bacterial nanocellulose-pectin bionanocomposite as novel protective prebiotic matrices | |
Jiang et al. | Recent advances in the design and fabrication of probiotic delivery systems to target intestinal inflammation | |
AU2015100952A4 (en) | Probiotic- and enzyme-containing compositions and uses thereof | |
Luo et al. | Precise oral delivery systems for probiotics: A review | |
Swastha et al. | Alginate-based drug carrier systems to target inflammatory bowel disease: A review | |
Zeybek et al. | Designing robust xylan/chitosan composite shells around drug-loaded MSNs: Stability in upper GIT and degradation in the colon microbiota | |
CN1622816A (en) | Composition and method for augmenting kidney function | |
Escobar-Puentes et al. | Encapsulation of probiotics | |
Li et al. | Intestinal Delivery of Probiotics: Materials, Strategies, and Applications | |
AU2004275438B2 (en) | Probiotic storage and delivery | |
Baheti et al. | Different formulation approaches to improve the survivability of probiotics in the digestive tract | |
Cooka et al. | Microencapsulation of a synbiotic into PLGA/alginate | |
Zeybek et al. | Designing of a Xylan/Chitosan Shell with a Curcumin-Loaded Mesoporous Silica Nanoparticle Core: Evading GIT pH and Providing Microbially-Activated Drug Delivery in the Colon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16820073 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16820073 Country of ref document: EP Kind code of ref document: A1 |